Sentence,class,file
"June 14, 2016. http://www.hhs.gov/about/news/2016/06/14/hhs-selects-regional-ebola- treatment-center-southwestern- us.html.",Non-OADS,/arxiv_data1/oa_pdf/ad/a4/hs.2016.0105.PMC5404255.pdf
2015. http://www.cdc.gov.tw/professional/ info.aspx?treeid=10E4730DBC2EB10F&nowtreeid=86A5068 4EE54F4B8&tid=644AB0348E10CB34.,OADS,/arxiv_data1/oa_pdf/ad/a4/hs.2016.0105.PMC5404255.pdf
2015. http://www.cdc.gov.tw/professional/info.aspx?treeid=10e4730dbc2eb10f&nowtreeid=eed17251205b4e37&tid=DA26436E9A E7F61A.,OADS,/arxiv_data1/oa_pdf/ad/a4/hs.2016.0105.PMC5404255.pdf
"Aug 8, 2014. http://www.who.int/ mediacentre/ news/statements/2014/ebola-20140808/en/.",Non-OADS,/arxiv_data1/oa_pdf/ad/a4/hs.2016.0105.PMC5404255.pdf
http://netec.org/.,Non-OADS,/arxiv_data1/oa_pdf/ad/a4/hs.2016.0105.PMC5404255.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.Health Security Volume 15, Number 2, 2017 Mary Ann Liebert, Inc. DOI: 10.1089/hs.2016.0107 144",Non-OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
https://data.cdc.gov.tw/en/.,OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
http://data.gov.tw/.,OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
http://www.cdc.gov.tw/english/submenu.aspx?treeid= 00ed75d6c887bb27&nowtreeid= 8f1e239d0fd8877a.,Non-OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
2015. http://www.cdc.gov.tw/professional/programresultinfo.aspx?treei d=9068acd483c71fc1&nowtreeid= 3B791EACC1B5C579&tid=AB4E7C296841EC2D.,OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
"WHO statement on the ﬁrst meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observedincrease in neurological disorders and neonatal malformations.February 1, 2016. http://www.who.int/mediacentre/news/ statements/2016/1st-emergency-committee-zika/en/.",Non-OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
"August 17, 2016.http://www.cdc.gov.tw/englis h/info.aspx?treeid=bc2d4e89b 154059b&nowtreeid=ee0a2987cfba3222&tid=E285278D5 A2EE5A6.",OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
"Taiwan conﬁrms seventh imported Zika case in Singaporean, which is the ﬁrst imported case from Singapore [press release].September 12, 2016. http://www.cdc.gov.tw/english/info.aspx?treeid=bc2d4e89b154059b&nowtreeid=ee0a2987cfba 3222&tid=EB586FD553EC4297.",Non-OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
Taiwan Epidemiol Bull 2016;32(11):225- 235. http://www.cdc.gov.tw/english/info.aspx?treeid=3847719104be0678&nowtreeid=05056b75c73beba6&tid=BD37760C1102ED4F.,OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
"January 16, 2016. http://www.who.int/emergencies/zika-virus/situation-report/16-june-2016/en/.",Non-OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
"July 15, 2016. http://www.who.int/emergencies/zika-virus/response/en/.",Non-OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
"August 9, 2016. http://www.cdc.gov/zika/healtheffects/gbs-qa.html.",Non-OADS,/arxiv_data1/oa_pdf/aa/7e/hs.2016.0107.PMC5404256.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercialuse, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.Health Security Volume 15, Number 2, 2017 Mary Ann Liebert, Inc. DOI: 10.1089/hs.2016.0093 132",Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
2007. http://www.who.int/whr/2007/en/.,OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
2014. http://documents.worldbank.org/curated/en/524521468141287875/pdf/912190WP0see0a00070385314B00 PUBLIC0.pdf.,Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
"Updated August 8, 2016.http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/ cost-of-ebola.html.",Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
Geneva: WHO; 2015. http://apps.who.int/iris/bitstream/10665/251717/ 1/B136_22Add1-en.pdf.,OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
2015. http://www.who.int/csr/ resources/publications/ebola/ebola-panel-report/en/.,Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
https://www.ghsagenda.org/assessments.,Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
"March 2, 2016. https://2009-2017.state.gov/e/eb/rls/rm/2016/253915.htm.",Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
"March 30, 2016. http://www.cdc.gov.tw/ english/info.aspx?treeid=bc2d4e89b154059b&nowtreeid= ee0a2987cfba3 222&tid=0689D842E 9044A0C.",Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
2016. http://www.centerforhealthsecurity.,Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
"October 19, 2016. http://www.upmchealthsecurity.",Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
De- cember 2012. http://www.upmchealthsecurity.org/our-work/ pubs_archive/pubs-pdfs/2012/2012-12-21-taiwan_assessment_ rpt.pdf.,Non-OADS,/arxiv_data1/oa_pdf/15/8d/hs.2016.0093.PMC5404271.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/9d/c9/CG-CGCR170024.PMC5404341.pdf
Protocol CA209-153 .https://clinicaltrials.gov/ct2/ show/study/NCT02066636.,Non-OADS,/arxiv_data1/oa_pdf/9d/c9/CG-CGCR170024.PMC5404341.pdf
Protocol CA209-214 .https://clinicaltrials.gov/ct2/ show/NCT02231749.,Non-OADS,/arxiv_data1/oa_pdf/9d/c9/CG-CGCR170024.PMC5404341.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/71/92/CG-CGCR170020.PMC5404342.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/5e/fb/CG-CGCR170018.PMC5404343.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/f8/23/CG-CGCR170027.PMC5404344.pdf
The results of my calculations are available for download  at https://goo.gl/xqwphs and constitute a reverse-lookup database  that fully compromises the security of the proposed method.,OADS,/arxiv_data1/oa_pdf/3e/75/JPI-8-17.PMC5404349.pdf
Available from: https://www.census.gov/topics/ population/genealogy/data/2000_surnames.html.,OADS,/arxiv_data1/oa_pdf/3e/75/JPI-8-17.PMC5404349.pdf
Available FREE in open access from:  http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/3e/75/JPI-8-17.PMC5404349.pdf
Available FREE in open access from:  http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 2 J Pathol Inform 2017, 1:15  http://www.jpathinformatics.org/content/8/1/15defining factor to distinguish each entity.",OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 3 J Pathol Inform 2017, 1:15  http://www.jpathinformatics.org/content/8/1/15transport (OT) problem in continuous domain,[33] facilitating  classification.",Non-OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 4 J Pathol Inform 2017, 1:15  http://www.jpathinformatics.org/content/8/1/15choice of reference image is the average of the nuclei image set:  INI01=∑ i i=1N and the OT distance between the reference and  a given image Ii which is mathematically defined as follows: dI If xx Ix dxi fOT ii i(, )| () |( ) min 02=− ∫ Ω S. t. det ( Dfi [x]) I0 (fi [x]) = Ii (x) Where, x is the concatenation of image coordinates including  both horizontal and vertical directions.",OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 5 J Pathol Inform 2017, 1:15  http://www.jpathinformatics.org/content/8/1/15To visualize the discriminative information in the dataset  with two classes (benign and malignant in our case), we  apply the method described in the study by Wang et al.,[39]  namely penalized LDA  (pLDA), to a set of linear embedding  ZZ={}=iiN 1 in the PCA-derived space.",Non-OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 6 J Pathol Inform 2017, 1:15  http://www.jpathinformatics.org/content/8/1/15nuclei to have a chromatin distribution centered at the nuclei  periphery; on the contrary, nuclei of DN tend to have more  uniform chromatin distributions.",Non-OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 7 J Pathol Inform 2017, 1:15  http://www.jpathinformatics.org/content/8/1/15et al.",Non-OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 8 J Pathol Inform 2017, 1:15  http://www.jpathinformatics.org/content/8/1/1523.",Non-OADS,/arxiv_data1/oa_pdf/c8/88/JPI-8-15.PMC5404351.pdf
"Journal of Pathology Informatics 2 J Pathol Inform 2017, 1:14  http://www.jpathinformatics.org/content/8/1/14related literature, the authors concluded that digital pathology  systems are equivalent to glass slides for rendering diagnoses.",OADS,/arxiv_data1/oa_pdf/73/19/JPI-8-14.PMC5404353.pdf
Available FREE in open access from:  http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/73/19/JPI-8-14.PMC5404353.pdf
Available FREE in open access from:  http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/be/83/JPI-8-19.PMC5404354.pdf
"Journal of Pathology Informatics 2 J Pathol Inform 2017, 1:19  http://www.jpathinformatics.org/content/8/1/19digital pathology if precautions are not taken when collecting  new datasets.",Non-OADS,/arxiv_data1/oa_pdf/be/83/JPI-8-19.PMC5404354.pdf
"Journal of Pathology Informatics 3 J Pathol Inform 2017, 1:19  http://www.jpathinformatics.org/content/8/1/19caloric restriction diets.",Non-OADS,/arxiv_data1/oa_pdf/be/83/JPI-8-19.PMC5404354.pdf
"Journal of Pathology Informatics 4 J Pathol Inform 2017, 1:19  http://www.jpathinformatics.org/content/8/1/19ground-truth datasets.",Non-OADS,/arxiv_data1/oa_pdf/be/83/JPI-8-19.PMC5404354.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"4, 831 –835 http://dx.doi.org/10.1080/21645515.2016.1252886",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
Available at: http://apps.who.int/ iris/bitstream/10665/183117/1/9789241508841_eng.pdf?ua D1 (accessed 22 Nov 2016) [2] Peipert JF.,Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"N Engl J Med 2003; 349:2424-30; PMID:14681509; http://dx.doi.org/10.1056/ NEJMcp030542 [3] Brunham RC, Gottlieb SL, Paavonen J. Pelvic in ﬂammatory disease.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"N Engl J Med 2015; 372:2039-48; PMID:25992748; http://dx.doi.org/ 10.1056/NEJMra1411426 [4] Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, Goeman J, Behets F, Batter V, Alary M, et al.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Aids 1993; 7:95-102; PMID:8442924; http://dx.doi.org/10.1097/00002030-199301000-00015 [5] Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Am J Epidemiol 2005;162:668-75; PMID:16120706; http://dx.doi.org/10.1093/aje/kwi262 [6] Brunham RC, Rappuoli R. Chlamydia trachomatis control requires a vaccine.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
Vaccine 2013; 31:1892-7; PMID:23375977; http://dx.doi.org/10.1016/j.vaccine.2013.01.024 [7] World Health Organization.,Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
Available at: http://www.who.int/pbd/publica tions/trachoma/en/get_oct1998.,Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"J Infect Dis 2005; 192:591-9; PMID:16028127; http://dx.doi.org/10.1086/432070 [9] Brunham RC, Kuo CC, Cles L, Holmes KK.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"J Immunol 2012; 189:2441-9; http://dx.doi.org/10.4049/jimmunol.1103032 [11] Farris CM, Morrison RP.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Infect Immun 2011; 79:986-96; PMID:21078844; http://dx.doi.org/10.1128/IAI.00881-10 [12] Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P, Brunham RC.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Infect Immun 2012; 80:1510-8; PMID:22290151; http://dx.doi.org/10.1128/IAI.06338-11 [13] Vlcek KR, Li W, Manam S, Zanotti B, Nicholson BJ, Ramsey KH, Murthy AK.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Immunol Cell Biol 2016; 94:208-12; PMID:26323581; http://dx.doi.org/10.1038/icb.2015.74[14] Olivares-Zavaleta N, Whitmire WM, Kari L, Sturdevant GL, Caldwell HD.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"J Immunol 2014; 192:4648-54; http://dx.doi.org/10.4049/ jimmunol.1400120 [15] Morrison SG, Morrison RP.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"J Immunol 2005; 175:7536-42; http://dx.doi.org/10.4049/jimmunol.175.11.7536 [16] Naglak EK, Morrison SG, Morrison RP.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Infect Immun 2016; 84:3232-3242; PMID:27600502; http://dx.doi.org/10.1128/IAI.00749-16 [17] Olsen AW, Follmann F, Erneholm K, Rosenkrands I, Andersen P. Protection against chlamydia trachomatis infection and upper genitaltract pathological changes by vaccine-promoted neutralizing anti- bodies directed to the VD4 of the major outer membrane protein.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"J Infect Dis 2015; 212:978-89; PMID:25748320; http://dx.doi.org/10.1093/infdis/jiv137 [18] Hafner L, Beagley K, Timms P. Chlamydia trachomatis infection: host immune responses and pote ntial vaccines.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Mucosal Immu- nol 2008; 1:116-30; PMID:19079169; http://dx.doi.org/10.1038/mi.2007.19 [19] Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C. Recent develop- ments in tuberculosis vaccines.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Exp Rev Vaccines 2013; 12:1431-48;PMID:24195481; http://dx.doi.org/10.1586/14760584.2013.856765 [20] Roth K, Ferreira VH, Kaushic C. HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Microb Pathog 2013; 58:45-54; PMID:23159485; http://dx.doi.org/10.1016/j.micpath.2012.11.001 [21] Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Lancet 2013; 381:1021-8; PMID:23391465; http://dx.doi.org/10.1016/S0140-6736(13)60177-4 [22] Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij JP.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"J Control Release 2014; 190:580- 92; PMID:24911355; http://dx.doi.org/10.1016/j.jconrel.2014.05.060 [23] Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, Perro M, Vrbanac VD, Tager AM, Shi J, et al.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Infect Immun 2016; 84:868-73; PMID:26787715; http://dx.doi.org/10.1128/IAI.01378-15 [25] Lorenzen E, Follmann F, Boje S, Erneholm K, Olsen AW, Agerholm JS, Jungersen G, Andersen P. Intramuscular priming and intranasalboosting induce strong genital immunity through secretory IgA in minipigs infected with chlamydia trachomatis.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Front Immunol 2015; 6:628; PMID:26734002; http://dx.doi.org/10.3389/ ﬁmmu.2015.00628 [26] Murthy AK, Chaganty BK, Li W, Guentzel MN, Chambers JP, Seshu J, Zhong G, Arulanandam BP.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"FEMS ImmunolMed Microbiol 2009; 55:271-9; PMID:19281569; http://dx.doi.org/10.1111/j.1574-695X.2008.00517.x [27] Finco O, Frigimelica E, Buricchi F, Petracca R, Galli G, Faenzi E, Meoni E, Bonci A, Agnusdei M, Nardelli F, et al.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"J Immunol 2008; 180:2459-65; http://dx.doi.org/10.4049/jimmunol.180.4.2459 [29] Meoni E, Faenzi E, Frigimelica E, Zedda L, Skibinski D, Giovinazzi S, Bonci A, Petracca R, Bartolini E, Galli G, et al.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Infect Immun 2009;77:4168-76; PMID:19596772; http://dx.doi.org/10.1128/IAI.00344-09 [30] Bulir DC, Liang S, Lee A, Chong S, Simms E, Stone C, Kaushic C, Ash- kar A, Mahony JB.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Vaccine 2016; 34:3979-85; PMID:27325352; http://dx.doi.org/10.1016/j.vaccine.2016.06.046 [31] Linhares IM, Witkin SS.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Cell Stress Chaperones 2010; 15:467-73; PMID:20182835; http://dx.doi.org/10.1007/s12192-010-0171-4 [32] Belland RJ, Nelson DE, Virok D, Crane DD, Hogan D, Sturdevant D, Beatty WL, Caldwell HD.",OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
Infect Immun 2004; 72:2420-4; PMID:15039373; http://dx.doi.org/10.1128/IAI.72.4.,Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"Nature medicine 2011; 17:189-94; PMID:21258338; http://dx.doi.org/10.1038/nm.2285 [35] R eece ST, Nasser-Eddine A, Dietrich J, Stein M, Zedler U, Schommer-Leitner S, Ottenhoff TH, Andersen P, Kaufmann SH.",Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
Vaccine 2011; 29:8740-4; PMID:21871515; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/33/be/khvi-13-04-1252886.PMC5404357.pdf
"4, 843 –853 http://dx.doi.org/10.1080/21645515.2016.1249551",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"ORCID Patricia U. Simioni http://orcid.org/0000-0002-6951-5040 References [1] Yang JC-H, Hirsh V, Schuler M, Yamamoto N, O ’Byrne KJ, Mok TSK, Zazulina V, Shahidi M, Lungershausen J, Massey D, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Oncol 2013; 31:3342-50; PMID:23816967; http://dx.doi.org/10.1200/JCO.2012.46.1764 [2] Gardiner N, Jogai S, Wallis A.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Available online: http://seer.cancer.gov/csr/1975_2011/ .,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Carcinog 2013; 12:22; PMID:24574860; http://dx.doi.org/10.4103/1477-3163.123972 [6] Liu SV, Subramaniam D, Cyriac GC, Abdul-Khalek FJ, Giaccone G. Emerging protein kinase inhibitors for non-small cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Cell 2006; 9:421-3; PMID:16766261; http://dx.doi.org/10.1016/j.ccr.2006.05.014 [8] Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Cancer 2014; 120:1471-81;PMID:24700479; http://dx.doi.org/10.1002/cncr.28604 [9] Hirsh V. The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Front Oncol 2015; 5:20; PMID:25692098; http://dx.doi.org/10.3389/fonc.2015.00020 [10] Herst PM, Berridge MV.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Curr Pharm Biotechnol 2013; 14:289-99; PMID:22201593; http://dx.doi.org/10.2174/ 1389201011314030005 [11] Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth F-W, Tonn J- C, Belka C. Therapeutic options for recurrent malignant glioma.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Eur J Cancer 2015; 51:1857-64;PMID:26187510; http://dx.doi.org/10.1016/j.ejca.2015.06.119 [13] Wu F, Chakravarti S. Differential expression of in ﬂammatory and ﬁbrogenic genes and their regulation by NF- B inhibition in a mouse model of chronic colitis.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Immunol 2007; 179:6988-7000;PMID:17982090; http://dx.doi.org/10.4049/jimmunol.179.10.6988 [14] Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Cancer Sci 2015; 106:883-90; PMID:25867139; http://dx.doi.org/10.1111/cas.12674848 A. P. S. SILVA ET AL.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Transl Med 2015; 13:32; PMID:25622640; http://dx.doi.org/10.1186/s12967-015-0397-0 [16] Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Mol Ther 2014;23:602-8; PMID:25531693; http://dx.doi.org/10.1038/mt.2014.243 [17] Kimura H, Matsui Y, Ishikawa A, Nakajima T, Yoshino M, Sakairi Y. Randomized controlled phase III trial of adjuvant chemo-immu-notherapy with activated killer T cells and dendritic cells in patientswith resected primary lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Immunol Immunother 2014; 64:51-9; PMID:25262164; http://dx.doi.org/10.1007/s00262- 014-1613-0 [18] Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Immunol Res 2014; 2:616-31;PMID:24942756; http://dx.doi.org/10.1158/2326-6066.CIR-14-0027 [19] Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Immunother; 37:105-14; PMID:24509173; http://dx.do i.org/10.1097/CJI.0000000000000020 [20] Zhang Y, Wang J, Wang Y, Lu X-C, Fan H, Liu Y, Zhang Y, Feng K- C, Zhang W-Y, Chen M-X, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
BMC Cancer 2013; 13:613; PMID:24373380; http://dx.doi.org/10.1186/1471-2407-13-613 [22] Ou S-HI.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Drug DesDevel Ther 2011; 5:471-85; PMID:22162641; http://dx.doi.org/ 10.2147/DDDT.S19045 [23] Liu C-M, Chiu K-L, Chen T-S, Chang S-M, Yang S-Y, Chen L-H, Ni Y-L, Sher Y-P, Yu S-L, Ma W-L.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Clin Lung Cancer 2011; 12:387- 92; PMID:21729650; http://dx.doi.org/10.1016/j.cllc.2011.02.004 [25] D ’Arcangelo M, Cappuzzo F. Erlotinib in the ﬁrst-line treatment of non-small-cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Expert Rev Anticancer Ther 2013;13:523-33; http://dx.doi.org/10.1586/era.13.23 [26] Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, C o s t aD B ,R a b i nM S ,J a c k m a nD M ,J o h n s o nB E .T h ei m p a c to fi n i t i a lgeﬁtinib or erlotinib versus chemoth erapy on central nervous system progression in advanced non-small cell lung cancer with EGFR muta- tions.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Expert Opin Biol Ther 2014; 14:1007-17;PMID:24702205; http://dx.doi.org/10.1517/14712598.2014.907786 [30] Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Cancer Immunol Res 2013;1:365-72; PMID:24563870; http://dx.doi.org/10.1158/2326-6066.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Future Oncol 2016; 12:931-43;PMID:26882955; http://dx.doi.org/10.2217/fon-2015-0012 [32] Quirk SK, Shure AK, Agrawal DK.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Transl Res 2015; 166:412-24;PMID:26118951; http://dx.doi.org/10.1016/j.trsl.2015.06.005 [33] Garon EB.,OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Semin Oncol 2015; 42 Suppl 2:S11-8; PMID:26477470;http://dx.doi.org/10.1053/j.seminoncol.2015.09.019 [34] Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lancet Oncol 2016; 17:299-308; PMID:26858122; http://dx.doi.org/10.1016/ S1470-2045(15)00544-6 [35] Peters S, Antonia S, Goldberg SB, Heymach JV, Kim ES, Nakagawa K, Papadimitrakopoulou V, Mukhopadhyay P, McIntosh S, Rizvi NA.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Thorac Oncol 2016; 11:S139-40; PMID:27198327; http://dx.doi.org/10.1016/S1556-0864(16)30300-8 [36] Mok T, Schmid P, Ar /C19en O, Arrieta O, Gottfried M, Jazieh AR, Ram- lau R, Timcheva K, Martin C, McIntosh S. 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumabcombination therapy versus standa rd of care (SoC) platinum-based chemotherapy in the ﬁrst-line treatment of patients (pts) with advanced or metastatic NSCLC.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Thorac Oncol 2016; 11:S140-1; PMID:27198329; http://dx.doi.org/10.1016/S1556-0864(16)30301-X [37] Owonikoko TKT, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Poly (ADP) ribose polymerase enzyme inhibitor, velipa rib, potentiates chemotherapy and r a d i a t i o ni nv i t r oa n di nv i v oi ns m a l lc e l ll u n gc a n c e r .C a n c e rM e d2014; 3:1579-94; PMID:25124282; http://dx.doi.org/10.1002/cam4.317 [38] Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: A new era of targeted therapy.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Maturitas 2015; 81:5-9; PMID:25708226; http://dx.doi.org/10.1016/j.maturitas.2015.01.015 [39] Owonikoko T, Dahlberg S, Khan S. A phase 1 safety study of veli- parib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN cancer research.Lung Cancer 2015; 89(1):66-70; http://dx.doi.org/10.1016/j.lungcan.2015.04.015 [40] Owonikoko T, Zhang G, Deng X. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radia-tion in vitro and in vivo in small cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Med 2014; 3(6):1579-1594; http://dx.doi.org/10.1002/cam4.317 [41] Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Tranda ﬁr L, Aimone P, Fretault N, Dharan B, Tavorath R, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Onco Targets Ther 2016; 9:203-10; PMID:26793003; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Oncologist 2010; 15:976-86; PMID: 20798193; http://dx.doi.org/10.1634/theoncologist.2008-0290HUMAN VACCINES & IMMUNOTHERAPEUTICS 849,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Clin Cancer Res 2006; 12:5268-72; PMID:17000658; http://dx.doi.org/10.1158/1078-0432.CCR-05-1554 [44] Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WEE, Paz-Ares L, St €orkel S, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lancet Oncol2012; 13:33-42; PMID:22056021; http://dx.doi.org/10.1016/S1470-2045(11)70318-7 [45] Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Clin Cancer Res 2011; 17:2521- 7; PMID:21248303; http://dx.doi.org/10.1158/1078-0432.CCR-10- 2662 [46] Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Clin Lung Cancer 2010; 11:198-203; PMID:20439197; http://dx.doi.org/10.3816/CLC.2010.n.026 [48] Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssou ﬁan H, Katz TL, Sheth G, Lee HJ.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Thorac Oncol 2013; 8:338-45; PMID:23370316; http://dx.doi.org/10.1097/JTO.0b013e318282ded5 [49] Langenberg MHG, Witteveen PO, Lankheet NAG, Roodhart JM, Rosing H, van den Heuvel IJGM, Beijnen JH, Voest EE.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Neoplasia 2010; 12:206-13;PMID:20126478; http://dx.doi.org/10.1593/neo.91864 [50] Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Mar- shall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, et al.Phase I dose-escalation study to determine the safety, pharmacoki- netics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinalmalignancies who have failed prior therapy.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Br J Cancer 2011;105:44-52; PMID:21629245; http://dx.doi.org/10.1038/bjc.2011.182 [51] Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Oncol 2010; 28:911-7; PMID:20100966; http://dx.doi.org/10.1200/JCO.2009.21.9618 [52] Li X, Shan B-E, Wang J, Xing L-P, Guo X-J, Zhang Y-H, Shi P-H, Wang Z-Y.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in can- cer patients: a meta-analysis of 21 randomized controlled trials.PLoS One 2013; 8:e81897; PMID:24312376; http://dx.doi.org/ 10.1371/journal.pone.0081897 [53] Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ram- lau R, Vynnychenko I, Park K, Yu C-T, Ganul V, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lancet (London, England) 2009; 373:1525-31; PMID:19410716; http://dx.doi.org/10.1016/S0140-6736(09)60569-9 [54] Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ram- lau R, Vynnychenko I, Park K, Eberhardt WEE, de Marinis F, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Lung Cancer 2012;77:376-82; PMID:22498112; http://dx.doi.org/10.1016/j.lungcan.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"PLoS One 2015; 10:e0125364; PMID:26020783; http://dx.doi.org/ 10.1371/journal.pone.0125364 [56] Ra ﬁi S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and hae- matopoietic stem cells: novel targets for anti-angiogenesis therapy?",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Nat Rev Cancer 2002; 2:826-35; PMID:12415253; http://dx.doi.org/ 10.1038/nrc925 [57] Gimbrone MA, Leapman SB, Cotran RS, Folkman J. Tumor angio- genesis: iris neovascularization at a distance from experimental intraocular tumors.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"MAbs 2010; 2:165-75; PMID:20190566; http://dx.doi.org/10.4161/mabs.2.2.11360 [59] Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Oncol 2005; 23:2544-55; PMID:15753462; http://dx.doi.org/ 10.1200/JCO.2005.02.477 [60] Becker S, Bohn P, Bouyeure-Petit A-C, Modzelewski R, Gensanne D, Picquenot J-M, Dubray B, Vera P. Bevacizumab enhances ef ﬁ- ciency of radiotherapy in a lung adenocarcinoma rodent model: Role of avb3 imaging in determining optimal window.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Nucl Med Biol 2015; 42:923-30; PMID:26410810; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Int J Radiat Oncol Biol Phys 2009; 75:463-7; PMID:19735869; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Expert Rev Anticancer Ther 2009; 9:425-35; PMID:19374597; http://dx.doi.org/10.1586/era.09.3 [65] Saijo H, Tatsumi N, Arihiro S, Kato T, Okabe M, Tajiri H, Hashi- moto H. Microangiopathy triggers, and inducible nitric oxide syn-thase exacerbates dextran sulfate sodium-induced colitis.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lab Invest 2015; 95:728-48; PMID:25938626; http://dx.doi.org/10.1038/ labinvest.2015.60 [66] Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R. Prediction of overall survival or progression free survival by dis- ease control rate at week 8 is independent of ethnicity: Western ver- sus Chinese patients with ﬁrst-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Pharmacol 2014; 54:253-7; PMID:24122760; http://dx.doi.org/ 10.1002/jcph.191 [67] Kubota T, Okano Y, Sakai M, Takaoka M, Tsukuda T, Anabuki K, Kawase S, Miyamoto S, Ohnishi H, Hatakeyama N, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Acad Sci U S A 2015; 112:1547-52; PMID:25605928; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Thorac Oncol 2013; 8:1409-16; PMID:24077452; http://dx.doi.org/ 10.1097/JTO.0b013e3182a46bcf [70] Keir ME, Butte MJ, Freeman GJ, Sharpe AH.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Invest 2015; 125:3384-91; PMID:26325035; http://dx.doi.org/10.1172/JCI80011 [72] Gridelli C, Besse B, Brahmer JR, CrinR L, Felip E, de Marinis F. The evolving role of nivolumab in non-small-cell lung cancer for sec- ond-line treatment: A new cornerstone for our treatment algo- rithms.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Clin Lung Cancer 2016; 17 (3):161-168; http://dx.doi.org/10.1016/j.cllc.2016.01.004; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26908078 .,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Oncologist 2016;21(5):634-642; http://dx.doi.org/10.1634/theoncologist.2015-0507;Available from: http://www.ncbi.nlm.nih.gov/pubmed/26984449 .,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Ann Oncol 2016; 27(7):1354-1356; http://dx.doi.org/10.1093/annonc/mdw148 [76] Seetharamu N, Budman DR, Sullivan KM.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Future Oncol 2016; 12(9):1151-1163; PMID:27019997; http://dx.doi.org/10.2217/fon.16.20 [77] Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Curr Treat Options Oncol 2014; 15:658-69; PMID:25096781; http://dx.doi.org/10.1007/s11864-014-0305-5 [78] Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors expressprogrammed death-ligand 1.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Oncologist 2016; 21:643-50; PMID:27026676; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"N Engl J Med 2015;372:2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa 1501824 [80] Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyr- phostins of the tyrosine kinase activity of the epidermal growth fac- tor receptor and analysis by a new computer program.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Oncologist 2014; 19:e5-11;PMID:25170012; http://dx.doi.org/10.1634/theoncologist.2014-0241 [82] Li X, Liu X, Gao F, Yin X. Crizotinib treatment in a lung adenocar- cinoma harboring ALK fusion gene with bone marrow metastasis:case report and literature review.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"N Engl J Med2014; 371:2167-77; PMID:25470694; http://dx.doi.org/10.1056/NEJMoa1408440 [86] Metro G, CrinRL.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Expert Rev Anticancer Ther 2011;11:673-82; PMID:21554040; http://dx.doi.org/10.1586/era.11.34 [87] Miller VA, Hirsh V, Cadranel J, Chen Y-M, Park K, Kim S-W, Zhou C, Su W-C, Wang M, Sun Y, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lancet Oncol 2012; 13:528-38; PMID:22452896; http://dx.doi.org/10.1016/ S1470-2045(12)70087-6 [88] Sequist LV, Yang JC-H, Yamamoto N, O ’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai C-M, Boyer M, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Oncol 2013; 31:3327-34;PMID:23816960; http://dx.doi.org/10.1200/JCO.2012.44.2806 [89] Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu C-P, O ’Byrne K, Feng J, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lancet Oncol 2015; 16:141-51; PMID:25589191; http://dx.doi.org/10.1016/S1470-2045(15)00400-3 [90] Geater SL, Xu C-R, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Thorac Oncol 2015; 10:883-9; PMID:25933111; http://dx.doi.org/10.1097/JTO.0000000000000517 [91] Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Drug Des Devel Ther 2014; 8:1037-46;PMID:25114510; http://dx.doi.org/10.2147/DDDT.S50358 [93] J €anne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Oncol 2012; 30:2063-9; http://dx.doi.org/10.1200/JCO.2011.40.1315 [94] Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib inpatients with multiple brain metastases from lung adenocarcinoma.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Pathol Oncol Res 2014; 20:11-25; PMID:24306880; http://dx.doi.org/10.1007/s12253-013-9719-9 [97] Yeo W-L, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huber- man MS, Kris MG, Tenen DG, Pao W, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Thorac Oncol 2010; 5:1048-53; PMID:20512075; http://dx.doi.org/ 10.1097/JTO.0b013e3181dd1386 [98] Cohen MH, Johnson JR, Chattopadhyay S, Tang S, Justice R, Srid- hara R, Pazdur R. Approval summary: erlotinib maintenance ther- apy of advanced/metastatic non-small cell lung cancer (NSCLC).",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Oncologist 2010; 15:1344-51; PMID:21148614; http://dx.doi.org/10.1634/theoncologist.2010-0257 [99] Yadav M, Singh AK, Kumar H, Rao G, Chakravarti B, Gurjar A, Dogra S, Kushwaha S, Vishwakarma AL, Yadav PN, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Biochim Biophys Acta 2016; 1860 (10):2178-2190; http://dx.doi.org/10.1016/j.bbagen.2016.05.011 [100] Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R. FDA approval of ge ﬁtinib for the treatment of patients with met- astatic EGFR mutation-positive non-small cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Clin Cancer Res 2016; 22:1307-12; PMID:26980062; http://dx.doi.org/10.1158/1078-0432.CCR-15-2266 [101] Bogdanowicz BS, Hoch MA, Hartranft ME.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Arch Physiol Biochem 2008; 114:23-37; PMID:18465356; http://dx.doi.org/10.1080/13813450801969715 [103] Bel ﬁore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid can-cer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Biochimie 1999; 81:403-7; PMID:10401676; http://dx.doi.org/ 10.1016/S0300-9084(99)80088-1 [104] Kim JG, Kang MJ, Yoon Y-K, Kim H-P, Park J, Song S-H, Han S-W, Park J-W, Kang GH, Kang KW, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"PLoS One 2012; 7:e33322; PMID:22438913; http://dx.doi.org/ 10.1371/journal.pone.0033322 [105] Langer CJ, Novello S, Park K, Krzakowski M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ, Jassem J. Randomized, phase III trial of ﬁrst-line ﬁgitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patientswith advanced non-small-cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
J Clin Oncol 2014; 32:2059-66; PMID:24888810; http://dx.doi.org/10.1200/JCO.2013.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Oncol 2010; 28:4985-95; PMID:20975071; http://dx.doi.org/10.1200/JCO.2009.27.5040 [107] Rossi A, Maione P, Bareschino MA, Schettino C, Sacco PC, Ferrara ML, Castaldo V, Gridelli C. The emerging role of histology in the choice of ﬁrst-line treatment of advanced non-small cell lung can- cer: implication in the clinical decision-making.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Curr Med Chem2010; 17:1030-8; PMID:20156162; http://dx.doi.org/10.2174/ 092986710790820589 [108] Pearson JW, Sivam G, Manger R, Wiltrout RH, Morgan AC, Longo DL.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Clin Nucl Med 2000; 25:54-5;PMID:10634533; http://dx.doi.org/10.1097/00003072-200001000-00013 [110] Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Semin Nucl Med 2002; 32:276-92; PMID:12524652;http://dx.doi.org/10.1053/snuc.2002.126053 [111] Okamoto I. Nimotuzumab, a novel monoclonal antibody to the epi- dermal growth factor receptor, in the treatment of non-small cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lung Cancer Targets Ther 2011; 2:59; http://dx.doi.org/10.2147/LCTT.S16440[112] Lin S, Yan Y, Liu Y, Gao C-Z, Shan D, Li Y, Han B. Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimo-tuzumab is associated with enhanced apoptosis and cell cycle arrestin the G2/M phase.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cell Biol Int 2015; 39:146-51; PMID:25044496; http://dx.doi.org/10.1002/cbin.10342 [113] Choi HJ, Sohn JH, Lee CG, Shim HS, Lee I-J, Yang WI, Kwon JE, Kim SK, Park M-S, Lee JH, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"LungCancer 2011; 71:55-9; PMID:20451284; http://dx.doi.org/10.1016/j.lungcan.2010.04.010 [114] Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R, Brade A.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Chemother Phar- macol 2011; 67:837-45; PMID:20563810; http://dx.doi.org/10.1007/s00280-010-1379-9 [115] Qi D-L, Wang H-Q, Li Y, Huang C-B, Wang Q-S, Xu L, Yang Y-Z, Cui Y, Xin L. Ef ﬁcacy and adverse effets of nimotuzumab plus pali- taxel liposome and carboplatin in the treatment for advanced non-small cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Biol Ther 2014; 15:504-9; PMID:24521695; http://dx.doi.org/10.4161/cbt.28021 [117] Kim SH, Shim HS, Cho J, Jeong JH, Kim SM, Hong YK, Sung JH, Ha S-J, Kim HR, Chang H, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Lung Cancer 2013; 79:270-5; PMID:23261229; http://dx.doi.org/10.1016/j.lungcan.2012.11.017 [118] D ’Arcangelo M, Cappuzzo F. Focus on the potential role of ﬁclatu- zumab in the treatment of non-small cell lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Biologics2013; 7:61-8; Available from: https://www.dovepress.com/focus-on- the-potential-role-of- ﬁclatuzumab-in-the-treatment-of-non-sm- peer-reviewed-article-BTT .,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Br J Cancer 2014; 111:272-80; PMID:24901237; http://dx.doi.org/10.1038/bjc.2014.290 [120] Scagliotti GV, Novello S, von Pawel J.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Treat Rev 2013; 39:793-801; PMID:23453860; http://dx.doi.org/10.1016/j.ctrv.2013.02.001 [121] Go /C19zdzik-Spychalska J, Szyszka-Barth K, Spychalski L, Ramlau K, W/C19ojtowicz J, Batura-Gabryel H, Ramlau R. C-MET inhibitors in the treatment of lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Curr Treat Options Oncol 2014; 15:670-82; PMID:25266653; http://dx.doi.org/10.1007/s11864-014-0313-5 [122] Branstetter D, Rohrbach K, Huang L-Y, Soriano R, Tometsko M, Blake M, Jacob AP, Dougall WC.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Bone Oncol 2015; 4:59-68; PMID:27556008; http://dx.doi.org/10.1016/j.jbo.2015.06.002 [123] Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Thorac Oncol 2012; 7:1823-9; PMID:23154554; http://dx.doi.org/10.1097/ JTO.0b013e31826aec2b [124] Carbone F, Crowe LA, Roth A, Burger F, Lenglet S, Braunersreuther V, Brandt KJ, Quercioli A, Mach F, Vall /C19ee J-P, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Mol Cell Cardiol2016; 94:82-94; PMID:27056420; http://dx.doi.org/10.1016/j.yjmcc.2016.03.013 [125] Krummel MF, Allison JP.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
J Exp Med 1995; 182:459-65; PMID:7543139; http://dx.doi.org/10.1084/jem.182.2.459852 A. P. S. SILVA ET AL.,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Update Cancer Ther 2007; 2:133-9; PMID:19543441; http://dx.doi.org/10.1016/j.uct.2007.09.001 [127] Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Am J Ophthalmol 2007; 143:958-69; PMID: 17434437; http://dx.doi.org/10.1016/j.ajo.2007.02.035 [128] Tarhini AA, Kirkwood JM.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Thorac Oncol 2015; 10:1319-27; PMID:26098748; http://dx.doi.org/10.1097/JTO.0000000000000607 [130] James A, Blumenstein L, Glaenzel U, Jin Y, Demailly A, Jakab A, Hansen R, Hazell K, Mehta A, Tranda ﬁr L, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Chemother Pharmacol 2015;76:751-60; PMID:26254025; http://dx.doi.org/10.1007/s00280-015- 2842-4 [131] Mayer IA, Abramson V, Formisano L, Balko JM, Estrada MV, Sanders M, Juric D, Solit D, Berger MF, Won H, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Drug Resist Updat 2016; 24:13-22; PMID:26830312; http://dx.doi.org/10.1016/j.drup.2015.11.001 [134] Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"J Clin Oncol 2014; 32:1202-9; PMID:24663045; http://dx.doi.org/10.1200/JCO.2013.54.0518 [135] Rodon J, Bra ~na I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tom- aso E, Sarr C, Tranda ﬁr L, Massacesi C, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Phase I dose-escala- tion and -expansion study of buparlisib (BKM120), an oral pan- Class I PI3K inhibitor, in patients with advanced solid tumors.Invest New Drugs 2014; 32:670-81; PMID:24652201; http://dx.doi.org/10.1007/s10637-014-0082-9 [136] Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Cancer Chemother Pharmacol 2015; 75:747-55; PMID:25672916; http://dx.doi.org/10.1007/s00280-015-2693-z [137] Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Van- steenkiste J, Van Cutsem E, P /C19erez-Garc /C19ıa J, Stathis A, Britten CD, et al.",Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"Clin Cancer Res 2015; 21:730-8; PMID:25500057; http://dx.doi.org/10.1158/1078-0432.CCR-14-1814 [138] Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, Sato M, Kakizume T, Robson M, Quadt C, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"CancerSci 2014; 105:347-53; PMID:24405565; http://dx.doi.org/10.1111/ cas.12350 [139] Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, et al.",OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
Clin Cancer Res 2014; 20:1935-45; PMID:24470511; http://dx.doi.org/10.1158/1078-0432.CCR-13-1070HUMAN VACCINES & IMMUNOTHERAPEUTICS 853,Non-OADS,/arxiv_data1/oa_pdf/2e/59/khvi-13-04-1249551.PMC5404364.pdf
"For more information visit http://intervexion.com/ CONTACT Misty Stevens misty.stevens@intervexion.com 4301 W. Markham St. #831, Little Rock, AR 72205, USA.",Non-OADS,/arxiv_data1/oa_pdf/4a/0a/khvi-13-04-1294955.PMC5404366.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.HUMAN VACCINES & IMMUNOTHERAPEUTICS 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/4a/0a/khvi-13-04-1294955.PMC5404366.pdf
"4, 740http://dx.doi.org/10.1080/21645515.2017.1294955",Non-OADS,/arxiv_data1/oa_pdf/4a/0a/khvi-13-04-1294955.PMC5404366.pdf
"4, 784 –785 http://dx.doi.org/10.1080/21645515.2016.1250049",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"BMJ Open 2014; 4(6):C004833; http://dx.doi.org/ 10.1136/bmjopen-2014-004833 [2] Gagliardi AMZ, Andriolo BNG, Torloni MR, Soares BGO.",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"Cochrane Database Syst Rev 2016; 3:CD008858; http://dx.doi.org/10.1002/14651858.CD008858.pub3 [3] Mick G, Hans G. Post herpetic neuralgia in Europe: the scale of the problem and outlook for the future.",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"J Clin Geront Geriatrics 2013; 4: 102-8; http://dx.doi.org/10.1016/j.jcgg.2013.03.001 [4] Oxman MN, Levin MJ and Shingles Prevention Study Group.",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"J Infect Dis 2008; 197: S228-36; PMID:18419402; http://dx.doi.org/10.1086/522159 [5] Halperin S, Kohl KS, Gidudu J, Ball L, Hammer SJ, Heath P, Hennig R, Labadie J, Rothstein E, Schuind A, et al.",OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"Vaccine 2007; 25: 5803-20; PMID: 17548135; http://dx.doi.org/10.1016/j.vaccine.2007.04.059 [6] Vesikari T, Hardt R, Rumke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A. Immunogenicity and safety of a live attenuatedshingles (herpes zoster) vaccine (Zostavax /C210) in individuals ages /C21 70 years.",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
Human Vaccin Immunother 2013; 9: 858-64; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
Clin Infect Dis 2013; 56: 1763-4; PMID:23457076; http://dx.doi.org/10.1093/cid/cit126 [8] Cook IF.,OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"Pediatr Infect Dis J 1993; 12: 368-71; PMID:8327295; http://dx.doi.org/10.1097/00006454-199305000-00003 [10] Woo EJ, Burwen DR, Gatumu SNM, Ball R and the Vaccine Adverse Event Reporting System (VAERS).",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"Clin Infect Dis 2003; 37: 351-8; PMID:12884159; http://dx.doi.org/10.1086/375820 [11] Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, et al.",OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
Pediatrics 1997; 100: 772-88; PMID:9346976; http://dx.doi.org/10.1542/peds.100.5.772 [12] Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as aﬁve-dose series: Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).,Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"MMWR 2000, 49 (RR13): 1-8; available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4913ai.htm [13] Nelson K, Goldman JA, Perlino CA.",OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"South Med J 1980; 73: 264-5; PMID:7355337;http://dx.doi.org/10.1097/00007611-198002000-00042 [14] Hasan S, Yousef M, Shridarani S. Severe febrile systemic reaction to pneumococcal vaccine.",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"Allergy Asthma Proc 2008; 29: 397-9; PMID:18702888; http://dx.doi.org/10.2500/aap.2008.29.3144 [17] Moore L, Remy V, Martin AM, Beillat M, McGuire A.",Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
Cost Eff Resour Alloc 2010; 30: 8; http://dx.doi.org/10.1186/1478-7547-8-7HUMAN VACCINES & IMMUNOTHERAPEUTICS 785,Non-OADS,/arxiv_data1/oa_pdf/8f/27/khvi-13-04-1250049.PMC5404368.pdf
"This study conforms to all STROBE guidelines and reports the required information accordingly (see Supple-mentary Checklist, http://links.lww.com/PHM/A316).",Non-OADS,/arxiv_data1/oa_pdf/53/06/phm-96-315.PMC5404395.pdf
"A validation framework is provided in the on- line supplemental digital content (Appendix A, http://links.lww.com/PHM/A317).",Non-OADS,/arxiv_data1/oa_pdf/53/06/phm-96-315.PMC5404395.pdf
"Cell culture Cancer cells were grown in cell culture media recom-mended by the vendors, and supplemented with 10% FBS maintained at 37 °C in a humidified atmosphere at 5% CO 2(Supplementary Table 1, Supplemental digital content 1, http://links.lww.com/ACD/A194 ).",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
Mutation analysis Mutational status of cell lines was obtained from the COSMIC database ( http://cancer.sang er.ac.uk/cosmic ).,OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"Reverse phase protein analysis AN3CA, IGROV-1, and Caov-3 cells were plated in a six-well plate and then treated with various concentrations of ARQ 092 or ARQ 087 as single agents or combination for 2 h. The cell pellet was collected, snap frozen, and shipped to Theranostics Health (Gaithersburg, Maryland, USA) ( http://www.theranosticshealth.com ).",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"Combined treatment of ARQ 092 and ARQ 087 resulted in a synergistic effect in 24% (11 out of 45), additive in 62% (28 out 0 f 45), and antagonistic in 13% (6 out of 45) of cancer cell lines tested (Supplementary Table 2, Supplemental digital content 1, http://links.lww.com/ACD/ A194 ).",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"To determine whether syner- gism of ARQ 087 and ARQ 092 can be predicted by genetic characteristics of treated cells, we analyzed the somatic mutational status of selected genes in the entire Table 1 Combination of ARQ 092 and ARQ 087 showed more synergism in endometrial and ovarian cancer cell lines Combination Cell lines Origin Tissue type CI Effect MFE296 Endometrial Adenocarcinoma 0.43 ±0.16 Synergistic AN3CA Endometrial Adenocarcinoma 0.48 ±0.20 Synergistic EN Endometrial Adenocarcinoma 0.67 ±0.13 Synergistic MFE-280 Endometrial Adenocarcinoma 0.70 ±0.10 Synergistic SNG-II Endometrial Adenocarcinoma 0.90 ±0.12 Additive Ishikawa Endometrial Adenocarcinoma 0.91 ±0.06 Additive HEC-1B Endometrial Adenocarcinoma 0.95 ±0.15 Additive HEC-251 Endometrial Adenocarcinoma 0.96 ±0.06 Additive RL95 –2 Endometrial Adenosquamous 1.00 ±0.00 Additive IGROV-1 Ovary Adenocarcinoma 0.59 ±0.21 Synergistic SKOV-3 Ovary Adenocarcinoma 0.80 ±0.12 Synergistic OVCAR3 Ovary Adenocarcinoma 0.82 ±0.08 Synergistic TOV21G Ovary Clear cell 0.92 ±0.11 Additive MCAS Ovary Mucinous 0.92 ±0.05 Additive CaoV-3 Ovary Adenocarcinoma 1.01 ±0.06 Additive OVMANA Ovary Clear cell 1.01 ±0.06 Additive OVISE Ovary Clear cell 1.34 ±0.12 Antagonistic Combination study of ARQ 092 and ARQ 087 was performed in 45 cancer cell lines (Supplementary Table 2, Supplemental digital content 1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"1b and Supplementary Table 2, Supplemental digital content 1, http://links.lww.com/ACD/ A194 , in cell lines with mutant PIK3CA/PIK3R1, 59% (10 out of 17) of cell lines with wild-type Ras showed synergism; however, only 8% (1 out of 12) of cell lines with mutant Ras displayed synergism following ARQ 087and ARQ 092 treatment.",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"1(Supplemental digital content 1, http://links.lww.com/ACD/ A194 ) in AN3CA cells, combined treatment led to cell cycle arrest in G1 phase, concomitant with a decrease inthe percentage of cells in S phase.",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"2 (Supplemental digital content 1, http://links.lww.com/ACD/A194 ), ARQ 092 inhibited AKT phosphorylation and its downstream targets PRAS40 and S6 but elevated phopho ERK, whereas ARQ 087 sup- pressed FGFR phosphorylation.",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"3, Supplemental digital content 1, http://links.lww.com/ACD/A194 ).",Non-OADS,/arxiv_data1/oa_pdf/2f/d2/cad-28-503.PMC5404396.pdf
"The English version of the survey used in the UnitedStates is included as Supplemental Digital Content 1, http://links.lww.com/MP A/A587.",Non-OADS,/arxiv_data1/oa_pdf/45/7e/mpa-46-639.PMC5404397.pdf
Then the data were inspected with the artifact detection toolbox (ART: http://www.nitrc.org/proj-ects/artifact_detect).,OADS,/arxiv_data1/oa_pdf/7f/9f/jhype-35-1252.PMC5404398.pdf
"It resulted in a scattered pattern of small clusters across thewhole brain [see the figure, Supplemental Digital Content (SDC) 1, http://links.lww.com/HJH/A735, which illustrates the significant clusters and the table, SDC 2, http://links.lww.com/HJH/A736, which lists direct coordinates and Z- statistics for the peak voxels of the significant clusters).",OADS,/arxiv_data1/oa_pdf/7f/9f/jhype-35-1252.PMC5404398.pdf
"The dataproved so with intergroup differences forming continuous clusters along the brain midline (see the figure, SDC 3, http://links.lww.com/HJH/A737, which illustrates theuncorrected results of the full factorial fMRI analysis).",Non-OADS,/arxiv_data1/oa_pdf/7f/9f/jhype-35-1252.PMC5404398.pdf
"But distinctively – no Left hemisphere Right hemisphere Superior view Superior view 07 07CON > HTN HTN > VONZ  value Z  value0 Z  value 10Inferior view Left hemisphere Right hemisphere Inferior viewCondition main effect (a) (b) Group effects FIGURE 2 A surface template brain presentation of the significant clusters of the functional MRI full factorial analysis with task conditions (control, reading, congru- ent, incongruent) and groups (the control group and the hypertensive group) as factors ( P<0.05, family-wise error corrected at voxel level, masked with covariate BMI and waist–hip ratio dependent map – see the Results section and Supple-mental Digital Content 1, http://links.lww.com/HJH/A735 and Supplemental Digital Content 2, http://links.lww.com/HJH/A736 for details).",Non-OADS,/arxiv_data1/oa_pdf/7f/9f/jhype-35-1252.PMC5404398.pdf
*A list of all EMERG-AF Investigators is given in the Appendix.The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.,OADS,/arxiv_data1/oa_pdf/4e/5b/str-48-1344.PMC5404399.pdf
E-mail bcvinent@clinic.cat Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.116.014855 © 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/4e/5b/str-48-1344.PMC5404399.pdf
"Baseline-adjusted results for estradiol were similar to the unadjusted results (Supplemental Table S1, Supplemental Digital Content 1, http://links.lww.com/MENO/A205).",OADS,/arxiv_data1/oa_pdf/10/a6/menop-24-510.PMC5404400.pdf
Clinical Trial Registration —URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368268.,Non-OADS,/arxiv_data1/oa_pdf/77/97/str-48-1293.PMC5404401.pdf
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.116.016293,Non-OADS,/arxiv_data1/oa_pdf/77/97/str-48-1293.PMC5404401.pdf
2012; Available from: http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/dcp171776_258607.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8d/4d/jhype-35-1276.PMC5404403.pdf
Clinical Trial Registration —URL: http://www.clinicaltrials.gov .,Non-OADS,/arxiv_data1/oa_pdf/55/2a/str-48-1262.PMC5404405.pdf
The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.,OADS,/arxiv_data1/oa_pdf/55/2a/str-48-1262.PMC5404405.pdf
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.116.014321,Non-OADS,/arxiv_data1/oa_pdf/55/2a/str-48-1262.PMC5404405.pdf
http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2010/09/WC500096793.pdf.,Non-OADS,/arxiv_data1/oa_pdf/55/2a/str-48-1262.PMC5404405.pdf
CLINICAL TRIAL REGISTRATION: URL: http://clinicaltrials.gov .,Non-OADS,/arxiv_data1/oa_pdf/1b/d8/cir-135-1586.PMC5404406.pdf
"29 Therefore, we are conducting a multicenter,  stepped-wedge, cluster randomized trial to determine the  efficacy and safety of our pathway (Figure II in the online- only Data Supplement) in unselected consecutive patients  across Scotland (URL: http://clinicaltrials.gov .",Non-OADS,/arxiv_data1/oa_pdf/1b/d8/cir-135-1586.PMC5404406.pdf
The online-only Data Supplement is available with this arti- cle at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/  CIRCULATIONAHA.116.025021/-/DC1.,Non-OADS,/arxiv_data1/oa_pdf/1b/d8/cir-135-1586.PMC5404406.pdf
Circulation is available at http://circ.ahajournals.org.,Non-OADS,/arxiv_data1/oa_pdf/1b/d8/cir-135-1586.PMC5404406.pdf
2014. https://www.nice.org.uk/guidance/dg15.,Non-OADS,/arxiv_data1/oa_pdf/1b/d8/cir-135-1586.PMC5404406.pdf
"The MENQOL was first introduced in China by our team in 2002.12The translated Chinese version (see Appendix, Supplemental Digital Content 1, http://links.lww.com/MENO/A199, which is the Chinese version of MENQOL) was approved, and permission was granted to use the questionnaire.",Non-OADS,/arxiv_data1/oa_pdf/b5/42/menop-24-546.PMC5404407.pdf
"The online-only Data Supplement, podcast, and transcript are  available with this article at http://circ.ahajournals.org/lookup/ suppl/doi:10.1161/CIRCULATIONAHA.116.025629/-/DC1.",Non-OADS,/arxiv_data1/oa_pdf/02/79/cir-135-1577.PMC5404408.pdf
Circulation is available at http://circ.ahajournals.org.,Non-OADS,/arxiv_data1/oa_pdf/02/79/cir-135-1577.PMC5404408.pdf
"17 Procedures were identified using the following current  procedural terminology (CPT) codes: 19160, 19162, 19180,  19182, 19200, 19220, 19240, 19301, 19302, 19303, 19304,  19305, 19306, and 19307 for mastectomy (either partial or total), and 19340, 19342, 19357, 19361, 19364, 19366, 19367, 19368, and 19369 for breast reconstruction (see  table, Supplemental Digital Content 1, which provides a de-scription of the CPT codes utilized for this study; http://links.lww.com/PRSGO/A359).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"(see table, Supplemental Digital Content 1, http://links.lww.com/PRSGO/A359).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"The population demographic characteristics are shown in table, Supplemental Digital Content 2, which displays gen-eral and preoperative patient characteristics; http://links.lww.com/PRSGO/A360.",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"For all outcomes, complication rates of the exposed group (those receiving NRT) were compared with the unexposed group (those not receiving NRT; see table, Supplemental Digital  Content 3, which displays percentages of patients by NRT  status who experienced morbidity; http://links.lww.com/PRSGO/A361).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"Similarly, after adjustment using multivari- able regression, NRT was not associated with higher local complication rates in the group undergoing mastectomy alone (aOR = 1.41; 95% CI: 0.76–2.63, P  = 0.276; see ta- ble, Supplemental Digital Content 2, http://links.lww.com/ PRSGO/A360).Immediate Reconstruction Group (Mastectomy with Concurrent  Reconstruction) Among 75 patients in the immediate breast reconstruc- tion group who received NRT, four (5.3%) experienced  local morbidity.",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"Moreover, after extensive adjustment using mul- tivariable regression, NRT was not associated with higher  surgical site morbidity rates in this group (aOR = 1.05; 95%  CI: 0.37–2.96, P  = 0.934; see table, Supplemental Digital  Content 2, http://links.lww.com/PRSGO/A360).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"Additionally, we identified the predictors of 30-day  surgical site morbidity among women undergoing mastec-tomy with or without immediate reconstruction (see table,  Supplemental Digital Content 4, which displays predictors  of 30-day surgical site morbidity among women undergo- ing mastectomy with or without immediate reconstruc- tion; http://links.lww.com/PRSGO/A362).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"PRS Global Open • 2017 4Correspondingly, after extensive adjustment using multi- variable regression, NRT was not associated with higher systemic morbidity rates in this group (aOR = 0.72; 95% CI: 0.40–1.26, P = 0.252; see table, Supplemental Digital  Content 3, http://links.lww.com/PRSGO/A361).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"Ad-ditionally, after adjustment using multivariable regression, NRT was not associated with higher systemic morbid-ity rates in this group (aOR = 1.14; 95% CI: 0.47–2.73, P = 0.773; see table, Supplemental Digital Content 3, http://links.lww.com/PRSGO/A361).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"Independent predictors of 30-day systemic morbid- ity among women undergoing mastectomy with or with-out immediate reconstruction included increasing age, NCT, BMI, smoking, work relative value unit, operation year, ASA classes 2 and 3, contaminated or dirty/infected wounds, previous respiratory or hematology/oncology morbidity, increasing operative time, and Asian race (see table, Supplemental Digital Content 5, which displays  predictors of 30-day systematic morbidity among women  undergoing mastectomy with or without immediate recon-struction; http://links.lww.com/PRSGO/A363).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"Similarly, after adjustment us- ing multivariable regression, NRT was not associated with higher overall morbidity in this group (aOR = 0.85; 95% CI: 0.54–1.33; P = 0.477; see table, Supplemental Digital Content  4, http://links.lww.com/PRSGO/A362).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"Analogously, after adjustment using multivari- able regression, NRT did not show significant association  with higher overall morbidity in this group (aOR = 1.54; 95% CI: 0.78–3.04; P  = 0.215; see table, Supplemental Digi- tal Content 4, http://links.lww.com/PRSGO/A362).Finally, we identified the predictors of overall 30-day  postoperative morbidity among women undergoing mas- tectomy with or without immediate reconstruction (see ta- ble, Supplemental Digital Content 6, which displays overall  30-day postoperative morbidity among women undergo-ing mastectomy with or without immediate reconstruc-tion; http://links.lww.com/PRSGO/A364).",Non-OADS,/arxiv_data1/oa_pdf/80/b8/gox-5-e1108.PMC5404430.pdf
"One plas-tic surgeon and 1 mammography nurse commented on the décolleté, the position of the implant, and difference  between the left and right breast, due to use of different  operation techniques (Table 7; see figure, Suppplemental  Digital Content 1, http://links.lww.com/PRSGO/A392).",Non-OADS,/arxiv_data1/oa_pdf/d4/c0/gox-5-e1254.PMC5404439.pdf
"6,18,21–31 Sub- clinical infections where bacteria remain dormant within  a protective biofilm have also been implicated in capsule  formation and contracture32–34 (see figure, Supplemental  Digital Content 1, http://links.lww.com/PRSGO/A390).",Non-OADS,/arxiv_data1/oa_pdf/97/4f/gox-5-e1258.PMC5404443.pdf
"More recently, proteins, members of the TGFβ family,  have been identified as proinflammatory and profibrotic  agents and controllers of the inflammatory response (see  figure, Supplemental Digital Content 1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/97/4f/gox-5-e1258.PMC5404443.pdf
"37 The capacity of Fst to bind activins  and attenuate their inflammatory and fibrotic actions has established Fst as a potential therapeutic agent for limit- ing inflammation and fibrosis associated with capsular  contracture 36,37 (see figure, Supplemental Digital Content  1, http://links.lww.com/PRSGO/A390).",Non-OADS,/arxiv_data1/oa_pdf/97/4f/gox-5-e1258.PMC5404443.pdf
"• Breast capsular contracture Serum Cytokines and Fst288 Serum activin A levels were significantly higher  (48.6%) in the Fst implant group (49.3 ± 3.9 pg/mL, n = 7)  compared with those in the baseline group (25.4 ± 3.7  pg/mL, n = 7) at day 7 (mean difference 23.9 ± 5.4 pg/ mL, P  < 0.01; see figure, Supplemental Digital Content 2,  http://links.lww.com/PRSGO/A391).",Non-OADS,/arxiv_data1/oa_pdf/97/4f/gox-5-e1258.PMC5404443.pdf
"Serum IL-6 levels in the Fst implant group (2.6 ± 2.1  pg/mL, n = 7) decreased significantly (79.7%) compared  with those in the baseline group (12.9 ± 3.6 pg/mL, n = 7)  at day 3 (mean difference 10.3 pg/mL, P < 0.05; see fig-ure, Supplemental Digital Content 2, http://links.lww.com/ PRSGO/A391).",Non-OADS,/arxiv_data1/oa_pdf/97/4f/gox-5-e1258.PMC5404443.pdf
This video is  available in the “Related Videos” section of the Full-Text  article on PRSGlobalOpen.com or available at http://links.lww.com/PRSGO/A394.,Non-OADS,/arxiv_data1/oa_pdf/c4/da/gox-5-e1270.PMC5404453.pdf
This video is available in the “Re- lated Videos” section of the Full-Text article on PRSGlo- balOpen.com or available at http://links.lww.com/PRSGO/ A395.,Non-OADS,/arxiv_data1/oa_pdf/c4/da/gox-5-e1270.PMC5404453.pdf
http://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c4/da/gox-5-e1270.PMC5404453.pdf
Available  at: http://apps.who.int/medicinedocs/documents/s19032en/ s19032en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/24/cd/gox-5-e1282.PMC5404456.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0120; March 2017 DOI: 10.1530/EDM-16-0120Full-length S TAR for  physiological requirementA Piya and others De novo  disruption of promoter and exon 1 of  STAR  gene reveals essential role for gonadal  development Anil Piya1,2, Jasmeet Kaur1,4, Alan M Rice2,3 and Himangshu S Bose1,4 1Laboratory of Biochemistry, Mercer University School of Medicine, Savannah, Georgia, USA, 2Division of Pediatric  Endocrinology, Memorial University Medical Center, Savannah, Georgia, USA, 3Augusta University School of  Medicine, Augusta, Georgia, USA, and 4Anderson Cancer Institute, Memorial University Medical Center, Savannah,  Georgia, USA Summary Cholesterol transport into the mitochondria is required for synthesis of the first steroid, pregnenolone.",Non-OADS,/arxiv_data1/oa_pdf/25/84/edmcr-2017-160120.PMC5404458.pdf
"A Piya and others Full-length S TAR for  physiological requirementID: 16-0120; March 2017 DOI: 10.1530/EDM-16-0120 http://www.edmcasereports.com  2Although a large number of clinical reports from Japan  have described patients with large adrenal glands and  babies born with abnormal female genitalia, more detailed  information is missing ( 4).",Non-OADS,/arxiv_data1/oa_pdf/25/84/edmcr-2017-160120.PMC5404458.pdf
"A Piya and othersID: 16-0120; March 2017 DOI: 10.1530/EDM-16-0120 Full-length S TAR for  physiological requirement http://www.edmcasereports.com  3which was reduced to 36 ng/mL/h after 18 days (1–7 days:  2.0–35.0 ng/mL/h); aldosterone levels were 6.5 ng/dL  (1–3 weeks: 6.0–179 ng/dL), ACTH levels were 842 pg/mL  (high) and cortisol was 2.8 µg/dL at 15:56 h (am: 6.7–22.6,  pm: <10 µg/dL).",Non-OADS,/arxiv_data1/oa_pdf/25/84/edmcr-2017-160120.PMC5404458.pdf
A Piya and others Full-length S TAR for  physiological requirementID: 16-0120; March 2017 DOI: 10.1530/EDM-16-0120 http://www.edmcasereports.com  4mineralocorticoid replacement.,Non-OADS,/arxiv_data1/oa_pdf/25/84/edmcr-2017-160120.PMC5404458.pdf
A Piya and othersID: 16-0120; March 2017 DOI: 10.1530/EDM-16-0120 Full-length S TAR for  physiological requirement http://www.edmcasereports.com  5protein that is identified after cleavage of the N-terminal  sequence (arrowhead).,Non-OADS,/arxiv_data1/oa_pdf/25/84/edmcr-2017-160120.PMC5404458.pdf
A Piya and others Full-length S TAR for  physiological requirementID: 16-0120; March 2017 DOI: 10.1530/EDM-16-0120 http://www.edmcasereports.com  6Declaration of interest The authors declare that there is no conflict of interest that could be  perceived as prejudicing the impartiality of the research reported.,Non-OADS,/arxiv_data1/oa_pdf/25/84/edmcr-2017-160120.PMC5404458.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0131; March 2017 DOI: 10.1530/EDM-16-0131Ocular changes from cocaine  mimic diabetesW L Stuard and others Alterations in corneal nerves following crack  cocaine use mimic diabetes-induced   nerve damage Whitney L Stuard, Bryan K Gallerson  and Danielle M Robertson Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas, USA Summary The use of in vivo  confocal microscopy (IVCM) is rapidly emerging as an important clinical tool to evaluate changes in  corneal sensory nerves as a surrogate measure for diabetic peripheral neuropathy.",Non-OADS,/arxiv_data1/oa_pdf/e7/41/edmcr-2017-160131.PMC5404459.pdf
W L Stuard and others Ocular changes from cocaine  mimic diabetesID: 16-0131; March 2017 DOI: 10.1530/EDM-16-0131 http://www.edmcasereports.com  2diabetes ( 2).,OADS,/arxiv_data1/oa_pdf/e7/41/edmcr-2017-160131.PMC5404459.pdf
W L Stuard and othersID: 16-0131; March 2017 DOI: 10.1530/EDM-16-0131 Ocular changes from cocaine  mimic diabetes http://www.edmcasereports.com  3for remote controlled scanning and real-time image  streaming.,Non-OADS,/arxiv_data1/oa_pdf/e7/41/edmcr-2017-160131.PMC5404459.pdf
W L Stuard and others Ocular changes from cocaine  mimic diabetesID: 16-0131; March 2017 DOI: 10.1530/EDM-16-0131 http://www.edmcasereports.com  4heroin addicts for ocular surface disease ( 5).,OADS,/arxiv_data1/oa_pdf/e7/41/edmcr-2017-160131.PMC5404459.pdf
W L Stuard and othersID: 16-0131; March 2017 DOI: 10.1530/EDM-16-0131 Ocular changes from cocaine  mimic diabetes http://www.edmcasereports.com  5Patient consent Written informed consent was acquired prior to her participation in the  study.,Non-OADS,/arxiv_data1/oa_pdf/e7/41/edmcr-2017-160131.PMC5404459.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0109; February 2017 DOI: 10.1530/EDM-16-0109Diabetic ketoacidosis in   type 2 diabetesC Small and others Diabetic ketoacidosis: a challenging diabetes  phenotype Cliona Small, Aoife M Egan, El Muntasir Elhadi, Michael W O’Reilly,   Aine Cunningham  and Francis M Finucane HRB Clinical Research Facility, Galway University Hospitals, National University of Ireland,   Galway, Ireland Summary We describe three patients presenting with diabetic ketoacidosis secondary to ketosis prone type 2, rather than type 1  diabetes.",Non-OADS,/arxiv_data1/oa_pdf/70/e4/edmcr-2017-160109.PMC5404460.pdf
C Small and others Diabetic ketoacidosis in   type 2 diabetesID: 16-0109; February 2017 DOI: 10.1530/EDM-16-0109 http://www.edmcasereports.com  2phenotype and differentiate between type 1 and ketosis  prone type 2 diabetes variants.,Non-OADS,/arxiv_data1/oa_pdf/70/e4/edmcr-2017-160109.PMC5404460.pdf
C Small and othersID: 16-0109; February 2017 DOI: 10.1530/EDM-16-0109 Diabetic ketoacidosis in   type 2 diabetes http://www.edmcasereports.com  3he continues to do well on metformin monotherapy with  an HbA1c in the non-diabetic range at 42 mmol/mol.,Non-OADS,/arxiv_data1/oa_pdf/70/e4/edmcr-2017-160109.PMC5404460.pdf
"C Small and others Diabetic ketoacidosis in   type 2 diabetesID: 16-0109; February 2017 DOI: 10.1530/EDM-16-0109 http://www.edmcasereports.com  4previously been described in a patient of white Irish  ethnicity, usually occurring in patients of black African  or Asian descent ( 9).",Non-OADS,/arxiv_data1/oa_pdf/70/e4/edmcr-2017-160109.PMC5404460.pdf
Accessed at http://www.diabetologists-abcd.org.uk/JBDS/JBDS.htm.,Non-OADS,/arxiv_data1/oa_pdf/70/e4/edmcr-2017-160109.PMC5404460.pdf
C Small and othersID: 16-0109; February 2017 DOI: 10.1530/EDM-16-0109 Diabetic ketoacidosis in   type 2 diabetes http://www.edmcasereports.com  5Americans with diabetic ketoacidosis.,Non-OADS,/arxiv_data1/oa_pdf/70/e4/edmcr-2017-160109.PMC5404460.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0087; February 2017 DOI: 10.1530/EDM-16-0087Thyroid Langerhans   cell histiocytosisO Oz Gul and others An unusual case of adult-onset multi-systemic  Langerhans cell histiocytosis with perianal and  incident thyroid involvement Ozen Oz Gul1, Pinar Sisman1, Soner Cander1, Erdem Gozden2, Meral Kurt3,  Ozlem Saraydaroglu4, Turkay Kirdak5, Canan Ersoy1 and Erdinc Erturk1 1Department of Endocrinology and Metabolism, Departments of 2Hematalogy, 3Radiation Oncology,  4Pathology, and 5Surgery, Uluda ğ University Medical School, Bursa, Turkey Summary Langerhans cell histiocytosis (LCH) is a rare sporadic disease characterized by histiocytic neoplastic infiltration of various  organ systems and a wide spectrum of clinical manifestations, ranging from benign and self-limiting to lethal.",Non-OADS,/arxiv_data1/oa_pdf/93/a4/edmcr-2017-160087.PMC5404461.pdf
"O Oz Gul and others Thyroid Langerhans   cell histiocytosisID: 16-0087; February 2017 DOI: 10.1530/EDM-16-0087 http://www.edmcasereports.com  2Background Langerhans cell histiocytosis (LCH) is a rare sporadic  disease that occurs predominantly, but not exclusively, in  children (1 per 200 000 per year) ( 1, 2) and characterized  by a clonal neoplastic proliferation, accumulation and  pathological dissemination of histiocytes (Langerhans  cell, undifferentiated cell, dendrocyte or macrophage)  resulting in the destruction of hard and soft tissues ( 3).",Non-OADS,/arxiv_data1/oa_pdf/93/a4/edmcr-2017-160087.PMC5404461.pdf
O Oz Gul and othersID: 16-0087; February 2017 DOI: 10.1530/EDM-16-0087 Thyroid Langerhans   cell histiocytosis http://www.edmcasereports.com  3abundant lightly eosinophilic to eosinophilic cytoplasm  during pathological assessment confirmed the diagnosis  of Langerhans cell histiocytosis ( Fig.,Non-OADS,/arxiv_data1/oa_pdf/93/a4/edmcr-2017-160087.PMC5404461.pdf
O Oz Gul and others Thyroid Langerhans   cell histiocytosisID: 16-0087; February 2017 DOI: 10.1530/EDM-16-0087 http://www.edmcasereports.com  4thyroid FNA specimens such as enlarged and loosely  cohesive cells and irregular nuclear contours have been  indicated to raise suspicion for LCH involving thyroid  (12).,Non-OADS,/arxiv_data1/oa_pdf/93/a4/edmcr-2017-160087.PMC5404461.pdf
"O Oz Gul and othersID: 16-0087; February 2017 DOI: 10.1530/EDM-16-0087 Thyroid Langerhans   cell histiocytosis http://www.edmcasereports.com  5 6 Patten DK, Wani Z & Tolley N 2012 Solitary langerhans histiocytosis  of the thyroid gland: a case report and literature review.",Non-OADS,/arxiv_data1/oa_pdf/93/a4/edmcr-2017-160087.PMC5404461.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0142; April 2017 DOI: 10.1530/EDM-16-0142CSW following TBI P Taylor and others Cerebral salt wasting following traumatic  brain injury Peter Taylor1,2, Sasan Dehbozorgi3, Arshiya Tabasum1, Anna Scholz1, Harsh Bhatt3,  Philippa Stewart3, Pranav Kumar1, Mohd S Draman1,2, Alastair Watt4, Aled Rees1,5,  Caroline Hayhurst3 and Stephen Davies1 1Department of Diabetes and Endocrinology, University Hospital of Wales, Heath Park, Cardiff, UK,  2Thyroid Research Group, Division of Infection and Immunity, School of Medicine, Cardiff University,  Heath Park, Cardiff, UK, 3Department of Neurosurgery, University Hospital of Wales, Heath Park,  Cardiff, UK, 4Department of Diabetes and Endocrinology, North Devon District Hospital, Barnstaple, UK,  and 5Institute of Neuroscience and Mental Health Research Institute, School of Medicine, Cardiff  University, Cardiff, UK Summary Hyponatraemia is the most commonly encountered electrolyte disturbance in neurological high dependency and intensive  care units.",Non-OADS,/arxiv_data1/oa_pdf/d9/e7/edmcr-2017-160142.PMC5404462.pdf
PROOF ONLY P Taylor and others CSW following TBIID: 16-0142; April 2017 DOI: 10.1530/EDM-16-0142 http://www.edmcasereports.com  2sustained a traumatic brain injury resulting in a marked  expressive dysphasia.,Non-OADS,/arxiv_data1/oa_pdf/d9/e7/edmcr-2017-160142.PMC5404462.pdf
PROOF ONLY P Taylor and othersID: 16-0142; April 2017 DOI: 10.1530/EDM-16-0142 CSW following TBI http://www.edmcasereports.com  3primary sodium losses which are not related to volume  expansion.,OADS,/arxiv_data1/oa_pdf/d9/e7/edmcr-2017-160142.PMC5404462.pdf
PROOF ONLY P Taylor and others CSW following TBIID: 16-0142; April 2017 DOI: 10.1530/EDM-16-0142 http://www.edmcasereports.com  4peptide in patients with aneurysmal subarachnoid haemorrhage.,Non-OADS,/arxiv_data1/oa_pdf/d9/e7/edmcr-2017-160142.PMC5404462.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0119; February 2017 DOI: 10.1530/EDM-16-0119Hyponatremia and   bowel preparationN Samad and I Fraser Severe symptomatic hyponatremia associated  with the use of polyethylene glycol-based  bowel preparation Navira Samad  and Ian Fraser Epworth HealthCare, Melbourne, Victoria, Australia Summary Colonoscopy is a useful tool in modern medicine and is increasingly employed for both diagnostic and treatment reasons.",Non-OADS,/arxiv_data1/oa_pdf/93/f6/edmcr-2017-160119.PMC5404463.pdf
PROOF ONLY N Samad and I Fraser Hyponatremia and   bowel preparationID: 16-0119; February 2017 DOI: 10.1530/EDM-16-0119 http://www.edmcasereports.com  2who was diagnosed with bowel cancer under the age of  55 years ( 1) (see reference for Cancer Council).,Non-OADS,/arxiv_data1/oa_pdf/93/f6/edmcr-2017-160119.PMC5404463.pdf
PROOF ONLY N Samad and I FraserID: 16-0119; February 2017 DOI: 10.1530/EDM-16-0119 Hyponatremia and   bowel preparation http://www.edmcasereports.com  3Discussion Hyponatremia is one of the most common electrolyte  disorders encountered in clinical practice with a reported  incidence of 15–30% ( 7).,Non-OADS,/arxiv_data1/oa_pdf/93/f6/edmcr-2017-160119.PMC5404463.pdf
PROOF ONLY N Samad and I Fraser Hyponatremia and   bowel preparationID: 16-0119; February 2017 DOI: 10.1530/EDM-16-0119 http://www.edmcasereports.com  4Table 1  Summary of clinical findings in patients with polyethylene (PEG)-related hyponatremia.,Non-OADS,/arxiv_data1/oa_pdf/93/f6/edmcr-2017-160119.PMC5404463.pdf
"PROOF ONLY N Samad and I FraserID: 16-0119; February 2017 DOI: 10.1530/EDM-16-0119 Hyponatremia and   bowel preparation http://www.edmcasereports.com  5attributed to newly developed SIADH, resulting from  PEG use.",Non-OADS,/arxiv_data1/oa_pdf/93/f6/edmcr-2017-160119.PMC5404463.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0113; March 2017 DOI: 10.1530/EDM-16-0113Diagnosis and treatment  parathyroid carcinomaL Rozhinskaya and others Diagnosis and treatment challenges of  parathyroid carcinoma in a 27-year-old woman  with multiple lung metastases Liudmila Rozhinskaya1, Ekaterina Pigarova1, Ekaterina Sabanova1, Elizaveta Mamedova1, Iya Voronkova2,   Julia Krupinova4, Larisa Dzeranova4, Anatoly Tiulpakov3, Vera Gorbunova5, Nadezhda Orel5,   Artur Zalian5, Galina Melnichenko4 and Ivan Dedov4 Departments of 1Neuroendocrinology and Bone Diseases, 2Pathomorphology, 3Department and Laboratory   of Inherited Endocrine Disorders, 4Endocrinology Research Centre, Moscow, Russia, and 5Department of   Chemotherapy, Cancer Research Center, Moscow, Russia Summary Parathyroid carcinoma is an extremely rare disorder with little treatment options.",Non-OADS,/arxiv_data1/oa_pdf/0c/67/edmcr-2017-160113.PMC5404464.pdf
L Rozhinskaya and others Diagnosis and treatment  parathyroid carcinomaID: 16-0113; March 2017 DOI: 10.1530/EDM-16-0113 http://www.edmcasereports.com  2institution with suspected primary hyperparathyroidism.,Non-OADS,/arxiv_data1/oa_pdf/0c/67/edmcr-2017-160113.PMC5404464.pdf
"L Rozhinskaya and othersID: 16-0113; March 2017 DOI: 10.1530/EDM-16-0113 Diagnosis and treatment  parathyroid carcinoma http://www.edmcasereports.com  3Given the high prevalence of cell cycle division 73  gene ( CDC73 ; NM_024529) mutations in patients with PC  (up to 30%), we performed next-generation sequencing  (NGS) with a custom-designed Ion AmpliSeq gene  panel, which included CDC73 , using a semiconductor  sequencer Ion Torrent PGM (Thermo Fisher Scientific-Life  Technologies).",OADS,/arxiv_data1/oa_pdf/0c/67/edmcr-2017-160113.PMC5404464.pdf
L Rozhinskaya and others Diagnosis and treatment  parathyroid carcinomaID: 16-0113; March 2017 DOI: 10.1530/EDM-16-0113 http://www.edmcasereports.com  4Funding Some parts of the research were done using funds of the grant of the  President of the Russian Federation №MK-8689.2016.7 and some parts of  the research were done using funds of the state assingnment.,OADS,/arxiv_data1/oa_pdf/0c/67/edmcr-2017-160113.PMC5404464.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0115; March 2017 DOI: 10.1530/EDM-16-0115Thyroid storm treated by CRRT H S Park and others Successful treatment of thyroid storm  presenting as recurrent cardiac arrest and subsequent multiorgan failure by continuous  renal replacement therapy Han Soo Park1, Su Kyoung Kwon1 and Ye Na Kim2 1Department of Internal Medicine, Division of Endocrinology and Metabolism, and 2Division of Nephrology,   Kosin University College of Medicine, Busan, Republic of Korea Summary Thyroid storm is a rare and potentially life-threatening medical emergency.",Non-OADS,/arxiv_data1/oa_pdf/f3/36/edmcr-2017-160115.PMC5404465.pdf
proof only H S Park and others Thyroid storm treated by CRRTID: 16-0115; March 2017 DOI: 10.1530/EDM-16-0115 http://www.edmcasereports.com  2we describe our experience with a rare case of thyroid  storm that presented as recurrent cardiac arrest with subsequent multiple organ failure (MOF) and was successfully treated with continuous veno-venous renal replacement therapy (CRRT).,Non-OADS,/arxiv_data1/oa_pdf/f3/36/edmcr-2017-160115.PMC5404465.pdf
"proof only H S Park and othersID: 16-0115; March 2017 DOI: 10.1530/EDM-16-0115 Thyroid storm treated by CRRT http://www.edmcasereports.com  3for thyroid function were as follows: free thyroxine  (FT4): 4.19   ng/dL (reference value: 0.78–1.54   ng/dL),   triiodothyronine (T3) > 800   ng/dL (reference  value: 65–150   ng/dL) and thyroid-stimulating  hormone (TSH): 0.007   μU/mL (reference value:   0.55–4.78   μU/mL).",Non-OADS,/arxiv_data1/oa_pdf/f3/36/edmcr-2017-160115.PMC5404465.pdf
"proof only H S Park and others Thyroid storm treated by CRRTID: 16-0115; March 2017 DOI: 10.1530/EDM-16-0115 http://www.edmcasereports.com  4CRRT, her body temperature and pulse rate began to stabilize  within 1   h, and her blood pressure increased to 100/60   mmHg  2   h later and 120/60   mmHg within 6   h ( Fig.",Non-OADS,/arxiv_data1/oa_pdf/f3/36/edmcr-2017-160115.PMC5404465.pdf
proof only H S Park and othersID: 16-0115; March 2017 DOI: 10.1530/EDM-16-0115 Thyroid storm treated by CRRT http://www.edmcasereports.com  5column ( 8 ) and albumin dialysis ( 9 ) have shown some  clinical benefits.,Non-OADS,/arxiv_data1/oa_pdf/f3/36/edmcr-2017-160115.PMC5404465.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0096; March 2017 DOI: 10.1530/EDM-16-0096Psychosis in PROP1 mutation D P Chaudhary and others PROP1 gene mutations in a 36-year-old female  presenting with psychosis Durgesh Prasad Chaudhary1, Tshristi Rijal1, Kunal Kishor Jha2 and Harpreet Saluja3 1BP Koirala Institute of Health Sciences, Dharan, Nepal, 2Critical Care Medicine, Geisinger Medical  Center, Danville, Pennsylvania, USA, and 3RCSI, Busaiteen, Bahrain Summary Combined pituitary hormonal deficiency (CPHD) is a rare disease that results from mutations in genes coding for  transcription factors that regulate the differentiation of pituitary cells.",Non-OADS,/arxiv_data1/oa_pdf/b8/1e/edmcr-2017-160096.PMC5404466.pdf
PROOF ONLY D P Chaudhary and others Psychosis in PROP1 mutationID: 16-0096; March 2017 DOI: 10.1530/EDM-16-0096 http://www.edmcasereports.com  2difficulty in interpretation and her judgment was intact.,Non-OADS,/arxiv_data1/oa_pdf/b8/1e/edmcr-2017-160096.PMC5404466.pdf
"PROOF ONLY D P Chaudhary and othersID: 16-0096; March 2017 DOI: 10.1530/EDM-16-0096 Psychosis in PROP1 mutation http://www.edmcasereports.com  3follow-up, her symptoms were mild and we treated her  with hormonal therapy.",Non-OADS,/arxiv_data1/oa_pdf/b8/1e/edmcr-2017-160096.PMC5404466.pdf
"PROOF ONLY D P Chaudhary and others Psychosis in PROP1 mutationID: 16-0096; March 2017 DOI: 10.1530/EDM-16-0096 http://www.edmcasereports.com  4References  1 Gupta SK, Agarwal MP, Gupta A, Mehra BB & Dwivedi S 1995  Sheehan’s syndrome presenting as psychosis.",Non-OADS,/arxiv_data1/oa_pdf/b8/1e/edmcr-2017-160096.PMC5404466.pdf
"PROOF ONLY This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0123; February 2017 DOI: 10.1530/EDM-16-0123DKA as initial manifestation of  Cushing’sR Acharya and U M Kabadi Case of diabetic ketoacidosis as an initial  presentation of Cushing’s syndrome Runa Acharya1 and Udaya M Kabadi2,3,4,5 1University of Pittsburgh Medical Center-Endocrinology, Diabetes and Metabolism Fellowship Program, Pittsburgh,  Pennsylvania, USA, 2Veteran Affairs Medical Center and Broadlawns Medical Center, Des Moines University of  Osteopathic Medicine, Des Moines, Iowa, USA, 3University of Iowa, Carver College of Medicine, Iowa City,   Iowa, USA, 4Medicine and Endocrinology, University of Iowa, Iowa City, Iowa, USA, and 5Des Moines University,  Des Moines, Iowa, USA Summary Diabetic ketoacidosis (DKA) is commonly encountered in clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/78/ca/edmcr-2017-160123.PMC5404467.pdf
PROOF ONLY R Acharya and U M Kabadi DKA as initial manifestation of  Cushing’sID: 16-0123; February 2017 DOI: 10.1530/EDM-16-0123 http://www.edmcasereports.com  2Investigation Complete blood count was significant for WBC 21.600/mL   with segmented neutrophils 69%.,Non-OADS,/arxiv_data1/oa_pdf/78/ca/edmcr-2017-160123.PMC5404467.pdf
"PROOF ONLY R Acharya and U M KabadiID: 16-0123; February 2017 DOI: 10.1530/EDM-16-0123 DKA as initial manifestation of  Cushing’s http://www.edmcasereports.com  3LH and free T4, the exception being low serum TSH  level.",Non-OADS,/arxiv_data1/oa_pdf/78/ca/edmcr-2017-160123.PMC5404467.pdf
"PROOF ONLY R Acharya and U M Kabadi DKA as initial manifestation of  Cushing’sID: 16-0123; February 2017 DOI: 10.1530/EDM-16-0123 http://www.edmcasereports.com  4multiple types of anion gap acidosis are present, e.g.",Non-OADS,/arxiv_data1/oa_pdf/78/ca/edmcr-2017-160123.PMC5404467.pdf
PROOF ONLY R Acharya and U M KabadiID: 16-0123; February 2017 DOI: 10.1530/EDM-16-0123 DKA as initial manifestation of  Cushing’s http://www.edmcasereports.com  5adenoma.,Non-OADS,/arxiv_data1/oa_pdf/78/ca/edmcr-2017-160123.PMC5404467.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0126; February 2017 DOI: 10.1530/EDM-16-0126Octreotide and fetal   growth restrictionM Geilswijk and others Octreotide therapy and restricted fetal  growth: pregnancy in familial hyperinsulinemic hypoglycemia Marianne Geilswijk1, Lise Lotte Andersen2,4, Morten Frost3,4, Klaus Brusgaard1,4,  Henning Beck-Nielsen3,4, Anja Lisbeth Frederiksen1,4 and Dorte Møller Jensen2,3,4 Departments of 1Clinical Genetics, 2Obstetrics, 3Endocrinology, Odense University Hospital, Odense,  Denmark, and 4Department of Clinical Research, Faculty of Health, University of Southern Denmark,  Odense, Denmark Summary Hypoglycemia during pregnancy can have serious health implications for both mother and fetus.",Non-OADS,/arxiv_data1/oa_pdf/42/81/edmcr-2017-160126.PMC5404468.pdf
"M Geilswijk and others Octreotide and fetal   growth restrictionID: 16-0126; February 2017 DOI: 10.1530/EDM-16-0126 http://www.edmcasereports.com 2GCK mutations cause impaired insulin secretion and  mild hyperglycemia, i.e., maturity onset diabetes of  young, type 2 (MODY2), activating GCK mutations lead  to hyperinsulinism and subsequently hypoglycemia (1).",Non-OADS,/arxiv_data1/oa_pdf/42/81/edmcr-2017-160126.PMC5404468.pdf
M Geilswijk and othersID: 16-0126; February 2017 DOI: 10.1530/EDM-16-0126 Octreotide and fetal   growth restriction http://www.edmcasereports.com 3delivered spontaneously in GA 37 + 5 weeks after stripping  membranes two days earlier.,Non-OADS,/arxiv_data1/oa_pdf/42/81/edmcr-2017-160126.PMC5404468.pdf
M Geilswijk and others Octreotide and fetal   growth restrictionID: 16-0126; February 2017 DOI: 10.1530/EDM-16-0126 http://www.edmcasereports.com 4symptoms of severe hypoglycemia.,Non-OADS,/arxiv_data1/oa_pdf/42/81/edmcr-2017-160126.PMC5404468.pdf
"M Geilswijk and othersID: 16-0126; February 2017 DOI: 10.1530/EDM-16-0126 Octreotide and fetal   growth restriction http://www.edmcasereports.com 5hypoglycemia has been associated with both congenital  malformations and impaired fetal growth in animal  studies, there is no evidence to confirm a similar  teratogenic effect of hypoglycemia in pregnancy in  humans (4, 5, 12).",Non-OADS,/arxiv_data1/oa_pdf/42/81/edmcr-2017-160126.PMC5404468.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0135; March 2017 DOI: 10.1530/EDM-16-0135PBMAH due to ARMC5  mutationT Rego and others ARMC5 mutation in a Portuguese family with  primary bilateral macronodular adrenal hyperplasia (PBMAH) Teresa Rego1, Fernando Fonseca1, Stéphanie Espiard2, Karine Perlemoine2,  Jérôme Bertherat2 and Ana Agapito1 1Endocrinology Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon,  Portugal and 2Endocrinology Department, INSERM U1016, Institut Cochin, Paris Descartes University, &  Center for Rare Adrenal Diseases, Hôpital Cochin, APHP-Paris, France Summary PBMAH is a rare etiology of Cushing syndrome (CS).",Non-OADS,/arxiv_data1/oa_pdf/3f/8b/edmcr-2017-160135.PMC5404469.pdf
T Rego and others PBMAH due to ARMC5  mutationID: 16-0135; March 2017 DOI: 10.1530/EDM-16-0135 http://www.edmcasereports.com 2Background Primary bilateral macronodular adrenal hyperplasia  (PBMAH) was first described in 1964 by Kirschner  et al.,Non-OADS,/arxiv_data1/oa_pdf/3f/8b/edmcr-2017-160135.PMC5404469.pdf
T Rego and othersID: 16-0135; March 2017 DOI: 10.1530/EDM-16-0135 PBMAH due to ARMC5  mutation http://www.edmcasereports.com 3authors in 2006 for severe hypercortisolism (Fig.,Non-OADS,/arxiv_data1/oa_pdf/3f/8b/edmcr-2017-160135.PMC5404469.pdf
"T Rego and others PBMAH due to ARMC5  mutationID: 16-0135; March 2017 DOI: 10.1530/EDM-16-0135 http://www.edmcasereports.com 4ACTH <5 pg/mL, UFC of 532 µg/24 h (normal range  20–90), serum cortisol at 12:00 h of 19.3 µg/dL and failure  to suppress on the low-dose dexamethasone test (0.5 mg  every 6 h for 48 h): cortisol 21 µg/dL, UFC 592 µg/24 h. MR  imaging showed bilateral enlarged adrenal glands (Fig. 4).",Non-OADS,/arxiv_data1/oa_pdf/3f/8b/edmcr-2017-160135.PMC5404469.pdf
T Rego and othersID: 16-0135; March 2017 DOI: 10.1530/EDM-16-0135 PBMAH due to ARMC5  mutation http://www.edmcasereports.com 5been established yet.,Non-OADS,/arxiv_data1/oa_pdf/3f/8b/edmcr-2017-160135.PMC5404469.pdf
T Rego and others PBMAH due to ARMC5  mutationID: 16-0135; March 2017 DOI: 10.1530/EDM-16-0135 http://www.edmcasereports.com 6 2 Lacroix A 2009 ACTH-independent macronodular adrenal  hyperplasia.,Non-OADS,/arxiv_data1/oa_pdf/3f/8b/edmcr-2017-160135.PMC5404469.pdf
(1) this is an open access article under the cc B y-nc-nd license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/79/22/acp-13-011.PMC5404470.pdf
"PROOF ONLY This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0140; March 2017 DOI: 10.1530/EDM-16-0140Pasireotide primary treatment  in Cushing’s syndromeR Attanasio and others Efficacy of pasireotide in controlling severe  hypercortisolism until cardiac transplantation Roberto Attanasio1,2, Liana Cortesi1, Daniela Gianola1, Claudia Vettori3,   Fulvio Sileo1 and Roberto Trevisan1 1Endocrinology Service, Galeazzi Institute IRCCS, Milan, Italy, 2Endocrinology and Diabetology, and  3Cardiology, Papa Giovanni XXIII Hospital, Bergamo, Italy Summary Cushing’s syndrome is associated with increased morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/a5/c8/edmcr-2017-160140.PMC5404471.pdf
"PROOF ONLY R Attanasio and others Pasireotide primary treatment  in Cushing’s syndromeID: 16-0140; March 2017 DOI: 10.1530/EDM-16-0140 http://www.edmcasereports.com  2(the  true  Cushing’s disease, CD) or ectopic ACTH (or  rarely CRH) secreted by ectopic tumors in about one- third of cases.",Non-OADS,/arxiv_data1/oa_pdf/a5/c8/edmcr-2017-160140.PMC5404471.pdf
"PROOF ONLY R Attanasio and othersID: 16-0140; March 2017 DOI: 10.1530/EDM-16-0140 Pasireotide primary treatment  in Cushing’s syndrome http://www.edmcasereports.com  3rupture, three episodes of acute rejection, massive  cerebral bleeding requiring transcranial neurosurgery and  pneumonia), but they were adequately treated, including  treatment with high-dose steroids.",Non-OADS,/arxiv_data1/oa_pdf/a5/c8/edmcr-2017-160140.PMC5404471.pdf
PROOF ONLY R Attanasio and others Pasireotide primary treatment  in Cushing’s syndromeID: 16-0140; March 2017 DOI: 10.1530/EDM-16-0140 http://www.edmcasereports.com  4The clinical outcome of this case report confirms the  recent data by Cannavò  et al.,OADS,/arxiv_data1/oa_pdf/a5/c8/edmcr-2017-160140.PMC5404471.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0116; February 2017 DOI: 10.1530/EDM-16-0116Takotsubo in amiodarone  hyperthyroidismI Capel and others Takotsubo cardiomyopathy in   amiodarone-induced hyperthyroidism Ismael Capel, Elisabet Tasa-Vinyals, Albert Cano-Palomares, Irene Bergés-Raso,  Lara Albert, Mercedes Rigla and Assumpta Caixàs Endocrinology Department, Parc Taulí Sabadell University Hospital, Sabadell Barcelona, Spain  Summary Takotsubo cardiomyopathy (TC) is an atypical, severe but reversible form of acute heart insufficiency.",Non-OADS,/arxiv_data1/oa_pdf/b5/85/edmcr-2017-160116.PMC5404472.pdf
"I Capel and others Takotsubo in amiodarone  hyperthyroidismID: 16-0116; February 2017 DOI: 10.1530/EDM-16-0116 http://www.edmcasereports.com 2by an acute left ventricular cardiac failure which can  clinically, analytically and electrocardiographically mimic  an acute myocardial infarction.",Non-OADS,/arxiv_data1/oa_pdf/b5/85/edmcr-2017-160116.PMC5404472.pdf
"I Capel and othersID: 16-0116; February 2017 DOI: 10.1530/EDM-16-0116 Takotsubo in amiodarone  hyperthyroidism http://www.edmcasereports.com 3compared to previous data, which already showed a stent  stenosis of approximately 30 percent.",OADS,/arxiv_data1/oa_pdf/b5/85/edmcr-2017-160116.PMC5404472.pdf
"I Capel and others Takotsubo in amiodarone  hyperthyroidismID: 16-0116; February 2017 DOI: 10.1530/EDM-16-0116 http://www.edmcasereports.com 4Here, we present a case of TC in a patient with  amiodarone-induced hyperthyroidism.",Non-OADS,/arxiv_data1/oa_pdf/b5/85/edmcr-2017-160116.PMC5404472.pdf
"proof only This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License.© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0125; March 2017 DOI: 10.1530/EDM-16-0125CHI and Poland syndrome D Giri, P Patil and others Congenital hyperinsulinism and Poland  syndrome in association with 10p13–14 duplication  Dinesh Giri1,*, Prashant Patil1,*, Rachel Hart2, Mohammed Didi1 and   Senthil Senniappan1 1Alder Hey Children’s NHS Foundation Trust, Liverpool, UK and 2Liverpool Women’s NHS Foundation  Trust, Liverpool, UK *(D Giri and P Patil contributed equally to this work) Summary Poland syndrome (PS) is a rare congenital condition, affecting 1 in 30  000 live births worldwide, characterised by a  unilateral absence of the sternal head of the pectoralis major and ipsilateral symbrachydactyly occasionally associated  with abnormalities of musculoskeletal structures.",Non-OADS,/arxiv_data1/oa_pdf/f7/04/edmcr-2017-160125.PMC5404473.pdf
"proof only D Giri, P Patil and others CHI and Poland syndromeID: 16-0125; March 2017 DOI: 10.1530/EDM-16-0125 http://www.edmcasereports.com  2hypoplasia to aplasia of the breasts and ribs, chest wall  depression, subcutaneous fat, partial agenesis of the ribs (usually II–IV or II–V) ( 4 ).",Non-OADS,/arxiv_data1/oa_pdf/f7/04/edmcr-2017-160125.PMC5404473.pdf
"proof only D Giri, P Patil and othersID: 16-0125; March 2017 DOI: 10.1530/EDM-16-0125 CHI and Poland syndrome http://www.edmcasereports.com  3Outcome and follow-up Currently, the patient is 18  months old with normal  blood glucose concentrations and continues to require diazoxide to maintain normoglycaemia.",Non-OADS,/arxiv_data1/oa_pdf/f7/04/edmcr-2017-160125.PMC5404473.pdf
"proof only D Giri, P Patil and others CHI and Poland syndromeID: 16-0125; March 2017 DOI: 10.1530/EDM-16-0125 http://www.edmcasereports.com  4role of UCMA contributing to the phenotype of PS and a  potential role of HK1 in the pathogenesis of CHI.",Non-OADS,/arxiv_data1/oa_pdf/f7/04/edmcr-2017-160125.PMC5404473.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0089; February 2017 DOI: 10.1530/EDM-16-0089Metastatic differentiated  thyroid cancerS D Cooray and D J Topliss The management of metastatic   radioiodine-refractory differentiated thyroid  cancer requires an integrated approach  including both directed and systemic therapies Shamil D Cooray1 and Duncan J Topliss1,2 1Department of Endocrinology and Diabetes, The Alfred, Melbourne, Australia and 2Department of  Medicine, Monash University, Melbourne, Australia Summary A 58-year-old man with metastatic radioiodine-refractory differentiated thyroid cancer (DTC) presented with left thigh  and right flank numbness.",Non-OADS,/arxiv_data1/oa_pdf/4c/70/edmcr-2017-160089.PMC5404474.pdf
"S D Cooray and D J Topliss Metastatic differentiated  thyroid cancerID: 16-0089; February 2017 DOI: 10.1530/EDM-16-0089 http://www.edmcasereports.com  2prognosis, with a median overall survival of   2.5–3.5 years ( 1).",Non-OADS,/arxiv_data1/oa_pdf/4c/70/edmcr-2017-160089.PMC5404474.pdf
"S D Cooray and D J ToplissID: 16-0089; February 2017 DOI: 10.1530/EDM-16-0089 Metastatic differentiated  thyroid cancer http://www.edmcasereports.com  3Outcome and follow-up Two weeks after commencement of sorafenib, the patient  developed a hand-foot skin reaction, and increased bowel  and urinary frequency.",Non-OADS,/arxiv_data1/oa_pdf/4c/70/edmcr-2017-160089.PMC5404474.pdf
"S D Cooray and D J Topliss Metastatic differentiated  thyroid cancerID: 16-0089; February 2017 DOI: 10.1530/EDM-16-0089 http://www.edmcasereports.com  4The  patient underwent a right total hip replacement,  intra-lesional curettage and cementing.",Non-OADS,/arxiv_data1/oa_pdf/4c/70/edmcr-2017-160089.PMC5404474.pdf
"S D Cooray and D J ToplissID: 16-0089; February 2017 DOI: 10.1530/EDM-16-0089 Metastatic differentiated  thyroid cancer http://www.edmcasereports.com  5Figure 5 Management approach to radioiodine-refractory differentiated thyroid cancer (adapted from ( 2, 4)).",Non-OADS,/arxiv_data1/oa_pdf/4c/70/edmcr-2017-160089.PMC5404474.pdf
S D Cooray and D J Topliss Metastatic differentiated  thyroid cancerID: 16-0089; February 2017 DOI: 10.1530/EDM-16-0089 http://www.edmcasereports.com  6Sorafenib was the first TKI approved for the treatment  of patients with thyroid cancer in Australia.,Non-OADS,/arxiv_data1/oa_pdf/4c/70/edmcr-2017-160089.PMC5404474.pdf
S D Cooray and D J ToplissID: 16-0089; February 2017 DOI: 10.1530/EDM-16-0089 Metastatic differentiated  thyroid cancer http://www.edmcasereports.com  7Declaration of interest D J T was a principal site investigator for the SELECT trial of lenvatinib in  advancing non-iodine avid differentiated thyroid cancer.,Non-OADS,/arxiv_data1/oa_pdf/4c/70/edmcr-2017-160089.PMC5404474.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0133; March 2017 DOI: 10.1530/EDM-16-0133Hyperinsulinism, renal Fanconi  syndrome and HNF4AM Clemente and others Hyperinsulinaemic hypoglycaemia, renal  Fanconi syndrome and liver disease due to a mutation in the HNF4A gene María Clemente1, Alejandro Vargas1, Gema Ariceta2, Rosa Martínez3,  Ariadna Campos1 and Diego Yeste1 1Paediatric Endocrinology Unit, Department of Paediatrics and 2Paediatric Nephrology Service,  Vall d’Hebron Hospital, Autonomous University of Barcelona, CIBERER, Barcelona, Spain, and  3Hospital Universitario Cruces, UPV-EHU, BioCruces, CIBERDEM, CIBERER, Bilbao, Spain Summary HNF4A gene mutations have been reported in cases of transient and persistent hyperinsulinaemic hypoglycaemia of  infancy (HHI), particularly in families with adulthood diabetes.",Non-OADS,/arxiv_data1/oa_pdf/de/9e/edmcr-2017-160133.PMC5404475.pdf
"PROOF ONLY M Clemente and others Hyperinsulinism, renal Fanconi  syndrome and HNF4AID: 16-0133; March 2017 DOI: 10.1530/EDM-16-0133 http://www.edmcasereports.com  2inappropriately low betahydroxybutyrate plasma levels  (10.2   µmol/L), inappropriate insulin (6.1   IU/L) and  C-peptide levels (2.7   ng/mL) and low cortisol levels  (1.3   µg/dL and 5.2   µg/dL) in hypoglycaemia.",Non-OADS,/arxiv_data1/oa_pdf/de/9e/edmcr-2017-160133.PMC5404475.pdf
"PROOF ONLY M Clemente and othersID: 16-0133; March 2017 DOI: 10.1530/EDM-16-0133 Hyperinsulinism, renal Fanconi  syndrome and HNF4A http://www.edmcasereports.com  3c.187C  >  T (reference sequence: NM_175914.4).",Non-OADS,/arxiv_data1/oa_pdf/de/9e/edmcr-2017-160133.PMC5404475.pdf
"PROOF ONLY M Clemente and others Hyperinsulinism, renal Fanconi  syndrome and HNF4AID: 16-0133; March 2017 DOI: 10.1530/EDM-16-0133 http://www.edmcasereports.com  4R76W mutation causes an atypical dominant Fanconi  syndrome in addition to the beta cell phenotype.",Non-OADS,/arxiv_data1/oa_pdf/de/9e/edmcr-2017-160133.PMC5404475.pdf
"PROOF ONLY M Clemente and othersID: 16-0133; March 2017 DOI: 10.1530/EDM-16-0133 Hyperinsulinism, renal Fanconi  syndrome and HNF4A http://www.edmcasereports.com  5 6 Hamilton AJ, Bingham C, McDonald TJ, Cook PR, Caswell RC,  Weedon MN, Oram RA, Shields BM, Shepherd M, Inward CD, et al.",Non-OADS,/arxiv_data1/oa_pdf/de/9e/edmcr-2017-160133.PMC5404475.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0117; March 2017 DOI: 10.1530/EDM-16-0117Kisspeptin: a novel test of  GnRH functionS Vimalesvaran and others Using kisspeptin to assess GnRH function in an  unusual case of primary amenorrhoea S Vimalesvaran1, S Narayanaswamy1, L Yang1, J K Prague1, A Buckley1, A D Miras2,  S Franks2, K Meeran2 and W S Dhillo1 1Department of Endocrinology & Metabolism, Imperial College London, UK and 2Department of  Diabetes & Endocrinology, Imperial Healthcare NHS Trust, London, UK Summary Primary amenorrhoea is defined as the failure to commence menstruation by the age of 15 years, in the presence  of normal secondary sexual development.",Non-OADS,/arxiv_data1/oa_pdf/7f/be/edmcr-2017-160117.PMC5404476.pdf
proof only S Vimalesvaran and others Kisspeptin: a novel test of  GnRH functionID: 16-0117; March 2017 DOI: 10.1530/EDM-16-0117 http://www.edmcasereports.com  2plethora of current endocrine testing.,Non-OADS,/arxiv_data1/oa_pdf/7f/be/edmcr-2017-160117.PMC5404476.pdf
proof only S Vimalesvaran and othersID: 16-0117; March 2017 DOI: 10.1530/EDM-16-0117 Kisspeptin: a novel test of  GnRH function http://www.edmcasereports.com  3Investigation Her basal endocrine blood test results are shown in Table 1 .,Non-OADS,/arxiv_data1/oa_pdf/7f/be/edmcr-2017-160117.PMC5404476.pdf
proof only S Vimalesvaran and others Kisspeptin: a novel test of  GnRH functionID: 16-0117; March 2017 DOI: 10.1530/EDM-16-0117 http://www.edmcasereports.com  4This further illustrates the heterogeneous presentation of  PCOS and the variability in potential presenting features.,Non-OADS,/arxiv_data1/oa_pdf/7f/be/edmcr-2017-160117.PMC5404476.pdf
"proof only S Vimalesvaran and othersID: 16-0117; March 2017 DOI: 10.1530/EDM-16-0117 Kisspeptin: a novel test of  GnRH function http://www.edmcasereports.com  5 9 de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL & Milgrom E  2003 Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54.",Non-OADS,/arxiv_data1/oa_pdf/7f/be/edmcr-2017-160117.PMC5404476.pdf
"MeSH Keywords:  Cytogenetics • Leukemia, Megakaryoblastic, Acute • Pediatrics • Translocation, Genetic  Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/901855Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Pathology and Laboratory Medicine, Weill Cornell Medicine/   New York Presbyterian Hospital, New York, NY, U.S.A. 2 Department of Pediatrics, Weill Cornell Medicine/New York Presbyterian Hospital,  New York, NY, U.S.A.ISSN 1941-5923 © Am J Case Rep, 2017; 18: 422-426 DOI: 10.12659/AJCR.901855 422 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/f3/44/amjcaserep-18-422.PMC5404477.pdf
"MeSH Keywords:  Nephrotic Syndrome • Oliguria • Pre-Eclampsia • Proteinuria  Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/902910Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection GDepartment of Obstetrics and Gynecology, Hyogo Prefectural Amagasaki General  Medical Center, Amagasaki, JapanISSN 1941-5923 © Am J Case Rep, 2017; 18: 418-421 DOI: 10.12659/AJCR.902910 418 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/ff/12/amjcaserep-18-418.PMC5404478.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/64/0b/ijgm-10-131.PMC5404491.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/64/0b/ijgm-10-131.PMC5404491.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).International Journal of General Medicine 2017:10 131–135International Journal of General Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress 131 ORIGINAL RESEARCH   open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJGM.S129075Factors predicting the outcomes of elderly  hospitalized myasthenia gravis patients: a   national database study Somsak Tiamkao1,2 Sineenard Pranboon3 Kaewjai Thepsuthammarat4 Kittisak Sawanyawisuth1,5,6 1Department of Medicine, Faculty  of Medicine, 2The Neuroscience  Research and Development Group,   3Nursing Division, Srinagarind  Hospital, 4Clinical Epidemiology Unit,   Faculty of Medicine, 5Research Center  in Back, Neck, Other Joint Pain and  Human Performance (BNOJPH),   6Ambulatory Medicine Research  Group, Khon Kaen University, Khon Kaen, ThailandBackground: Myasthenia gravis (MG) in elderly populations is increasing.",Non-OADS,/arxiv_data1/oa_pdf/64/0b/ijgm-10-131.PMC5404491.pdf
"Data were retrieved from the national health Correspondence: Somsak Tiamkao Department of Medicine, Faculty of Medicine, Khon Kaen University,   123 Mitraphrap Road, Khon Kaen,   40002, Thailand Tel +66 43 363 664 Fax +66 43 348 399 Email somtia@kku.ac.th Journal name: International Journal of General Medicine Article Designation: ORIGINAL RESEARCH Y ear: 2017V olume: 10Running head verso: Tiamkao et alRunning head recto: Elderly MG mortality predictorsDOI: http://dx.doi.org/10.2147/IJGM.S129075",Non-OADS,/arxiv_data1/oa_pdf/64/0b/ijgm-10-131.PMC5404491.pdf
"International Journal of General Medicine 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress International Journal of General Medicine Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/international-journal-of-general-medicine-journalThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/64/0b/ijgm-10-131.PMC5404491.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 135 Elderly MG mortality predictors,Non-OADS,/arxiv_data1/oa_pdf/64/0b/ijgm-10-131.PMC5404491.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/25/ed/amep-8-293.PMC5404492.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/25/ed/amep-8-293.PMC5404492.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2017:8 293–297Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 293 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S134081 What factors influence UK medical students’  choice of foundation school?",Non-OADS,/arxiv_data1/oa_pdf/25/ed/amep-8-293.PMC5404492.pdf
"Correspondence: Saiful Miah Division of Surgery and Interventional Science, University College London, 21 University Street, London, WC1E 6AU, UKEmail saiful.miah@ucl.ac.ukJournal name: Advances in Medical Education and Practice Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 8Running head verso: Miah et alRunning head recto: Factors influencing foundation school choiceDOI: http://dx.doi.org/10.2147/AMEP .S134081",Non-OADS,/arxiv_data1/oa_pdf/25/ed/amep-8-293.PMC5404492.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/25/ed/amep-8-293.PMC5404492.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 297 Factors influencing foundation school choice of the importance of clinical specialties that will be under - taken during their future FY1 and FY2 years.,Non-OADS,/arxiv_data1/oa_pdf/25/ed/amep-8-293.PMC5404492.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of COPD 2017:12 1221–1231International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1221OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S12070 6 home monitoring of breathing rate in people  with chronic obstructive pulmonary disease:  observational study of feasibility, acceptability,  and change after exacerbation noah rubio1 richard a Parker2 ellen M Drost1 hilary Pinnock3,4 Christopher J Weir2 Janet hanley5 leandro C Mantoani1 William Macn ee1 Brian McKinstry2,4 roberto a rabinovich1 1edinburgh lung and the environment  group Initiative ( eleg I) Colt  laboratory, Centre for Inflammation  research, 2edinburgh Clinical Trials  Unit, Usher Institute of Population  health sciences and Informatics, The  University of edinburgh, 3allergy  and respiratory research group,   Usher Institute of Population  health sciences and Informatics,   The University of edinburgh, Medical  school, T eviot Place, 4ehealth group,   Usher Institute of Population health  sciences and Informatics, The  University of edinburgh, 5school of  health and social Care, edinburgh  napier University, edinburgh,   lothian, UKAbstract:  Telehealth programs to promote early identification and timely self-management  of acute exacerbations of chronic obstructive pulmonary diseases (AECOPDs) have yielded  disappointing results, in part, because parameters monitored (symptoms, pulse oximetry, and  spirometry) are weak predictors of exacerbations.",Non-OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
"Keywords:  COPD exacerbation, telemedicine, COPD management, heart rate Introduction Worldwide, 65 million people live with COPD, and this number is predicted to increase  by one-third by 2030.1 Self-management, supporting early identification, and timely  treatment of acute exacerbations of COPD (AECOPD) is promoted to reduce hospital  admissions, improve time to recovery, slow disease deterioration, and reduce health  care use/cost.2–8 As .50% of the costs of COPD are due to hospital admissions, reduc - ing these is a priority for health services.9 Globally, health care policies encourage telehealthcare-supported self-manage - ment of long-term conditions, but current telehealth systems are limited by what can Correspondence: roberto a rabinovich edinburgh lung and the environment  group Initiative (elegI) Colt laboratory,  Centre for Inflammation Research, The  Queen’s Medical research Institute,  University of edinburgh, 47 little  France Crescent, edinburgh eh16 4TJ,  scotland, UK Tel +44 131 242 9201 Fax +44 131 242 6582 email roberto.rabinovich@ed.ac.u k Journal name: International Journal of COPD Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Rubio et al Running head recto: Measuring breathing rate in people with COPD DOI: http://dx.doi.org/10.2147/COPD.S120706",Non-OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
"Available from: http://www.gov.scot/ resource/doc/274194/0082012.pd f. Accessed July 30, 2016.",Non-OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
"Available from: http://www.goldcopd.org/uploads/users/files/ GOLD_Report_2015.pd f. Accessed July 30, 2016.",OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
Available from: https://www.R-project.org /.,Non-OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/f4/a0/copd-12-1221.PMC5404493.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/0c/f5/ijn-12-3295.PMC5404494.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2017:12 3295–3302International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3295OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S12855 6 Peroxidase-like activity of nanocrystalline cobalt  selenide and its application for uric acid detection Quan-Quan Zhuang1 Zhi-hang lin1 Yan-cheng Jiang1 hao-hua Deng2 shao-Bin he1,3 li-Ting su4 Xiao-Qiong shi2 Wei chen2 1Department of Pharmacy, affiliated  Quanzhou First hospital of Fujian  Medical University, Quanzhou,   2Department of Pharmaceutical  analysis, school of Pharmacy,   Fujian Medical University, Fuzhou,   3Department of Pharmacy, Quanzhou  Infectious Disease hospital,   4Department of Pharmaceutical  analysis, Quanzhou Medical college,   Quanzhou, People’s republic of chinaAbstract:  Dendrite-like cobalt selenide nanostructures were synthesized from cobalt and  selenium powder precursors by a solvothermal method in anhydrous ethylenediamine.",Non-OADS,/arxiv_data1/oa_pdf/0c/f5/ijn-12-3295.PMC5404494.pdf
"A short-term stability test shows that HRP  shows dramatically decreased catalytic ability over a few hours at room temperature  and loses most of its activity after 24 h.1 Since the pioneering study reported by Gao  et al2 that showed that magnetic Fe3O4 nanoparticles exhibit intrinsic peroxidase-like  activity, increasing attention has been paid to nanoscale peroxidase mimics such as  V2O5 nanowires,3 bimetallic Fe–Co alloy nanoparticles,4 cupric oxide nanoparticles,5 correspondence: Wei chen Department of Pharmaceutical analysis,  school of Pharmacy, Fujian Medical  University, Fuzhou 350004, People’s  republic of china Tel/fax +86 591 2286 2016 email chenandhu@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Zhuang et al Running head recto: Peroxidase-like activity of nanocrystalline cobalt selenide DOI: http://dx.doi.org/10.2147/IJN.S128556",Non-OADS,/arxiv_data1/oa_pdf/0c/f5/ijn-12-3295.PMC5404494.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/0c/f5/ijn-12-3295.PMC5404494.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/0c/f5/ijn-12-3295.PMC5404494.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d0/dd/ijn-12-3267.PMC5404496.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Nanomedicine 2017:12 3267–3280International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3267OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/IJN.S13504 5 role of hedgehog–gli1 signaling in the enhanced  proliferation and differentiation of Mg63 cells  enabled by hierarchical micro-/nanotextured  topography Yao lin1 Yinghe huang1 Junbing he2 Feng chen2 Yanfang he2 Wenying Zhang2 1Department of stomatology,   Taishan People’s hospital, affiliated  to guangdong Medical University,   Taishan, 2guangdong Key laboratory  of age-related cardiac and cerebral  Diseases, Institute of Neurology,   affiliated hospital of guangdong  Medical University, Zhanjiang,   guangdong, People’s republic  of chinaAbstract:  Hedgehog–Gli1 signaling is evolutionarily conserved and plays an essential role in  osteoblast proliferation and differentiation as well as bone formation.",Non-OADS,/arxiv_data1/oa_pdf/d0/dd/ijn-12-3267.PMC5404496.pdf
"Our results showed that the MG63  cells seeded onto the MNTs exhibited significantly enhanced cell adhesion, proliferation, and correspondence: Yinghe huang Department of stomatology,  Taishan People’s Hospital, Affiliated  to guangdong Medical University,  80 huanbei avenue, Taicheng  Town, Taishan, guangdong 529200,  People’s republic of china Tel +86 137 0221 8459 Fax +86 75 0555 2059 email yinghehuang_gmc@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Lin et al Running head recto: Hedgehog–Gli1 signaling and biomaterial topographies DOI: http://dx.doi.org/10.2147/IJN.S135045",OADS,/arxiv_data1/oa_pdf/d0/dd/ijn-12-3267.PMC5404496.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/d0/dd/ijn-12-3267.PMC5404496.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d0/dd/ijn-12-3267.PMC5404496.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/16/1d/ccid-10-117.PMC5404497.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/16/1d/ccid-10-117.PMC5404497.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2017:10 117–132Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 117 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S111041 Management of the psychological comorbidities  of dermatological conditions: practitioners’  guidelines Cody J Connor Department of Dermatology,   University of Alabama at Birmingham,  Birmingham, AL, USAAbstract: Dermatological disease can be devastating for patients, and although dermatologists  are focused on remedying the cutaneous manifestations of these conditions, it is easy to miss the  psychological suffering lurking below.",Non-OADS,/arxiv_data1/oa_pdf/16/1d/ccid-10-117.PMC5404497.pdf
"To add knowledge of such a complex concept to the already dynamic repertoire of a practicing dermatologist is a daunting proposal, but the necessity of this addition manifests itself daily in the faces of suffering patients struggling with dermatological  Correspondence: Cody J Connor Department of Dermatology,   University of Alabama at Birmingham,   500 CEFH, 1720 2nd Avenue South, Birmingham, AL 35294, USATel +1 205 934 2518Fax +1 205 934 5766Email codyjconnor@gmail.comJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: REVIEWY ear: 2017V olume: 10Running head verso: ConnorRunning head recto: Management of the psychological comorbidities of dermatological conditionsDOI: http://dx.doi.org/10.2147/CCID.S111041",Non-OADS,/arxiv_data1/oa_pdf/16/1d/ccid-10-117.PMC5404497.pdf
"Clinical, Cosmetic and Investigational Dermatology 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/16/1d/ccid-10-117.PMC5404497.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 132 Connor 108.,Non-OADS,/arxiv_data1/oa_pdf/16/1d/ccid-10-117.PMC5404497.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/dd/a5/idr-10-121.PMC5404498.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/dd/a5/idr-10-121.PMC5404498.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Infection and Drug Resistance 2017:10 121–134Infection and Drug Resistance Dovepress submit your manuscript | www.dovepress.com Dovepress 121 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IDR.S105473Drug resistance in influenza A virus: the  epidemiology and management Mazhar Hussain   Henry D Galvin*   Tatt Y Haw*   Ashley N Nutsford*   Matloob Husain Department of Microbiology and  Immunology, University of Otago,  Dunedin, New Zealand *These authors contributed equally to  this workAbstract: Influenza A virus (IA V) is the sole cause of the unpredictable influenza pandemics and  deadly zoonotic outbreaks and constitutes at least half of the cause of regular annual influenza  epidemics in humans.",Non-OADS,/arxiv_data1/oa_pdf/dd/a5/idr-10-121.PMC5404498.pdf
"In addition, two classes of antiviral drugs, 1) M2 ion channel inhibitors Correspondence: Matloob Husain   Department of Microbiology and  Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand   Tel +64 3 470 3420   Fax +64 3 479 8540Email matloob.husain@otago.ac.nzJournal name: Infection and Drug Resistance  Article Designation: REVIEWY ear: 2017V olume: 10Running head verso: Hussain et alRunning head recto: Drug resistance in influenza A virusDOI: http://dx.doi.org/10.2147/IDR.S105473",Non-OADS,/arxiv_data1/oa_pdf/dd/a5/idr-10-121.PMC5404498.pdf
"Infection and Drug Resistance 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Infection and Drug Resistance Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journalInfection and Drug Resistance is an international, peer-reviewed open- access journal that focuses on the optimal treatment of infection (bacte-rial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance.",Non-OADS,/arxiv_data1/oa_pdf/dd/a5/idr-10-121.PMC5404498.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 134 Hussain et al,Non-OADS,/arxiv_data1/oa_pdf/dd/a5/idr-10-121.PMC5404498.pdf
Available FREE in open access from:  http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
"J Pathol Inform 2017, 1:18  http://www.jpathinformatics.org/content/8/1/18Journal of Pathology Informatics 2even a single molecular diagnostics test provides a unique  challenge for proper quality analytics.",Non-OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
"J Pathol Inform 2017, 1:18  http://www.jpathinformatics.org/content/8/1/18Journal of Pathology Informatics 3calculations and transformations that we required to arrive  at a finalized QA report.",Non-OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
"J Pathol Inform 2017, 1:18  http://www.jpathinformatics.org/content/8/1/18Journal of Pathology Informatics 4also available at the end of each report; it includes the specific  accession number, specific ordering and reporting dates, TAT,  and actual test result.",OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
"J Pathol Inform 2017, 1:18  http://www.jpathinformatics.org/content/8/1/18Journal of Pathology Informatics 5LIS’s are implemented on the premise that they meet  these technological and workload demands.",Non-OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
"J Pathol Inform 2017, 1:18  http://www.jpathinformatics.org/content/8/1/18Journal of Pathology Informatics 6Program-Microbiology Checklist; 2011.",Non-OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
Available from: https://www.wiki.ucern.com/display/1101discernHP/ Discern+Explorer+Main+Help.,Non-OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
Available from:  http://www.w3schools.com/php/default.asp.,Non-OADS,/arxiv_data1/oa_pdf/00/81/JPI-8-18.PMC5404607.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/4b/62/CG-CGCR170016.PMC5404617.pdf
Available FREE in open access from: http://www.clinicalimagingscience.,Non-OADS,/arxiv_data1/oa_pdf/de/33/JCIS-7-15.PMC5404618.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/cb/c7/CG-CGCR170025.PMC5404628.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/96/92/CG-CGCR170022.PMC5404629.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CASE REPORTS IN PLASTIC SURGERY AND HAND SURGERY, 2017 VOL.",Non-OADS,/arxiv_data1/oa_pdf/cc/c9/icrp-4-017.PMC5404631.pdf
"1, 17 –20 http://dx.doi.org/10.1080/23320885.2017.1296362",Non-OADS,/arxiv_data1/oa_pdf/cc/c9/icrp-4-017.PMC5404631.pdf
Available FREE in open access from:  http://www.jpathinformatics.org/text.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
"J Pathol Inform 2017, 1:16  http://www.jpathinformatics.org/content/8/1/16Journal of Pathology Informatics 2phone had a 5 MP camera.",Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
"J Pathol Inform 2017, 1:16  http://www.jpathinformatics.org/content/8/1/16Journal of Pathology Informatics 3equal to 97.5%, 94.8%, and 88.8% for quality, adequacy, and  video, respectively.",Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
"J Pathol Inform 2017, 1:16  http://www.jpathinformatics.org/content/8/1/16Journal of Pathology Informatics 4anything higher maybe superfluous.",Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
"Although not used  in this study, a grid template (https://images.nlm.nih.gov/ pathlab/template/) for small biopsies and larger specimens  could be printed and placed under the glass slide [Figure  2]  as the first image  (orientation slide) sent off the telepathology  consultation.",Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from: https://www.gsmaintelligence.com/research/2014/9/ smartphone‑forecasts‑and‑assumptions‑20072020/443/.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
"J Pathol Inform 2017, 1:16  http://www.jpathinformatics.org/content/8/1/16Journal of Pathology Informatics 5Lessons learned.",Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from: http://www.idc.com/getdoc.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from:  http://www.telescopeadapters.com/index.htm?all_canon.htm.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from: https://www.gsmaintelligence.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from:  http://www.census.gov/popclock/.,OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from: http://www.cnet.com/ news/camera-megapixels-why-more-isnt-always-better-smartphones- unlocked/.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available  from: http://www.dx.doi.org/10.1117/12.687433.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from: http://www.pogue.blogs.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from: http://www.nytimes.,Non-OADS,/arxiv_data1/oa_pdf/f0/eb/JPI-8-16.PMC5404633.pdf
Available from: http://www.who.int/nutrition/topics/infantfeeding/ en/.,Non-OADS,/arxiv_data1/oa_pdf/0a/09/IJPVM-8-28.PMC5404635.pdf
Available from: http://people.umass.edu/aizen/pdf/ tpb.measurement.pdf.,OADS,/arxiv_data1/oa_pdf/0a/09/IJPVM-8-28.PMC5404635.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.",Non-OADS,/arxiv_data1/oa_pdf/76/67/CG-CGCR170023.PMC5404640.pdf
Available from: https://www.en.wikipedia.org/wiki/ Birthday.,Non-OADS,/arxiv_data1/oa_pdf/d7/98/IJPVM-8-21.PMC5404641.pdf
Available from: https://www.en.wikipedia.org/wiki/ Birthday_problem.,Non-OADS,/arxiv_data1/oa_pdf/d7/98/IJPVM-8-21.PMC5404641.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CASE REPORTS IN PLASTIC SURGERY AND HAND SURGERY, 2017 VOL.",Non-OADS,/arxiv_data1/oa_pdf/b7/0c/icrp-4-035.PMC5404643.pdf
"1, 35 –41 http://dx.doi.org/10.1080/23320885.2017.1316201",Non-OADS,/arxiv_data1/oa_pdf/b7/0c/icrp-4-035.PMC5404643.pdf
Available from: http://www.eerqi.eu.,Non-OADS,/arxiv_data1/oa_pdf/9f/eb/IJPVM-8-27.PMC5404647.pdf
Available from: http://www.iranculture.org.,Non-OADS,/arxiv_data1/oa_pdf/9f/eb/IJPVM-8-27.PMC5404647.pdf
Available from: http://www.science‑metrix.com/30years‑Paper.,Non-OADS,/arxiv_data1/oa_pdf/9f/eb/IJPVM-8-27.PMC5404647.pdf
"4, 889 –894 http://dx.doi.org/10.1080/21645515.2016.1253644",Non-OADS,/arxiv_data1/oa_pdf/f5/66/khvi-13-04-1253644.PMC5404648.pdf
Vaccine 2014; 32:4713-25;PMID:24582632; http://dx.doi.org/10.1016/j.vaccine.2014.02.014 [3] European Medicines Agency.,Non-OADS,/arxiv_data1/oa_pdf/f5/66/khvi-13-04-1253644.PMC5404648.pdf
"Expert Rev Vaccines 2010; 9:1399-409; PMID:21105776; http://dx.doi.org/10.1586/erv.10.134 [7] Hoon Han S, Hee Woo J, Weber F, Joo Kim W, Ran Peck K, Il Kim S, Hwa Choi Y, Myung Kim J. Immunogenicity and safety of Intanza/C210/ IDﬂu/C210intradermal in ﬂuenza vaccine in South Korean adults: a multi- center, randomized trial.",Non-OADS,/arxiv_data1/oa_pdf/f5/66/khvi-13-04-1253644.PMC5404648.pdf
"Hum Vaccin Immunother 2013; 9:1971-7; PMID:23778938; http://dx.doi.org/10.4161/hv.25295 [8] Troy JD, Hill HR, Ewell MG, Frey SE.",OADS,/arxiv_data1/oa_pdf/f5/66/khvi-13-04-1253644.PMC5404648.pdf
"Vaccine 2015; 33:5425- 31; PMID:26319063; http://dx.doi.org/10.1016/j.vaccine.2015.08.032 [9] Beyer WE, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated in ﬂuenza vaccine, estab- lished by a meta-analysis of fourteen independent studies.",Non-OADS,/arxiv_data1/oa_pdf/f5/66/khvi-13-04-1253644.PMC5404648.pdf
Eur J Clin Microbiol Infect Dis 1996; 15:65-70; PMID:8641306; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f5/66/khvi-13-04-1253644.PMC5404648.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CASE REPORTS IN PLASTIC SURGERY AND HAND SURGERY, 2017 VOL.",Non-OADS,/arxiv_data1/oa_pdf/bd/57/icrp-4-030.PMC5404651.pdf
"1, 30 –34 http://dx.doi.org/10.1080/23320885.2017.1310620",Non-OADS,/arxiv_data1/oa_pdf/bd/57/icrp-4-030.PMC5404651.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CASE REPORTS IN PLASTIC SURGERY AND HAND SURGERY, 2017 VOL.",Non-OADS,/arxiv_data1/oa_pdf/a6/89/icrp-4-021.PMC5404652.pdf
"1, 21 –26 http://dx.doi.org/10.1080/23320885.2017.1296363",Non-OADS,/arxiv_data1/oa_pdf/a6/89/icrp-4-021.PMC5404652.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.CASE REPORTS IN PLASTIC SURGERY AND HAND SURGERY, 2017 VOL.",Non-OADS,/arxiv_data1/oa_pdf/b0/61/icrp-4-027.PMC5404658.pdf
"1, 27 –29 http://dx.doi.org/10.1080/23320885.2017.1308830",Non-OADS,/arxiv_data1/oa_pdf/b0/61/icrp-4-027.PMC5404658.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0158; April 2017 DOI: 10.1530/EDM-16-0158Fluticasone and iatrogenic  Cushing syndromeS A A van den Berg   and others Fluticasone furoate induced iatrogenic  Cushing syndrome in a pediatric patient  receiving anti-retroviral therapy S A A van den Berg1,2, N E van ‘t Veer3, J M A Emmen1 and R H T van Beek4 1Laboratory for Clinical Chemistry and Haematology, Amphia Hospital, Breda, The Netherlands, 2Laboratory  for Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands, Departments of 3Clinical Pharmacy, and  4Pediatrics, Amphia Hospital, Breda, The Netherlands Summary We present a case of iatrogenic Cushing’s syndrome, induced by treatment with fluticasone furoate (1–2 dd, 27.5 µg in  each nostril) in a pediatric patient treated for congenital HIV.",Non-OADS,/arxiv_data1/oa_pdf/a2/3b/edmcr-2017-160158.PMC5404706.pdf
"S A A van den Berg   and othersFluticasone and iatrogenic  Cushing syndromeID: 16-0158; April 2017 DOI: 10.1530/EDM-16-0158 http://www.edmcasereports.com  2propionate treatment may result in iatrogenic Cushing’s  syndrome, as some components of anti-retroviral therapy  inhibit CYP3A4/5 enzyme activity ( 3).",Non-OADS,/arxiv_data1/oa_pdf/a2/3b/edmcr-2017-160158.PMC5404706.pdf
S A A van den Berg   and othersID: 16-0158; April 2017 DOI: 10.1530/EDM-16-0158 Fluticasone and iatrogenic  Cushing syndrome http://www.edmcasereports.com  3tract and causes the minimal amount that is absorbed  to be rapidly metabolized by the liver ( 1).,Non-OADS,/arxiv_data1/oa_pdf/a2/3b/edmcr-2017-160158.PMC5404706.pdf
"S A A van den Berg   and othersFluticasone and iatrogenic  Cushing syndromeID: 16-0158; April 2017 DOI: 10.1530/EDM-16-0158 http://www.edmcasereports.com  4 6 Livanou T, Ferriman D & James VHT 1967 Recovery of hypothalamo- pituitary-adrenal function after corticosteroid therapy.",Non-OADS,/arxiv_data1/oa_pdf/a2/3b/edmcr-2017-160158.PMC5404706.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0153; March 2017 DOI: 10.1530/EDM-16-0153Delayed puberty due to  corticotroph adenomaD Giri and others Silent Crooke’s cell corticotroph adenoma   of the pituitary gland presenting as   delayed puberty Dinesh Giri1, Federico Roncaroli2,3, Ajay Sinha4, Mohammed Didi1 and   Senthil Senniappan1 1Department of Paediatric Endocrinology, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK,  2Department of Histopathology, Alder Hey Children’s Hospital, Liverpool, UK, 3Division of Neuroscience,  University of Manchester, Manchester, UK, and 4Department of Paediatric Neurosurgery, Alder Hey  Children’s Hospital, Liverpool, UK Summary Corticotroph adenomas are extremely rare in children and adolescents.",Non-OADS,/arxiv_data1/oa_pdf/b1/86/edmcr-2017-160153.PMC5404707.pdf
"proof only D Giri and others Delayed puberty due to  corticotroph adenomaID: 16-0153; March 2017 DOI: 10.1530/EDM-16-0153 http://www.edmcasereports.com  2(Kallman’s  syndrome and hypopituitarism) and  hypergonadotropic hypogonadism (Turner’s syndrome, Klinefelter and gonadal toxicity).",Non-OADS,/arxiv_data1/oa_pdf/b1/86/edmcr-2017-160153.PMC5404707.pdf
proof only D Giri and othersID: 16-0153; March 2017 DOI: 10.1530/EDM-16-0153 Delayed puberty due to  corticotroph adenoma http://www.edmcasereports.com  3Treatment The pituitary lesion was removed by transphenoidal  surgery and no evidence of calcification in the mass was noted.,Non-OADS,/arxiv_data1/oa_pdf/b1/86/edmcr-2017-160153.PMC5404707.pdf
proof only D Giri and others Delayed puberty due to  corticotroph adenomaID: 16-0153; March 2017 DOI: 10.1530/EDM-16-0153 http://www.edmcasereports.com  4associated with perioperative clinical or laboratory features  of hypercortisolaemia ( 6 ).,Non-OADS,/arxiv_data1/oa_pdf/b1/86/edmcr-2017-160153.PMC5404707.pdf
"proof only D Giri and othersID: 16-0153; March 2017 DOI: 10.1530/EDM-16-0153 Delayed puberty due to  corticotroph adenoma http://www.edmcasereports.com  5 8 Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV ,   Meyer FB, Laws ER Jr & Young WF Jr 2000 Clinically silent corticotroph tumors of the pituitary gland.",Non-OADS,/arxiv_data1/oa_pdf/b1/86/edmcr-2017-160153.PMC5404707.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0147; March 2017 DOI: 10.1530/EDM-16-0147Dyskinesia and psychosis in  hyponatraemiaV John and others Delayed dyskinesia and prolonged psychosis  in a patient presenting with profound hyponatraemia Victoria John1, Philip Evans2 and Atul Kalhan2 1Royal Glamorgan Hospital, Llantrisant, UK, and 2Consultant Diabetes & Endocrinology, Royal  Glamorgan Hospital, Llantrisant, UK Summary A 65-year-old woman was admitted to the emergency unit with a 48 h history of generalised weakness and confusion.",Non-OADS,/arxiv_data1/oa_pdf/16/0f/edmcr-2017-160147.PMC5404708.pdf
V John and others Dyskinesia and psychosis in  hyponatraemiaID: 16-0147; March 2017 DOI: 10.1530/EDM-16-0147 http://www.edmcasereports.com 2neuropsychiatric features persisting for a certain length  of time despite normalisation of the initial metabolic  trigger.,Non-OADS,/arxiv_data1/oa_pdf/16/0f/edmcr-2017-160147.PMC5404708.pdf
V John and othersID: 16-0147; March 2017 DOI: 10.1530/EDM-16-0147 Dyskinesia and psychosis in  hyponatraemia http://www.edmcasereports.com 3The cognitive function as well as dyskinetic  movements showed gradual improvement from week 3  onwards although she had persistent retrograde amnesia  for the events in the first 2 weeks of admission.,Non-OADS,/arxiv_data1/oa_pdf/16/0f/edmcr-2017-160147.PMC5404708.pdf
"V John and others Dyskinesia and psychosis in  hyponatraemiaID: 16-0147; March 2017 DOI: 10.1530/EDM-16-0147 http://www.edmcasereports.com 4The diagnosis of hyponatraemia-induced psychosis  and dyskinetic movements in this case was diagnosis  of exclusion as the rest of her biochemical tests, CSF  examination and radiological investigations were normal.",Non-OADS,/arxiv_data1/oa_pdf/16/0f/edmcr-2017-160147.PMC5404708.pdf
V John and othersID: 16-0147; March 2017 DOI: 10.1530/EDM-16-0147 Dyskinesia and psychosis in  hyponatraemia http://www.edmcasereports.com 5information.,Non-OADS,/arxiv_data1/oa_pdf/16/0f/edmcr-2017-160147.PMC5404708.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027Plurihormonal pituitary  adenoma in MEN1S Uraki and others Hypersecretion of ACTH and PRL from  pituitary adenoma in MEN1, adequately  managed by medical therapy Shinsuke Uraki1, Hiroyuki Ariyasu1, Asako Doi1, Hiroto Furuta1, Masahiro Nishi1,  Takeshi Usui2, Hiroki Yamaue3 and Takashi Akamizu1 1The 1st Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan, 2Department of  Medical Genetics, Shizuoka General Hospital, Shizuoka City, Japan, and 3The 2nd Department of Surgery,  Wakayama Medical University, Wakayama, Japan Summary A 54-year-old man had gastrinoma, parathyroid hyperplasia and pituitary tumor.",Non-OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
"S Uraki and others Plurihormonal pituitary  adenoma in MEN1ID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027 http://www.edmcasereports.com  2Background Multiple endocrine neoplasia type 1 (MEN1) is an  autosomal dominant inherited disease characterized by  parathyroid hyperplasia, endocrine enteropancreatic  tumors and pituitary adenomas.",Non-OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
S Uraki and othersID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027 Plurihormonal pituitary  adenoma in MEN1 http://www.edmcasereports.com  3not shown).,Non-OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
S Uraki and others Plurihormonal pituitary  adenoma in MEN1ID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027 http://www.edmcasereports.com  4cortisol and plasma ACTH levels and morning plasma  ACTH and serum cortisol levels were not suppressed  (Table  2 ).,Non-OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
S Uraki and othersID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027 Plurihormonal pituitary  adenoma in MEN1 http://www.edmcasereports.com  5after 6 months of treatment revealed no decrease in the  volume of the pituitary macroadenoma.,Non-OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
S Uraki and others Plurihormonal pituitary  adenoma in MEN1ID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027 http://www.edmcasereports.com  6Autopsy study in pituitary tumor MEN1  gene analysis  The genomic DNA was extracted  from the patient’s pituitary tumor at autopsy using  the Maxwell 16 DNA Purification Kit (Promega).,OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
S Uraki and othersID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027 Plurihormonal pituitary  adenoma in MEN1 http://www.edmcasereports.com  7(Fig.,Non-OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
S Uraki and others Plurihormonal pituitary  adenoma in MEN1ID: 17-0027; April 2017 DOI: 10.1530/EDM-17-0027 http://www.edmcasereports.com  8high-molecular-weight form of ACTH might have been  generated from impaired processing of POMC and/or  pro-ACTH.,Non-OADS,/arxiv_data1/oa_pdf/94/2b/edmcr-2017-170027.PMC5404709.pdf
"© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 16-0145; March 2017 DOI: 10.1530/EDM-16-0145Ethanol ablation therapy   for insulinomaA S Lages and others Endoscopic ultrasound-guided ethanol  ablation therapy for pancreatic insulinoma:   an unusual strategy Adriana de Sousa Lages1, Isabel Paiva1, Patrícia Oliveira1, Francisco Portela2 and  Francisco Carrilho1 Departments of 1Endocrinology, Diabetes and Metabolism and 2Gastroenterology, Coimbra Hospital  and University Center, Coimbra, Portugal` Summary Insulinomas are the most frequent cause of hyperinsulinaemic hypoglycaemia.",Non-OADS,/arxiv_data1/oa_pdf/48/e8/edmcr-2017-160145.PMC5404710.pdf
A S Lages and others Ethanol ablation therapy   for insulinomaID: 16-0145; March 2017 DOI: 10.1530/EDM-16-0145 http://www.edmcasereports.com  2pacemaker carrier due to a second-degree atrioventricular  block (Mobitz type II) and severe aortic valve disease was  admitted to the 1st time to our emergency department  (ED) due to acute prostration and confusion.,Non-OADS,/arxiv_data1/oa_pdf/48/e8/edmcr-2017-160145.PMC5404710.pdf
A S Lages and othersID: 16-0145; March 2017 DOI: 10.1530/EDM-16-0145 Ethanol ablation therapy   for insulinoma http://www.edmcasereports.com  3was necessary.,Non-OADS,/arxiv_data1/oa_pdf/48/e8/edmcr-2017-160145.PMC5404710.pdf
"A S Lages and others Ethanol ablation therapy   for insulinomaID: 16-0145; March 2017 DOI: 10.1530/EDM-16-0145 http://www.edmcasereports.com  4despite scarce clinical experience ( 1, 4, 5, 6, 7, 8).",Non-OADS,/arxiv_data1/oa_pdf/48/e8/edmcr-2017-160145.PMC5404710.pdf
"A S Lages and othersID: 16-0145; March 2017 DOI: 10.1530/EDM-16-0145 Ethanol ablation therapy   for insulinoma http://www.edmcasereports.com  5 6 Qin SY, Lu XP & Jiang HX 2014 EUS-guided ethanol ablation of  insulinomas: case series and literature review.",Non-OADS,/arxiv_data1/oa_pdf/48/e8/edmcr-2017-160145.PMC5404710.pdf
"This work is licensed under a Creative Commons  Attribution-NonCommercial-NoDerivs 3.0  Unported License .© 2017 The authors http://www.edmcasereports.com  Published by Bioscientifica LtdID: 17-0014; April 2017 DOI: 10.1530/EDM-17-0014Novel variant of TMEM127  gene K Saitoh and others Novel germline variant of TMEM127  gene in a  patient with familial pheochromocytoma Kohei Saitoh1, Takako Yonemoto1,2, Takeshi Usui2, Kazuhiro Takekoshi3,  Makoto Suzuki4, Yoshiharu Nakashima5, Koji Yoshimura5, Rieko Kosugi1,   Tatsuo Ogawa1 and Tatsuhide Inoue1 Departments of 1Diabetes and Endocrinology and 2Medical Genetics, Shizuoka General Hospital,  Shizuoka, Japan, 3Division of Sports Science, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan,  Departments of 4Pathology and 5Urology, Shizuoka General Hospital, Shizuoka, Japan Summary Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare tumours with a heterogeneous genetic background.",Non-OADS,/arxiv_data1/oa_pdf/69/05/edmcr-2017-170014.PMC5404711.pdf
K Saitoh and others Novel variant of TMEM127  geneID: 17-0014; April 2017 DOI: 10.1530/EDM-17-0014 http://www.edmcasereports.com  2Here we report a case of PCC in which a novel germline  variant was detected in the TMEM 127  gene.,Non-OADS,/arxiv_data1/oa_pdf/69/05/edmcr-2017-170014.PMC5404711.pdf
K Saitoh and othersID: 17-0014; April 2017 DOI: 10.1530/EDM-17-0014 Novel variant of TMEM127  gene http://www.edmcasereports.com  3The weight of the left glands with the mass was 89.5 g  (6.2 × 4.0 × 2.6 cm).,OADS,/arxiv_data1/oa_pdf/69/05/edmcr-2017-170014.PMC5404711.pdf
"K Saitoh and others Novel variant of TMEM127  geneID: 17-0014; April 2017 DOI: 10.1530/EDM-17-0014 http://www.edmcasereports.com  4PCC, 5 of whom had a family history of PCC ( 12).",Non-OADS,/arxiv_data1/oa_pdf/69/05/edmcr-2017-170014.PMC5404711.pdf
K Saitoh and othersID: 17-0014; April 2017 DOI: 10.1530/EDM-17-0014 Novel variant of TMEM127  gene http://www.edmcasereports.com  5Genomics and the Association for Molecular Pathology.,OADS,/arxiv_data1/oa_pdf/69/05/edmcr-2017-170014.PMC5404711.pdf
"MeSH Keywords:  Arthritis, Rheumatoid • Biomarkers, Pharmacological • Genetic Testing  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/900897Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Clinical Laboratory Medicine, Jiading Lanxiang Hospital, Shanghai,  P.R.",Non-OADS,/arxiv_data1/oa_pdf/96/b1/medscimonit-23-1849.PMC5404751.pdf
Material and Methods Search strategy Gene Expression Omnibus (GEO) ( https://www.ncbi.nlm.nih.,OADS,/arxiv_data1/oa_pdf/96/b1/medscimonit-23-1849.PMC5404751.pdf
gov/geo/)  and ArrayExpress ( http://www.ebi.ac.uk/arrayex - press/ ) are international public repositories that archive and  freely distribute microarray data submitted by the research  community.,OADS,/arxiv_data1/oa_pdf/96/b1/medscimonit-23-1849.PMC5404751.pdf
"Differential genes associated with infliximab response were  analyzed using the “gcRMA” package of R language (version  3.2.3, https://www.r-project.org/ ).",OADS,/arxiv_data1/oa_pdf/96/b1/medscimonit-23-1849.PMC5404751.pdf
"Gene ontology analysis To overview biological aspects of the biomarkers, the online  tool ToppGene ( https://toppgene.cchmc.org/ ) was used for a  gene ontology analysis of the molecular function, biological  processes, and cellular components in the biomarkers.",OADS,/arxiv_data1/oa_pdf/96/b1/medscimonit-23-1849.PMC5404751.pdf
"Mean ± SEM; bold arrow, defect margin; Endo, endocortical side; *p < 0.05 compared to wild-type mice; #compared to Lyz-TLR4 −/− mice, http://links.lww.com/PRS/C104.]",Non-OADS,/arxiv_data1/oa_pdf/02/57/prs-139-933e.PMC5404756.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/0f/5b/ijwh-9-235.PMC5404795.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).International Journal of Women’s Health 2017:9 235–243International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  235OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S12015 7 can mHealth improve access to safe blood  for transfusion during obstetric emergency?",Non-OADS,/arxiv_data1/oa_pdf/0f/5b/ijwh-9-235.PMC5404795.pdf
"Management of PPH includes admin - istration of non-pharmacological and/or pharmacological agents, (uterotonic drugs),  uterine tamponade or a range of surgical techniques to control bleeding, and blood  transfusion (BT) if blood loss becomes excessive.5 To prevent a significant number correspondence: aminur rahman Maternal and child Health Division,  icddr,b, 68 shaheed Tajuddin ahmed  sarani, Mohakhali, Dhaka 1212,  Bangladesh Tel +880 17 1325 7399 email draminur@icddrb.or g Journal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2017 Volume: 9 Running head verso: Rahman et al Running head recto: BIMA reduces BT lag time DOI: http://dx.doi.org/10.2147/IJWH.S120157",Non-OADS,/arxiv_data1/oa_pdf/0f/5b/ijwh-9-235.PMC5404795.pdf
Available from:  http://arxiv.org/pdf/1412.7276v 1.,Non-OADS,/arxiv_data1/oa_pdf/0f/5b/ijwh-9-235.PMC5404795.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international­journal­of­womens­health­journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/0f/5b/ijwh-9-235.PMC5404795.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/0f/5b/ijwh-9-235.PMC5404795.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/8f/b7/dddt-11-1263.PMC5404796.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1263–1265Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1263LeTTeropen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S13711 6 Pharmacokinetic interactions between glimepiride  and rosuvastatin in healthy Korean subjects: does  the SLCO1B1 or CYP2C9 genetic polymorphism  affect these drug interactions?",Non-OADS,/arxiv_data1/oa_pdf/8f/b7/dddt-11-1263.PMC5404796.pdf
"An ideal amount  for organic solvents (at 100% concentration) used for deproteinization should be more  than 3–4 volumes of the plasma sample to achieve optimum precipitation.5,6 However,  the authors have used only 10 µL of organic solvent (one-fifth of the plasma volume) Correspondence: ranjeet Prasad Dash Johns Hopkins University, North Wolfe  Street, Baltimore, MD 21205, USA email ranjeet.niper@gmail.co m Journal name: Drug Design, Development and Therapy Article Designation: Letter Y ear: 2017 Volume: 11 Running head verso: Thakkar and Dash Running head recto: Interactions between glimepiride and rosuvastatin in Korean subjects DOI: http://dx.doi.org/10.2147/DDDT.S137116",Non-OADS,/arxiv_data1/oa_pdf/8f/b7/dddt-11-1263.PMC5404796.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/8f/b7/dddt-11-1263.PMC5404796.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/b7/dddt-11-1263.PMC5404796.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/4b/19/nsa-10-069.PMC5404797.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/4b/19/nsa-10-069.PMC5404797.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Nanotechnology, Science and Applications 2017:10 69–77Nanotechnology, Science and Applications Dovepress submit your manuscript | www.dovepress.com Dovepress 69 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NSA.S129468 Interfacial surfactant competition and its impact  on poly(ethylene oxide)/Au and poly(ethylene  oxide)/Ag nanocomposite properties Merve Seyhan1 William Kucharczyk2 U Ecem Yarar1 Katherine Rickard2 Deniz Rende2,3 Nihat Baysal4 Seyda Bucak1 Rahmi Ozisik2,3 1Department of Chemical Engineering,   Yeditepe University, Istanbul, T urkey;   2Department of Materials Science and  Engineering, 3Center for Materials,   Devices, and Integrated Systems,   4Department of Chemical and  Biological Engineering, Rensselaer  Polytechnic Institute, Troy, NY, USAAbstract:  The structure and properties of nanocomposites of poly(ethylene oxide), with Ag  and Au nanoparticles, surface modified with a 1:1 (by volume) oleylamine/oleic acid mix- ture, were investigated via transmission electron microscopy, scanning electron microscopy,  thermogravimetric analysis, differential scanning calorimetry (DSC), infrared spectroscopy,  dynamic mechanical analysis, and static mechanical testing.",Non-OADS,/arxiv_data1/oa_pdf/4b/19/nsa-10-069.PMC5404797.pdf
"Polymer nanocomposites are used Correspondence: Seyda Bucak Department of Chemical Engineering, Yeditepe University, Istanbul 34755, TurkeyEmail seyda@yeditepe.edu.tr Rahmi Ozisik Department of Materials Science and Engineering, Rensselaer Polytechnic Institute, 110 8th Street, MRC-205, Troy, NY 12180, USA Email ozisik@rpi.eduJournal name: Nanotechnology, Science and Applications Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Seyhan et alRunning head recto: Interfacial surfactant competition in PEO nanocompositesDOI: http://dx.doi.org/10.2147/NSA.S129468",Non-OADS,/arxiv_data1/oa_pdf/4b/19/nsa-10-069.PMC5404797.pdf
"Nanotechnology, Science and Applications 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Nanotechnology, Science and Applications Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/nanotechnology-science-and-applications-journalNanotechnology, Science and Applications is an international, peer-reviewed, open  access journal that focuses on the science of nanotechnology in a wide range of industrial and academic applications.",Non-OADS,/arxiv_data1/oa_pdf/4b/19/nsa-10-069.PMC5404797.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 77 Interfacial surfactant competition in PEO nanocomposites  27.,Non-OADS,/arxiv_data1/oa_pdf/4b/19/nsa-10-069.PMC5404797.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/95/ff/ndt-13-1125.PMC5404798.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 1125–1129Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1125OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S13343 3 Plasma concentrations and dosing of 2 long-acting  injectable formulations of aripiprazole Phyllis M salzman1 arash raoufinia2 susan legacy3 Pedro such4 anna eramo5 1global Medical affairs, Otsuka  Pharmaceutical Development &  commercialization, inc., Princeton,  NJ, 2clinical Pharmacology, Otsuka  Pharmaceutical Development  &  commercialization, inc., rockville, MD,  3Us Medical affairs, Neuroscience,  Otsuka Pharmaceutical Development &   commercialization, inc., Princeton, NJ,  Usa; 4Medical affairs Psychiatry, h.  lundbeck a/s, Valby, Denmark; 5global  clinical Development, cNs, lundbeck  llc, Deerfield, il, UsaAbstract:  Maintaining therapeutic plasma concentrations of an antipsychotic agent is essential  in preventing relapse of symptoms in schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/95/ff/ndt-13-1125.PMC5404798.pdf
"For example, to achieve therapeutic aripiprazole concentrations dur - ing initiation of therapy, the first dose of AL should be accompanied by daily oral Correspondence: Arash Raoufinia clinical Pharmacology, Otsuka  Pharmaceutical Development &  commercialization, inc. 2440 research  Blvd, rockville, MD 20850, Usa Tel +1 240 683 3170 email Arash.Raoufinia@otsuka-us.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Salzman et al Running head recto: Plasma concentrations of 2 LAI formulations of aripiprazole DOI: http://dx.doi.org/10.2147/NDT.S133433",Non-OADS,/arxiv_data1/oa_pdf/95/ff/ndt-13-1125.PMC5404798.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/95/ff/ndt-13-1125.PMC5404798.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/95/ff/ndt-13-1125.PMC5404798.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/a0/2d/ott-10-2163.PMC5404799.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 2163–2171OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2163Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S13393 7 Monosomal karyotype in myeloid neoplasias:  a literature review Luisa Anelli Crescenza Pasciolla Antonella Zagaria Giorgina Specchia Francesco Albano Department of emergency and  Organ Transplantation (D.e.T.O.",Non-OADS,/arxiv_data1/oa_pdf/a0/2d/ott-10-2163.PMC5404799.pdf
"), Hematology  Section, University of Bari, Piazza Giulio  Cesare 11, 70124 Bari, italy Tel +39 080 547 8031 Fax +39 080 550 8369 email francesco.albano@uniba.i t Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2017 Volume: 10 Running head verso: Anelli et al Running head recto: Monosomal karyotype in myeloid neoplasias DOI: http://dx.doi.org/10.2147/OTT.S133937",Non-OADS,/arxiv_data1/oa_pdf/a0/2d/ott-10-2163.PMC5404799.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/a0/2d/ott-10-2163.PMC5404799.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a0/2d/ott-10-2163.PMC5404799.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Multidisciplinary Healthcare 2017:10 167–177Journal of Multidisciplinary Healthcare Dovepress submit your manuscript | www.dovepress.com Dovepress 167 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JMDH.S135370A qualitative study examining health literacy and  chronic illness self-management in Hispanic and  non-Hispanic older adults Robin J Jacobs1  Raymond L Ownby2  Amarilis Acevedo3  Drenna Waldrop-Valverde4 1Department of Family and  Community Medicine, Baylor College  of Medicine, Houston, TX, 2College  of Osteopathic Medicine, 3College  of Psychology, Nova Southeastern University, Fort Lauderdale, FL,  4Nell  Hodgson Woodruff School of Nursing,  Emory University, Atlanta, GA, USAPurpose: Chronic illness and low levels of health literacy affect health outcomes for many  individuals, particularly older adults and racial/ethnic minorities.",Non-OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
"9–13 Health literacy may be particularly important for management of Correspondence: Robin J Jacobs   Department of Family and Community  Medicine, Baylor College of Medicine, 3701 Kirby Drive, Suite 600, MS: BCM700, Houston, TX 77098, USA   Tel +1 713 798 1090   Fax +1 832 787 1307   Email rjjacobs@bcm.eduJournal name: Journal of Multidisciplinary Healthcare Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Jacobs et alRunning head recto: Qualitative study examining heath literacyDOI: http://dx.doi.org/10.2147/JMDH.S135370",Non-OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
"Journal of Multidisciplinary Healthcare 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-multidisciplinary-healthcare-journalThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
Visit http://www.dovepress.com/   testimonials.php to read real quotes from published authors.Dovepress 177 Qualitative study examining heath literacy 19.,Non-OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
Available at: http://www.nursingworld.org/MainMenuCategories/ANAMarketplace/ANA-Periodicals/OJIN/TableofContents/V ol142009/No3Sept09/Cultural-and-Linguistic-Barriers-.html.,Non-OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
Available at: http://www.qualitative-research.net/index.php/fqs/article/view/1428/3027.,Non-OADS,/arxiv_data1/oa_pdf/71/9c/jmdh-10-167.PMC5404800.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Multidisciplinary Healthcare 2017:10 179–194Journal of Multidisciplinary Healthcare Dovepress submit your manuscript | www.dovepress.com Dovepress 179 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JMDH.S127207A current affair: electrotherapy in wound healing Jerome Hunckler Achala de Mel UCL Division of Surgery and  Interventional Sciences, Faculty of Medical Sciences, University College London, London, UKAbstract: New developments in accelerating wound healing can have immense beneficial  socioeconomic impact.",Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
"Different treatment strategies exist for the management of chronic wounds; some are invasive, such as wound debridement and skin substitute therapy, while others are noninvasive, such as compression bandaging, wound  dressing, Correspondence: Achala de Mel UCL Division of Surgery and Interventional Sciences, Faculty of Medical Sciences, University College London, Pond Street, London, NW3 2QG, UKTel +44 20 7435 4608Email demelach@gmail.comJournal name: Journal of Multidisciplinary Healthcare Article Designation: REVIEWY ear: 2017V olume: 10Running head verso: Hunckler and de MelRunning head recto: Electrotherapy in wound healingDOI: http://dx.doi.org/10.2147/JMDH.S127207",Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
"Available from http://www.nature.com/.20 Figure C data from Pu and Zhao.19 Scratch Scratch Scratch Not reportedNotreported No EF Wound closesWound closesWound closesWound opens+ + – –No EFB C0 min 96 min 204 min+ + – –Wound closesWound closes Wound open s Toward the anode Toward the cathode Monocytes Fibroblasts Epidermal cellsCell migrationA NeutrophilsMacrophagesVascular endothelial cellsand ionic flow, to contribute toward intracellular polariza- tion and cellular response.77 Intracellular pathways, such as  phosphatidylinositol-3-OH kinase,20,78,79 and elements, such  as golgi apparatus,10,19 seem to play a role in the galvanotaxis  response.Individually, each cell type exhibits specific behaviors  under ES and no ES displays a significant reduction of cell viability or cytotoxic effect.",Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
Available from: https://www.diabetes.org.uk/Documents/nhs-diabetes/footcare/footcare-for-people-with-diabetes.pdf.,Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
Available from: http://www.cbc.ca/news/technology/printalive-3d-skin-tissue-printer-wins-canadian-dyson-award-1.277066794.,Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
"Journal of Multidisciplinary Healthcare 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-multidisciplinary-healthcare-journalThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
Visit http://www.dovepress.com/   testimonials.php to read real quotes from published authors.Dovepress 194 Hunckler and de Mel Supplementary material Video S1 The skin battery and the current of injury.,Non-OADS,/arxiv_data1/oa_pdf/9f/9a/jmdh-10-179.PMC5404801.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e1/04/opth-11-745.PMC5404802.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Ophthalmology 2017:11 745–752Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  745Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S13137 1 intersession test–retest variability of 10-2 Maia  microperimetry in fixation-threatening glaucoma evan n Wong1,2 William h Morgan1,3 Fred K Chen1,3 1Centre for Ophthalmology and  Visual science ( incorporating lions  eye institute), The University of  Western australia, 2Department  of Ophthalmology, sir Charles  gairdner hospital, 3Department of  Ophthalmology, royal Perth hospital,   Perth, W a, australiaPurpose:  To determine the intersession test–retest variability (TRV) of CenterVue Macular  Integrity Assessment (MAIA) microperimeter in glaucoma patients with fixation-threatening  field defects.",Non-OADS,/arxiv_data1/oa_pdf/e1/04/opth-11-745.PMC5404802.pdf
"This allows accurate assessment of  the central visual field even in the absence of stable and foveal fixation.4 While the Correspondence: Fred K Chen Centre for Ophthalmology and  Visual science (incorporating lions  eye institute), The University of  Western australia, 2 Verdun street,  nedlands, Wa 6009, australia Fax +61 8 9381 0700 email fredchen@lei.org.a u Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Wong et al Running head recto: Variability of MAIA perimetry in glaucoma DOI: http://dx.doi.org/10.2147/OPTH.S131371",Non-OADS,/arxiv_data1/oa_pdf/e1/04/opth-11-745.PMC5404802.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/e1/04/opth-11-745.PMC5404802.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e1/04/opth-11-745.PMC5404802.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/44/b1/pgpm-10-129.PMC5404803.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/44/b1/pgpm-10-129.PMC5404803.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Pharmacogenomics and Personalized Medicine 2017:10 129–142Pharmacogenomics and Personalized Medicine Dovepress submit your manuscript | www.dovepress.com Dovepress  129 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PGPM.S105854ABCG2 polymorphisms in gout: insights into  disease susceptibility and treatment approaches MC Cleophas1,2 LA Joosten1–3 LK Stamp4 N Dalbeth5 OM Woodward6 T ony R Merriman7 1Department of Internal Medicine,   2Radboud Institute for Molecular Life  Sciences, Radboud University Medical  Center, Nijmegen, the Netherlands;   3Department of Medical Genetics,   Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania;   4Department of Medicine, University  of Otago Christchurch, Christchurch,   5Department of Medicine, University  of Auckland, Auckland, New Zealand;   6Department of Physiology, University  of Maryland School of Medicine,  Baltimore, MD, USA;  7Department of  Biochemistry, University of Otago,  Dunedin, New ZealandAbstract: As a result of the association of a common polymorphism ( rs2231142, Q141K) in the  ATP-binding cassette G2 (ABCG2) transporter with serum urate concentration in a genome-wide  association study, it was revealed that ABCG2 is an important uric acid transporter.",Non-OADS,/arxiv_data1/oa_pdf/44/b1/pgpm-10-129.PMC5404803.pdf
"Approximately 30 genetic loci, including ABCG2, influence serum urate concentrations, 4 but less is understood about the genetic control of the formation  of MSU crystals and the subsequent inflammatory response.5 Urate-lowering therapy  is a cornerstone of gout management; however, for various reasons, it is often not Correspondence: Tony R Merriman Department of Biochemistry, University of Otago, Box 56, Dunedin 9054, New ZealandEmail tony.merriman@otago.ac.nzJournal name: Pharmacogenomics and Personalized Medicine Article Designation: REVIEWY ear: 2017V olume: 10Running head verso: Cleophas et alRunning head recto: ABCG2 polymorphisms in goutDOI: http://dx.doi.org/10.2147/PGPM.S105854",Non-OADS,/arxiv_data1/oa_pdf/44/b1/pgpm-10-129.PMC5404803.pdf
Numerous other rare (< 1%) variants are identified (http://www.ensembl.,Non-OADS,/arxiv_data1/oa_pdf/44/b1/pgpm-10-129.PMC5404803.pdf
"Pharmacogenomics and Personalized Medicine 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Pharmacogenomics and Personalized Medicine Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/pharmacogenomics-and-personalized-medicine-journalPharmacogenomics and Personalized Medicine is an international, peer- reviewed, open access journal characterizing the influence of genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.",Non-OADS,/arxiv_data1/oa_pdf/44/b1/pgpm-10-129.PMC5404803.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 142 Cleophas et al,Non-OADS,/arxiv_data1/oa_pdf/44/b1/pgpm-10-129.PMC5404803.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/25/c9/ott-10-2239.PMC5404804.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 2239–2247OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2239Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S12997 0 PiK3ca expression in diffuse large B cell  lymphoma tissue and the effect of its knockdown  in vitro Wenli cui1–4,* shutao Zheng5,6,* Zebing liu1–3 Weige Wang1–3 Ying cai1–3 rui Bi1–3 Bing cao1–3 Xiaoyan Zhou1–3 1Department of Pathology, shanghai  cancer center, Fudan University,   2Department of Oncology, shanghai  Medical college, Fudan University,   3institute of Pathology, Fudan  University, shanghai, 4Department  of Pathology, The First affiliated  hospital of Xinjiang Medical  University, 5clinical Medical research  institute, First affiliated hospital  of Xinjiang Medical University,   6state Key lab incubation Base of  Xinjiang Major Diseases research,   First affiliated hospital of Xinjiang  Medical University, Xinjiang Uygur  autonomous region, Urumqi, People’s  republic of china *These authors contributed equally   to this workAbstract:  PIK3CA has been extensively investigated from its molecular mechanism perspective  and epidemiological association with its mutations in different types of cancers.",Non-OADS,/arxiv_data1/oa_pdf/25/c9/ott-10-2239.PMC5404804.pdf
"Nevertheless, limited data are available regarding PIK3CA in DLBCL, correspondence: Xiaoyan Zhou Department of Pathology, Fudan  University shanghai cancer center,  Dong’an road 270, shanghai 200032,  People’s republic of china Tel +86 21 6417 5590 email xyzhou100@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Cui et al Running head recto: PIK3CA promoted proliferation in DLBCL DOI: http://dx.doi.org/10.2147/OTT.S129970",Non-OADS,/arxiv_data1/oa_pdf/25/c9/ott-10-2239.PMC5404804.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/25/c9/ott-10-2239.PMC5404804.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/25/c9/ott-10-2239.PMC5404804.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/02/12/jaa-10-123.PMC5404805.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/02/12/jaa-10-123.PMC5404805.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Asthma and Allergy 2017:10 123–130Journal of Asthma and Allergy Dovepress submit your manuscript | www.dovepress.com Dovepress 123 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JAA.S129159Managing the pediatric patient with refractory  asthma: a multidisciplinary approach James Cook1,2 Fran Beresford2 Valentina Fainardi1 Pippa Hall2 Georgie Housley2 Angela Jamalzadeh2 Michelle Nightingale2 David Winch2 Andrew Bush1,2 Louise Fleming1,2 Sejal Saglani1,2 1Inflammation, Repair and  Development, National Heart and  Lung Institute, Imperial College London,  2Respiratory Paediatrics,   Royal Brompton Hospital, London, UKAbstract:  Children with asthma that is refractory to high levels of prescribed treatment are  described as having problematic severe asthma.",Non-OADS,/arxiv_data1/oa_pdf/02/12/jaa-10-123.PMC5404805.pdf
"4 Children with on-going asthma symptoms despite maximal conventional treat- ments are described as having problematic severe asthma.5 Those in whom persistent  symptoms result from a failure of basic asthma management are described as having “difficult asthma” (DA), while those who remain symptomatic despite these factors having been addressed are described as having “severe therapy-resistant asthma” Correspondence: Sejal Saglani Respiratory Paediatrics, Imperial College London, 368 Sir Alexander Fleming Building, Exhibition Road, London, SW7 2AZ, UKTel +44 20 7594 3167Fax +44 20 7594 3119Email s.saglani@imperial.ac.ukJournal name: Journal of Asthma and Allergy Article Designation: REVIEWY ear: 2017V olume: 10Running head verso: Cook et alRunning head recto: Managing the pediatric patient with refractory asthmaDOI: http://dx.doi.org/10.2147/JAA.S129159",Non-OADS,/arxiv_data1/oa_pdf/02/12/jaa-10-123.PMC5404805.pdf
"Journal of Asthma and Allergy 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Asthma and Allergy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/journal-of-asthma-and-allergy-journalThe Journal of Asthma and Allergy is an international, peer-reviewed  open access journal publishing original research, reports, editorials and commentaries on the following topics: Asthma; Pulmonary physi-ology; Asthma related clinical health; Clinical immunology and the immunological basis of disease; Pharmacological interventions and new therapies.",Non-OADS,/arxiv_data1/oa_pdf/02/12/jaa-10-123.PMC5404805.pdf
Available from: http://www.legislation.gov.uk/ukpga/2004/31/contents.,Non-OADS,/arxiv_data1/oa_pdf/02/12/jaa-10-123.PMC5404805.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e4/58/ppa-11-801.PMC5404806.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Patient Preference and Adherence 2017:11 801–810Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  801OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S12567 2 Medication adherence as a predictor of 30-day  hospital readmissions Olga Z rosen1 rachel Fridman2 Bradley T rosen3,4 rita shane1 Joshua M Pevnick4,5 1Department of Pharmacy  services, cedars- sinai Medical  center, 2resources & Outcomes  Management, cedars- sinai health  system, 3Department of Medicine,   isP hospitalist service, cedars- sinai Medical center, 4University  of california, los Angeles school  of Medicine, 5Division of general  internal Medicine, Department of  Medicine, cedars- sinai Medical  center, los Angeles, cA, UsAPurpose:  The aim of this study was to test whether patient medication adherence, a modifiable  risk factor obtainable at hospital admission, predicts readmission within 30 days.",Non-OADS,/arxiv_data1/oa_pdf/e4/58/ppa-11-801.PMC5404806.pdf
"Models that include functional and social variables produce greater predictive correspondence: Olga Z rosen Department of Pharmacy services,  cedars-sinai Medical center, 8700  Beverly Boulevard, A903, los Angeles,  cA 90048, UsA Tel +1 424 315 4410 Fax +1 310 423 0037 email olga.rosen@cshs.or g Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Rosen et al Running head recto: Medication nonadherence predicts readmission DOI: http://dx.doi.org/10.2147/PPA.S125672",Non-OADS,/arxiv_data1/oa_pdf/e4/58/ppa-11-801.PMC5404806.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/e4/58/ppa-11-801.PMC5404806.pdf
Available from: http://www.bls.gov/oes /.,OADS,/arxiv_data1/oa_pdf/e4/58/ppa-11-801.PMC5404806.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/90/a6/jpr-10-941.PMC5404807.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/90/a6/jpr-10-941.PMC5404807.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Journal of Pain Research  2017:10 941–949Journal of Pain Research Dovepress submit your manuscript | www.dovepress.com Dovepress  941 ORIGINAL RESEARCH   open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S129313The efficacy of a preparatory phase of a  touch‑based approach in treating chronic low  back pain: a randomized controlled trial Federico Zangrando1 Giulia Piccinini2 Clara Tagliolini1 Gabriella Marsilli2 Marco Iosa3 Maria Chiara Vulpiani2 T eresa Paolucci1 1Complex Unit of Physical Medicine  and Rehabilitation, Policlinico  Umberto I Hospital, “Sapienza” University of Rome, Rome, Italy;   2Unit of Physical Medicine and  Rehabilitation, Sant’Andrea Hospital,  “Sapienza” University of Rome,  Rome, Italy;  3Clinical Laboratory of  Experimental Neurorehabilitation,  Santa Lucia Foundation, Rome, Italy Background: Massage therapy is an important element of rehabilitation in the treatment of  chronic low back pain (CLBP).",Non-OADS,/arxiv_data1/oa_pdf/90/a6/jpr-10-941.PMC5404807.pdf
"4 Correspondence: Teresa Paolucci Complex Unit of Physical Medicine and Rehabilitation, Policlinico Umberto I Hospital, “Sapienza” University of Rome, Piazzale Aldo Moro 5, 00185 Rome, ItalyTel +39 347 933 8625Fax +39 064 991 4552Email teresapaolucci@hotmail.com Journal name: Journal of Pain Research  Article Designation: ORIGINAL RESEARCH Y ear: 2017V olume: 10Running head verso: Zangrando et alRunning head recto: A touch-based approach in chronic low back painDOI: http://dx.doi.org/10.2147/JPR.S129313",Non-OADS,/arxiv_data1/oa_pdf/90/a6/jpr-10-941.PMC5404807.pdf
"The number of sessions and the time of each session were  chosen, considering routine good clinical medical practice with respect to massage therapy for CLBP 8 and the SIMFER  guidelines (http://www.simferweb.net).Traditional rehabilitative massage  program  We applied the following massage techniques34 to the lumbar  region of patients in both groups (TMG and SMG) (Figure 2):  •	touch surface (10 min): both hands held open with the  fingers gliding slowly over the skin without pressure or direction.",Non-OADS,/arxiv_data1/oa_pdf/90/a6/jpr-10-941.PMC5404807.pdf
"Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Journal of Pain Research  Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/journal‑of‑pain‑research‑journal The Journal of Pain Research is an international, peer reviewed, open  access, online journal that welcomes laboratory and clinical findings   in the fields of pain research and the prevention and management of pain.",Non-OADS,/arxiv_data1/oa_pdf/90/a6/jpr-10-941.PMC5404807.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 949 A touch‑based approach in chronic low back pain 20.,Non-OADS,/arxiv_data1/oa_pdf/90/a6/jpr-10-941.PMC5404807.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f6/83/ott-10-2227.PMC5404808.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 2227–2237OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2227Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S13350 4 novel role of granulocyte-macrophage  colony-stimulating factor: antitumor effects  through inhibition of epithelial-to-mesenchymal  transition in esophageal cancer Jingxin Zhang1,* Qiqi liu2,* lili Qiao3 Pingping hu2 guodong Deng2 ning liang2 Jian Xie2 hui luo4 Jiandong Zhang2 1Division of Oncology, Department of  graduate, Weifang Medical college,   Weifang, 2Department of radiation  Oncology, Qianfoshan hospital  affiliated to shandong University,   shandong University, 3Department  of Oncology, The Fifth Peoples’  hospital of Jinan, Jinan, 4Department  of radiation Oncology, henan cancer  hospital affiliated to Zhengzhou  University, Zhengzhou University,   Zhengzhou, henan, People’s republic  of china *These authors contributed equally  to this workPurpose:  Recent studies demonstrate the possible antitumor effects of granulocyte-macrophage  colony-stimulating factor (GM-CSF); however, the exact mechanism is still unclear.",Non-OADS,/arxiv_data1/oa_pdf/f6/83/ott-10-2227.PMC5404808.pdf
"Granulocyte-macrophage colony-stimulating factor (GM-CSF), a 22 kDa gly - coprotein, was first described as an in vitro inducer of differentiation and prolifera - tion of bone marrow progenitor cells into distinct colonies, including granulocytes  and macrophages.4 GM-CSF can also act on relatively early progenitor cells and   interacts with erythropoietin to stimulate eosinophil and megakaryocyte colony  formation in vitro.5 Thus, recombinant GM-CSF is an important agent used to enhance correspondence: Jiandong Zhang Department of radiation Oncology,  Qianfoshan Hospital Affiliated to  shandong University, 16766 Jingshi road,  Jinan, 250014, People’s republic of china Tel +86 531 135 8312 34 ext 86 email Jiandongzhang165@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Zhang et al  Running head recto: Novel role of granulocyte-macrophage colony-stimulating factor DOI: http://dx.doi.org/10.2147/OTT.S133504",Non-OADS,/arxiv_data1/oa_pdf/f6/83/ott-10-2227.PMC5404808.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/f6/83/ott-10-2227.PMC5404808.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/f6/83/ott-10-2227.PMC5404808.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/0b/d0/ndt-13-1131.PMC5404809.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 1131–1140Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1131Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S11599 6 Treatment-resistant Lennox-Gastaut syndrome:  therapeutic trends, challenges and future directions Adam P Ostendorf1 Yu-Tze Ng2 1Department of Pediatrics, Neurology  Section, Nationwide Children’s  Hospital, The Ohio State University,   Columbus, OH, 2Department of  Pediatrics, Baylor College of Medicine,   The Children’s Hospital of San  Antonio, San Antonio, TX, USAAbstract:  Lennox-Gastaut syndrome is a severe, childhood-onset electroclinical syndrome com - prised of multiple seizure types, intellectual and behavioral disturbances and characteristic findings  on electroencephalogram of slow spike and wave complexes and paroxysmal fast frequency activ - ity.",Non-OADS,/arxiv_data1/oa_pdf/0b/d0/ndt-13-1131.PMC5404809.pdf
"Patients’ families have reported that their  most significant concerns are fear of dying and the unpredictability of seizures, side  effects and social isolation.10,11 These data may suggest prioritizing seizure control  and facilitating interactions with appropriate support networks.Correspondence: Adam P Ostendorf Department of Pediatrics, Neurology  Section, Nationwide Children’s Hospital,  The Ohio State University, 700 Children’s  Drive, Columbus, OH 43205, USA Tel +1 614 722 4625 Fax +1 614 722 4633 email adam.ostendorf@ nationwidechildrens.or g  Yu-Tze Ng Department of Pediatrics, Baylor  College of Medicine, The Children’s  Hospital of San Antonio, San  Antonio, TX 78207, USA email ytng@bcm.ed u Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2017 Volume: 13 Running head verso: Ostendorf and Ng Running head recto: Treatment of LGS: past, present and future DOI: http://dx.doi.org/10.2147/NDT.S115996",Non-OADS,/arxiv_data1/oa_pdf/0b/d0/ndt-13-1131.PMC5404809.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/0b/d0/ndt-13-1131.PMC5404809.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/0b/d0/ndt-13-1131.PMC5404809.pdf
"MeSH Keywords:  Distant Surgery • Economic Surgery • Future Surgery • Medical Robotics • Medicine • Surgery •  Telemedicine  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/904666Executive Vice President, International Scientific Information, Inc., Melville, N.Y.,  U.S.A.e-ISSN 1643-3750 © Med Sci Monit, 2017; 23: 1856 DOI: 10.12659/MSM.904666 1856 Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]   [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]   [Chemical Abstracts/CAS] [Index Copernicus]EDITORIAL This work is licensed under Creative Common Attribution- NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/9a/d4/medscimonit-23-1856.PMC5404821.pdf
"MeSH Keywords:  Breast Neoplasms • Gene Expression Profiling • Gene Targeting • Information Systems • MicroRNAs  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/900030Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Pathology, The First Affiliated Hospital of Guangxi Medical  University, Nanning, Guangxi, P.R.",Non-OADS,/arxiv_data1/oa_pdf/e9/b4/medscimonit-23-1857.PMC5404822.pdf
"Retrieval of BC gene expression microarray data Microarray data for miR-101-3p transfected in BC cells were  searched in Gene Expression Omnibus (GEO, http://www.ncbi.",OADS,/arxiv_data1/oa_pdf/e9/b4/medscimonit-23-1857.PMC5404822.pdf
"GO, KEGG and network analysis To discern the biological attributes of the putative target genes,  GO and KEGG enrichment analyses were completed using DAVID  (https://david.ncifcrf.gov , version 6.7) [22].",OADS,/arxiv_data1/oa_pdf/e9/b4/medscimonit-23-1857.PMC5404822.pdf
"https://doi.org/10.1177/1179546817702149 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Clinical Medicine Insights: Cardiology Volume 11: 1–4 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1179546817702149 Primary Cardiovascular Prevention: A Conventional  Definition Primary cardiovascular (CV) prevention can be defined as the  pharmacological and/or nonpharmacological prophylaxis of atherothrombosis, evaluated as prevention of major cardiovas-cular events (MCEs) in subjects without history or clinical signs of underlying disease.",Non-OADS,/arxiv_data1/oa_pdf/8e/93/10.1177_1179546817702149.PMC5404896.pdf
"https://doi.org/10.1177/1178632917701123 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Health Services Insights Volume 10: 1–9 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1178632917701123 Introduction Cardiovascular disease (CVD) is increasingly a threat to both  developed and developing countries.1 The risk factors that con- tinue to jeopardize cardiovascular health and precede CVD onset—diabetes, hyperlipidemia, hypertension, obesity, physi-cal inactivity, poor nutrition, and smoking—disproportionately affect racial/ethnic minority populations and those of lower socioeconomic status.",Non-OADS,/arxiv_data1/oa_pdf/c3/3a/10.1177_1178632917701123.PMC5404898.pdf
"https://doi.org/10.1177/1177392817701726 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Drug Target Insights Volume 11: 1–14 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1177392817701726 Introduction Dengue is a mosquito-borne infection found in the tropical  and subtropical regions.",Non-OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
The entire sequence was further input into ClustalW2 server (http://www.ebi.ac.uk/Tools/clustalw2).,OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
The 3D structure of this enzyme can be later downloaded from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) through the http://www.rcsb.org/pdb/home/home.do.,Non-OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
"Computational ADME-Tox and synthetic  accessibility prediction In this study, the remaining ligand candidates were screened  through their ADME-Tox properties using various software, namely, OSIRIS Property Explorer (www.organic-chemistry.org), Toxtree (toxtree.sourceforge.net), and ADME-Tox (http://ilab.acdLabs.com).",OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
This alignment was done using ClustalW software via European Molecular Biology Laboratory (EMBL) European Bioinformatics Institute Web site (http://www.ebi.ac.uk).,OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
"Nowadays, the ADME-Tox prediction can be easily made with the help of computers using in silico method; one of the software that is frequently used in the analysis is ADME-Tox, which is an online software available in ACD/Labs (via https://ilab.acdLabs.com/iLab2/).",OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
https://www.ncbi.nlm.nih.gov/refseq/.,Non-OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
http://www8.cs.umu.,Non-OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
ACD/I-Lab 2.0. https://ilab.acdlabs.com/iLab2/index.php.,OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
http://www.organic-chemistry.org/prog/peo/.,OADS,/arxiv_data1/oa_pdf/30/80/10.1177_1177392817701726.PMC5404899.pdf
"https://doi.org/10.1177/1179172117701738 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Ophthalmology and Eye Diseases Volume 9: 1–5 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1179172117701738 Introduction Cataracts are the leading treatable cause of blindness in the  world.1 In sub-Saharan countries, many barriers contribute to  low rates of cataract surgical coverage, including lack of financial resources, difficult access to eye care services, igno-rance, and fear of surgery.",Non-OADS,/arxiv_data1/oa_pdf/d5/de/10.1177_1179172117701738.PMC5404900.pdf
"https://doi.org/10.1177/1176934317703401 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Evolutionary Bioinformatics Volume 13: 1–5 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1176934317703401 Introduction Glycoside hydrolases (GHs) are Carbohydrate-Active  enZymes (CAZymes) that assist the breakdown of glycoside bonds of complex sugars into carbohydrates.",Non-OADS,/arxiv_data1/oa_pdf/f1/68/10.1177_1176934317703401.PMC5404901.pdf
"https://doi.org/10.1177/1178632917701025 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Health Services Insights Volume 10: 1–21 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1178632917701025 Introduction The number of outpatient surgeries performed in physician  offices in the United States has risen dramatically over the past 30 years, increasing from about 110 000 procedures in  1981 to 12 million procedures in 2009.",Non-OADS,/arxiv_data1/oa_pdf/2a/00/10.1177_1178632917701025.PMC5404902.pdf
"TrendWatch ,  July 2006. http://www.aha.org/research/reports/tw/twjuly2006migration.pdf.",OADS,/arxiv_data1/oa_pdf/2a/00/10.1177_1178632917701025.PMC5404902.pdf
http://kff.org/statedata/.,Non-OADS,/arxiv_data1/oa_pdf/2a/00/10.1177_1178632917701025.PMC5404902.pdf
http://www.aha.org/content/15/hopdcomparison.,Non-OADS,/arxiv_data1/oa_pdf/2a/00/10.1177_1178632917701025.PMC5404902.pdf
"https://doi.org/10.1177/1177625017702393 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Gene Regulation and Systems Biology Volume 11: 1–21 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1177625017702393 Introduction In mammalian organisms, the circadian machinery (ie, the bio- logical time-keeping mechanisms which maintain 24-hour oscillations in cellular and physiological processes) is organized as a hierarchical, interconnected network of clocks.",Non-OADS,/arxiv_data1/oa_pdf/09/e5/10.1177_1177625017702393.PMC5404903.pdf
"https://doi.org/10.1177/1178626417703995 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Biochemistry Insights Volume 10: 1–10 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1178626417703995 Introduction There is substantial evidence that the growth hormone  (GH)/insulin-like growth factor (IGF) system is involved in the pathogenesis of obesity.",Non-OADS,/arxiv_data1/oa_pdf/c8/b7/10.1177_1178626417703995.PMC5404904.pdf
Information regarding primer sequences is listed in Table S1[available as Supplementary data at JAC Online (http://jac.oxford-journals.org/)].,OADS,/arxiv_data1/oa_pdf/77/e4/dkm054.PMC5404905.pdf
"http://www.info.gov.hk/tb_chest/doc/Annurept_2002.pdf (10 January 2007, date last accessed).",Non-OADS,/arxiv_data1/oa_pdf/77/e4/dkm054.PMC5404905.pdf
"https://doi.org/10.1177/1179546817701725 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Clinical Medicine Insights: Cardiology Volume 11: 1–23 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1179546817701725 Introduction Overweight/obesity is reaching epidemic proportions world- wide, where ~40% of the adult population are considered over-weight, with 13% classed as obese.",Non-OADS,/arxiv_data1/oa_pdf/5b/71/10.1177_1179546817701725.PMC5404906.pdf
http://www.who.int/ mediacentre/factsheets/fs311/en/.,Non-OADS,/arxiv_data1/oa_pdf/5b/71/10.1177_1179546817701725.PMC5404906.pdf
"This is an Open Access article distributed under the terms of the Creative  Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any  medium, provided the original work is not altered or transformed in any way, and that the work  is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ef/a7/ciw793.PMC5404930.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Oral mucositisMicrobiotaNasopharyngeal carcinoma Radiotherapy 1.,Non-OADS,/arxiv_data1/oa_pdf/ac/fd/main.PMC5405060.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.02.002 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ac/fd/main.PMC5405060.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ac/fd/main.PMC5405060.pdf
The raw sequence data for 16S rRNA gene sequencingdata sets is available from the European Bioinformatics Institute (http://www.ebi.ac.uk /) at accession number PRJEB15392.,OADS,/arxiv_data1/oa_pdf/ac/fd/main.PMC5405060.pdf
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.molcel.2017.03.005,Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"Molecular Cell Article Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication Iosiﬁna P. Foskolou,1Christian Jorgensen,2Katarzyna B. Leszczynska,1Monica M. Olcina,1Hanna Tarhonskaya,4 Bauke Haisma,1Vincenzo D’Angiolella,1William K. Myers,3Carmen Domene,2,4Emily Flashman,4 and Ester M. Hammond1,5,* 1Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK 2Department of Chemistry, King’s College London, Britannia House, 7 Trinity Street, London SE1 1DB, UK 3Inorganic Chemistry Laboratory, University of Oxford, South Parks Road, Oxford OX1 3QR, UK 4Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansﬁeld Road, Oxford OX1 3TA, UK 5Lead Contact *Correspondence: ester.hammond@oncology.ox.ac.uk http://dx.doi.org/10.1016/j.molcel.2017.03.005 SUMMARY Cells exposed to hypoxia experience replication stress but do not accumulate DNA damage, sug- gesting sustained DNA replication.",Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
STAR+METHODS Detailed methods are provided in the online version of this paper and include the following: dKEY RESOURCES TABLE dCONTACT FOR REAGENT AND RESOURCE SHARING dEXPERIMENTAL MODEL AND SUBJECT DETAILS dMETHOD DETAILS BCell culture and treatments BHypoxia treatment BImmunobloting and Immonuﬂuorescence BRT-qPCR BFlow cytometry (FACS) BDNA Fiber analysis and dNTP pool determination BImmunoprecipitation (IP) and Chromatin IP (ChIP) BColony survival and apoptosis BxCELLigence proliferation assay BXenografts and tissue IF staining BTCGA RNA-sequencing (RNA-seq) analysis and anal-ysis of colorectal cancer datasets BProtein overexpression and puriﬁcation BdCDP formation assays BDetermination of CDP/dCDP BCircular dichroism spectrometry BInductively coupled plasma mass spectrometry(ICP-MS) BElectron paramagnetic resonance (EPR) BMolecular Dynamics (MD) simulations BMD equilibration protocol BCode availability BMD simulation analysis BFree-energy simulations of tunnel entry BAnalysis of fenestrations BStatistical analysis dDATA AND SOFTWARE AVAILABILITY SUPPLEMENTAL INFORMATION Supplemental Information includes seven ﬁgures and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.molcel.2017.,Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"Continued REAGENT or RESOURCE SOURCE IDENTIFIER Bacterial and Virus Strains BL21-Gold(DE3) Competent Cells Agilent Technologies Cat# 230132 One Shot TOP10 Chemically Competent E. coli Thermo Fisher Scientiﬁc Cat# C404010 Chemicals, Peptides, and Recombinant Proteins Hydroxyurea (HU) Sigma Cat# H8627Doxorubicin hydrochloride (Adriamycin) Sigma Cat# D1515 5-Bromo-2 0-deoxyuridine (BrdU) Sigma Cat# B5002 Propidium iodide (PI) Sigma Cat# S7109 Protease Inhibitor Cocktail Roche Cat# 04693159001CldU (5-chloro-2 0-deoxyuridine) Sigma Cat# C6891 IdU (5-iodo-20-deoxyuridine) Sigma Cat# I7125 Cytidine 50-diphosphocholine sodium salt dehydrate (CDP) Sigma Cat# C9755 Protein G Sepharose, Fast Flow Sigma Cat# P3296 Isopropyl b-D-1-thiogalactopyranoside (IPTG) Sigma Cat# I6758 Deoxyadenosine 50-Triphosphate, [8-3H(N)] (dATP-H3) Perkin Elmer Cat# NET268250UC Deoxythymidine 50-Triphosphate ((dTTP) Tetrasodium Salt) (dTTP-H3)Perkin Elmer Cat# NET520A250UC TRIzol Reagent Thermo Fisher Scientiﬁc Cat# 15596018 DharmaFECT 1 Dharmacon Cat# T-2001 Lipofectamine Ltx Thermo Fisher Scientiﬁc Cat# 15338100 ProLong Gold Thermo Fisher Scientiﬁc Cat# P36931 Critical Commercial Assays Hypoxyprobe-1 Kit for the Detection of Tissue Hypoxia Chemicon International Cat# HP1-100Real-Time and Dynamic Monitoring of Cell Proliferation and Viability for Adherent CellsACEA Biosciences Inc/ Cambridge BioscCat# 00380601050 SYBR Green PCR Master Mix Applied Biosystems Cat# 4309155 Verso cDNA Synthesis Kit Thermo Fisher Scientiﬁc Cat# AB1453B HisTrap HP columns GE Healthcare Cat# 17-5248-02 QIAprep Spin Miniprep Kit QIAGEN Cat# 27106QuickChange II XL Site-Directed Mutagenesis Kit Agilent Technologies Cat# 200521 QIAquick PCR Puriﬁcation Kit QIAGEN Cat# 28106 QIAquick Gel Extraction Kit QIAGEN Cat# 28704 Deposited Data Original imaging data this study http://dx.doi.org/10.17632/ bp95v48kgm.1 Experimental Models: Cell Lines RKO ATCC CRL-2577 HCT116 ATCC CCL-247 H1299 ATCC CRL-5803 U2OS ATCC HTB-96 U87-MG ATCC HTB-14 OE21 ECACC 96062201 RKOHIF-1 a+/+ and RKOHIF-1 a/C0//C0 Dang L.H.",Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"EXPERIMENTAL MODEL AND SUBJECT DETAILSSource of cell lines used in the study is reported in the reagent and resource table.Continued REAGENT or RESOURCE SOURCE IDENTIFIER Oligonucleotides siRNA-RRM2B (sequence: UGAGUUUGUAGCUGACAGAUU)Sigma Piao et al., 2009 siRNA#2 - RRM2B (sequence: GGAACAAGCUUAAAGCAGA)Ambion / Life Technologies s224156 siRNA-p53 (sequence: GUAAUCUACUGGGACGGAA)Ambion / Life Technologies Leszczynska et al., 2015 AllStars Negative Control siRNA QIAGEN SI03650318 Primers for RRM2B Forward-ChIP (sequence: CTTGCTGGGAAATCTTGACC)Sigma Tanaka et al., 2007 Primers used for site-directed mutagenesis Table S1 N/A N/A Primers used for dNTP incorporation assay Table S1 N/A N/A Primers used for quantitative PCR (qPCR) Table S1 N/A N/A Recombinant DNA Plasmids used in this work are listed in Table S2 N/A N/A Software and Algorithms 7500 FAST Real-Time PCR thermocycler was used with v2.0.5 softwareApplied Biosystems http://www6.appliedbiosystems.com/ support/software/7500/ The software CAVER 3.0 was used for the analysis of the evolution of lateral fenestrations duringthe MD simulationsN/A N/A The particle mesh Ewald (PME) algorithm was used for evaluation of electrostatics interactionsDarden et al., 1993 N/A The multi time step algorithm Verlet-I/r-RESPA was used to integrate the equations of motionTuckerman et al., 1992; Verlet, 1967N/A The POPS (Parameter OPtimsed Surfaces) algorithm was used for calculation of the Solvent-Accessible Surface Area (SASA) of both proteins RRM2B and RRM2Cavallo et al., 2003; Fraternali and Van Gunsteren, 1996N/A The SETTLE algorithm was used for constrained the lengths of covalent bonds involving hydrogen atomsMiyamoto and Kollman, 1992 N/A Other For the analysis of RRM2B expression and genetic alterations in colorectal cancer datasets thecBioPortal and Prognoscanhttp://www.cbioportal.org/ ; http://www.abren.net/PrognoScan/Gao et al., 2013; Cerami et al., 2012; Mizuno et al., 2009 Gene Expression Omnibus; Smith et al., 2010 https://www.ncbi.nlm.nih.",OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"gov/geoaccession number GSE17536 ICP-MS was performed with ICP-MS Trace Element Analysishttps://www.earth.ox.ac.uk/ research/services/geochemical-analysis/icpms/N/A Molecular Cell 66, 206–220.e1–e9, April 20, 2017 e3",Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"org/) and Prognoscan ( http://www.abren.net/PrognoScan/ ) tools were used on the 5th Dec 2016 ( Gao et al., 2013; Cerami et al., 2012; Mizuno et al., 2009 ).",OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"This analysis used the publicly available dataset at Gene Expression Omnibus ( https://www.ncbi.nlm.nih.gov/geo ) with the accession number GSE17536 ( Smith et al., 2010 ).",OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
Additional information can be found at ( https://www.earth.ox.ac.uk/ research/services/geochemical-analysis/icpms/ ).,Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
A free license can be obtained at http://www.ks.uiuc.edu/Research/namd/ .,Non-OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"Version 1.9 of Visual Molecular Dynamics (VMD) was employed for analysis, with license obtained at http://www.ks.uiuc.edu/Research/vmd/ .",OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
"DATA AND SOFTWARE AVAILABILITY Original imaging data have been deposited to Mendeley Data and are available at http://dx.doi.org/10.17632/bp95v48kgm.1 Molecular Cell 66, 206–220.e1–e9, April 20, 2017 e9",OADS,/arxiv_data1/oa_pdf/ea/f8/main.PMC5405111.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: XRCCPolymorphismUrological neoplasmRiskMeta-analysis 1.,Non-OADS,/arxiv_data1/oa_pdf/6f/31/main.PMC5405151.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.0092352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/31/main.PMC5405151.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6f/31/main.PMC5405151.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Severe acute malnutritionEpigeneticBirthweightMuscle Jamaica 1.,Non-OADS,/arxiv_data1/oa_pdf/ed/15/main.PMC5405153.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.001 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ed/15/main.PMC5405153.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/15/main.PMC5405153.pdf
2012 ) in contrast to greater in- hibition that would essentially be an intensi ﬁcation of mitochondrial disease.EBioMedicine 18 (2017) 19 –20 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2017.02.013 .,Non-OADS,/arxiv_data1/oa_pdf/ec/f5/main.PMC5405155.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.016 2352-3964/Published by Elsevier B.V.,OADS,/arxiv_data1/oa_pdf/ec/f5/main.PMC5405155.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ec/f5/main.PMC5405155.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Atrial ﬁbrillation Previous stroke Secondary prevention ObservationalJapanUnited Kingdom 1.,Non-OADS,/arxiv_data1/oa_pdf/e1/e7/main.PMC5405156.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.022 2352-3964/© 2017 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/e1/e7/main.PMC5405156.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e1/e7/main.PMC5405156.pdf
Host contributions to ﬂora changes are re ﬂected by the substantial body of data demonstrating that neutropenia impacts the oral microbiotaEBioMedicine 18 (2017) 7 –8 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2017.02.002 .,OADS,/arxiv_data1/oa_pdf/62/f5/main.PMC5405157.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.017 2352-3964/© 2017 The Author.,Non-OADS,/arxiv_data1/oa_pdf/62/f5/main.PMC5405157.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/62/f5/main.PMC5405157.pdf
AMB Express http://dx.doi.org/10.1186/s13568- 015-0116-5 .,Non-OADS,/arxiv_data1/oa_pdf/62/f5/main.PMC5405157.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.02.002 .8 S.T.,OADS,/arxiv_data1/oa_pdf/62/f5/main.PMC5405157.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Tangier disease Induced pluripotent stem cellsiPSC-derived hepatocytesHDL biogenesisTriglyceride secretion 1.,Non-OADS,/arxiv_data1/oa_pdf/55/bb/main.PMC5405159.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.018 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/55/bb/main.PMC5405159.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/55/bb/main.PMC5405159.pdf
(http://www.wicell.org/home/stem-cell-lines/collections/collections.,Non-OADS,/arxiv_data1/oa_pdf/55/bb/main.PMC5405159.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.024 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/56/7f/main.PMC5405160.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/56/7f/main.PMC5405160.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: HIV-1Antiretroviral therapyReverse transcriptaseDrug resistanceTenofovir WHO-recommended ﬁrst-line 1.,Non-OADS,/arxiv_data1/oa_pdf/56/7f/main.PMC5405160.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: WNK4 HypertensionMetabolic syndrome 1.,Non-OADS,/arxiv_data1/oa_pdf/cd/0a/main.PMC5405161.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.011 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/cd/0a/main.PMC5405161.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cd/0a/main.PMC5405161.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Multiple myelomaPharmacologically-dosed ascorbic acid Apoptosis-inducing factor 1 1.,Non-OADS,/arxiv_data1/oa_pdf/79/0c/main.PMC5405162.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.02.0112352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/79/0c/main.PMC5405162.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/79/0c/main.PMC5405162.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Piperine FibrosisCardiac ﬁbroblast PPAR- γ AKT 1.,Non-OADS,/arxiv_data1/oa_pdf/b8/91/main.PMC5405163.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.021 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b8/91/main.PMC5405163.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b8/91/main.PMC5405163.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: MetforminHyperandrogenismInsulin resistanceMolecular mechanismPCOSRat uterus 1.,Non-OADS,/arxiv_data1/oa_pdf/71/fa/main.PMC5405166.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.0232352-3964/© 2017 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/71/fa/main.PMC5405166.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/71/fa/main.PMC5405166.pdf
Sci.http://dx.doi.org/10.1177/1933719116667606 .,Non-OADS,/arxiv_data1/oa_pdf/71/fa/main.PMC5405166.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Colorectal cancerDHX32 β-catenin VEGFAAngiogenesis 1.,Non-OADS,/arxiv_data1/oa_pdf/8d/da/main.PMC5405167.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.012 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/8d/da/main.PMC5405167.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8d/da/main.PMC5405167.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org /licenses/by-nc-nd/4.0/ ).Keywords: ImmunoglobulinGammaglobulinPrimary antibody de ﬁciency Immunode ﬁciency Respiratory tract infections 1.,Non-OADS,/arxiv_data1/oa_pdf/3b/0a/main.PMC5405168.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.025 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/3b/0a/main.PMC5405168.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3b/0a/main.PMC5405168.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Bacterial pathogensStreptococcus pneumoniaeProtein vaccines Pneumococcal disease ColonizationAdherenceHost glycoconjugatesAlpha-glycerophosphate oxidaseImmunization 1.,Non-OADS,/arxiv_data1/oa_pdf/34/29/main.PMC5405170.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.002 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/34/29/main.PMC5405170.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/34/29/main.PMC5405170.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: AMD CNV RAPLaser-CNVSemaphorinSema3fVLDLRNeovascularization Retina 1.,Non-OADS,/arxiv_data1/oa_pdf/f3/0c/main.PMC5405173.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.026 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/f3/0c/main.PMC5405173.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/0c/main.PMC5405173.pdf
"ImageJ (National Institutes of Health, http://imagej.nih.gov/ij/ ) was used for quanti ﬁcation of subretinal neovascularization lesion number and area inVldlr−/−retinas with designed plugins adapted from the method used to measure retinal neovascularization (SWIFT_NV) in the OIRmodel ( Stahl et al., 2009 ) which use a user-designated threshold to mark lesion structures that clearly stand out from background ﬂuores- cence of normal vessels, and can automatically remove small artifacts by selecting objects with a minimum size of 100 pixels.",OADS,/arxiv_data1/oa_pdf/f3/0c/main.PMC5405173.pdf
http://dx.doi.org/10.1111/aos.13364 .,Non-OADS,/arxiv_data1/oa_pdf/f3/0c/main.PMC5405173.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Endoplasmic reticulum stressClock out-put gene Diabetes mellitus Pancreatic islet β-cell Insulin secretion 1.,Non-OADS,/arxiv_data1/oa_pdf/3b/de/main.PMC5405175.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.0402352-3964/© 2017 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/3b/de/main.PMC5405175.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3b/de/main.PMC5405175.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.029 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/4b/1b/main.PMC5405176.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4b/1b/main.PMC5405176.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/1b/main.PMC5405176.pdf
"on PD-L1 as useful marker in the discrimination between EFVPTC and NIFTP on histology could be also helpful on cytology, with important implications in clinical and sur- gical assessment and in lowering of the possible overtreatment.EBioMedicine 18 (2017) 11 –12 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2017.03.031 .",Non-OADS,/arxiv_data1/oa_pdf/d2/43/main.PMC5405177.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.035 2352-3964/© 2017 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/d2/43/main.PMC5405177.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d2/43/main.PMC5405177.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: NFAT5 suppressorκB inhibitor Small moleculesHigh-throughput drug screening Chronic arthritis 1.,Non-OADS,/arxiv_data1/oa_pdf/7b/3a/main.PMC5405180.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.0392352-3964/© 2017 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/7b/3a/main.PMC5405180.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7b/3a/main.PMC5405180.pdf
The chemical library used in this study was kindly providedby Korea Chemical Bank ( http://www.chembank.org )o fK o r e a Research Institute of Chemical Technology.,Non-OADS,/arxiv_data1/oa_pdf/7b/3a/main.PMC5405180.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Thyroid cancer Follicular variant PTCNIFTPPD-L1InvasionProtein biomarker 1.,Non-OADS,/arxiv_data1/oa_pdf/08/a0/main.PMC5405181.pdf
1GF and OP contributed equally to this work http://dx.doi.org/10.1016/j.ebiom.2017.03.031 2352-3964/© 2017 Published by Elsevier B.V.,OADS,/arxiv_data1/oa_pdf/08/a0/main.PMC5405181.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/a0/main.PMC5405181.pdf
"Statistical analysis The data collected in a database designed for this study were ana- lyzed using The SPSS 24.0 (SPSS, Chicago, IL, http://www.ibm.com/ analytics/us/en/technology/spss/ ) program.",OADS,/arxiv_data1/oa_pdf/08/a0/main.PMC5405181.pdf
"College of American Patholo- gists, North ﬁeld, IL http://www.cap.org/apps/docs/committees/cancer/cancer_ protocols/2014/Thyroid_2014Protocol_3100.pdf .",Non-OADS,/arxiv_data1/oa_pdf/08/a0/main.PMC5405181.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: RASSF1A MethylationNPCPrognosisBiomarkerDiagnosis 1.,Non-OADS,/arxiv_data1/oa_pdf/3b/09/main.PMC5405182.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.038 2352-3964/© 2017 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/3b/09/main.PMC5405182.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/3b/09/main.PMC5405182.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Reference intervalsUrine proteomeCancerBiomarker Mass spectrometry 1.,Non-OADS,/arxiv_data1/oa_pdf/40/f2/main.PMC5405183.pdf
"Databases, such as Max-Planck Uni ﬁed Proteome database (http://mapuproteome.com/ )(Zhang et al., 2007 ), the Human Kidney and Urine Proteome Project ( http://www.hkupp.org/ )(Yamamoto et al., 2008 ), the Human Urinary Proteome Database ( http://mosaiques- diagnostics.de/diapatpcms/mosaiquescms/front_content.php?idcat=257)(Coon et al., 2008 ), Urinary Protein Biomarker (UPB) database (http://www.mybiosoftware.com/upb-20130710-urine-protein- biomarker-database.html )(Shao et al., 2011a ), and Urine Proteomics.",OADS,/arxiv_data1/oa_pdf/40/f2/main.PMC5405183.pdf
"org(http://urineproteomics.org/databases.html )(Kentsis et al., 2009 ), documented lists of urinary proteins, providing convenient resourcesEBioMedicine 18 (2017) 300 –310 ⁎Corresponding authors at: State Key Laboratory of Proteomics, National Center for Protein Sciences (The PHOENIX Center, Beijing), Beijing Proteome Research Center, Beijing 102206, China.",OADS,/arxiv_data1/oa_pdf/40/f2/main.PMC5405183.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.0282352-3964/© 2017 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/40/f2/main.PMC5405183.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/40/f2/main.PMC5405183.pdf
"Pathway analysis using Reactome Pathway Database (http://www.reactome.org )(Croft et al., 2011 ) revealed that manyoutliers were enriched in pathways associated with immune response (Fig.",OADS,/arxiv_data1/oa_pdf/40/f2/main.PMC5405183.pdf
http://dx.doi.org/10.1016/j.jdsr .2016.09.001 1882-7616/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/81/30/main.PMC5405184.pdf
This  is  an  open  access article under  the  CC  BY -NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/81/30/main.PMC5405184.pdf
"Stephanie E. McArdle (Nottingham, UK) and colleagues examined the pro ﬁle of Treg, myeloid-derived suppressor cell (MDSC), monocyte and NK cell subsets in the peripheral blood ofEBioMedicine 18 (2017) 5 –6 http://dx.doi.org/10.1016/j.ebiom.2017.04.001 2352-3964/© 2017 The Author.",Non-OADS,/arxiv_data1/oa_pdf/71/0a/main.PMC5405185.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/71/0a/main.PMC5405185.pdf
"152, S4 –12.EBioMedicine 18 (2017) 21 –22 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2017.02.015 .",OADS,/arxiv_data1/oa_pdf/38/a5/main.PMC5405186.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.04.007 2352-3964/© 2017 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/38/a5/main.PMC5405186.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/38/a5/main.PMC5405186.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: HIVSuperinfectionAntibodyNeutralizationBindingImmune correlate 1.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.04.005 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1038/nature01200 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1016/j.virol.2014.06.016 .,OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.01730-08 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.00673-09 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1097/ QAD.0b013e32805e8727 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.79.16.10701-10708.2005 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1371/journal.ppat.1002611 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
63 (1):31 –33.http://dx.doi.org/10.1097/QAI.0b013e3182874d41 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
211 (4): 508–51 7. http://dx.doi.org/10.1093/infdis/jiu444 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1016/j.jim.2005.09.018 .,OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.00198-11 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.01409-16 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.01730-06 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1089/088922202753747914 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1371/journal.ppat.1002739 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1172/ JCI81593DS1 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1371/journal.ppat.0030177 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1089/aid.2008.0100 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.01149-09 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1016/j.virol.2007.02.002 .,OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
"http://dx.doi.org/10.1128/JVI.01560-15 .Redd, A.D., Mullis, C.E., Serwadda, D., Kong, X., Martens, C., Ricklefs, S.M., Tobian, A.A.R., Xiao, C., Grabowski, M.K., Nalugoda, F., Kigozi, G., Laeyendecker, O., Kagaayi, J.,Sewankambo, N., Gray, R.H., Porcella, S.F., Wawer, M.J., Quinn, T.C., 2012.",Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1093/infdis/jis325 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1016/S1473- 3099(13)70066-5 .,OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1371/journal.ppat.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1097/QAD.0000000000000422 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1371/journal.ppat.1003618.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1001/jama.292.10.1177 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1128/JVI.01708-08 .,Non-OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
http://dx.doi.org/10.1016/j.ebiom.2015.09.001 .224 K. Ronen et al.,OADS,/arxiv_data1/oa_pdf/88/20/main.PMC5405187.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Depression Hypocretin Hypocretin receptorsHypothalamusSex difference 1.,Non-OADS,/arxiv_data1/oa_pdf/a7/21/main.PMC5405188.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.043 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a7/21/main.PMC5405188.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a7/21/main.PMC5405188.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.042 2352-3964/© 2017 The Author(s).,Non-OADS,/arxiv_data1/oa_pdf/63/86/main.PMC5405189.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/63/86/main.PMC5405189.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Twin studyAge at onsetSchizophreniaNationwide register-based data 1.,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.04.0022352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"http://www.ncbi.nlm.nih.gov/pubmed/24581549 [Accessed June 7, 2014].",OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"3 (11):872 –882 Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 12415317 [Accessed March 21, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"J. Psychiatry 181 (43):19s –125 Available at: http://bjp.rcpsych.org/cgi/doi/10.1192/bjp.181.43.s19 [Accessed July 8, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
http://dx.doi.org/10.1016/j.neubiorev.2016.03.017 .,OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"120 (1 –3):121 –130 Available at: http://www.ncbi.nlm.nih.gov/pubmed/ 20303240 [Accessed July 9, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"Res.133 (1 –3):143 –149 Available at: http://www.ncbi.nlm.nih.gov/pubmed/21996266 [Accessed July 7, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"41 (1 –2):8 –14 Available at: http://www.ncbi.nlm.nih.gov/pubmed/16115648 [Accessed July 11, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"256 (4):222 –229 Available at: http://www.pubmedcentral.nih.gov/arti clerender.fcgi?art id=3130033&tool= pmcentrez&rendertype=abstract [Accessed July 8, 2014].",OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
97 (1 –3) :43 –50 Available at: http://www.pubmedcentral.nih.gov/articlerender.,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"Psychiatry 35 (6):664 –667 Available at:http://www.ncbi.nlm.nih.gov/pubmed/23988234 [Accessed July 7, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
Public Health 39 (7 Suppl):54 –57 Available at: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"40 (2):201 –210 Available at: http://www.ncbi.nlm.nih.gov/pubmed/19607751 [Accessed May 28, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"Nature 468 (7321):203 –212 Available at: http://www.ncbi.nlm.nih.gov/pubmed/21068828 [Accessed April 28, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
Available at: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
53 (4):441 –449 Available at: http://www.ncbi.nlm.nih.gov/ pubmed/17150149 .,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"JAMA Psychiatry 71 (5):573 –581 Available at:http://www.ncbi.nlm.nih.gov/pubmed/24806211 [Accessed May 24, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"88 (1 –3):96 –101 Avail- able at: http://www.ncbi.nlm.nih.gov/pubmed/16962742 [Accessed July 7, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
3 (2):119 –133 Available at: http://www.ncbi.nlm.nih.gov/ pubmed/12139432 .,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"Public Health 39 (7 Suppl): 75–78 Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid= 3350839&tool=pmcentrez&rendertype=abstract [Accessed August 19, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
http://dx.doi.org/10.1016/S2215-0366(14)70379-7 .,OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"Public Health 40 (1):43 –50 Available at: http://www.ncbi.nlm.nih.gov/pubmed/21930618 [Accessed July 7, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
37 (4):479 –484 Available at: http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
60 (2):A4578 Available at: http://www.ncbi.nlm.nih.gov/pubmed/23461991 .,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
"44 (1):9 –16 Available at: http://www.ncbi.nlm.nih.gov/pubmed/23244442 [Accessed June 26, 2014].",Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
50 (2):333 –338 Available at: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/e8/a6/main.PMC5405190.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Maternal care Retinoic acid Vitamin AAdipose developmentBeige adipocyteVasculature 1.,Non-OADS,/arxiv_data1/oa_pdf/ed/c6/main.PMC5405191.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.041 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/ed/c6/main.PMC5405191.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ed/c6/main.PMC5405191.pdf
World Health Organization http://www.who.int/vmnis/database/ vitamina/x/en/ .,Non-OADS,/arxiv_data1/oa_pdf/ed/c6/main.PMC5405191.pdf
If truncal mutations are spotted and intervened earlyEBioMedicine 18 (2017) 1 –2 Contents lists available at ScienceDirect EBioMedicine journal homepage: www.ebiomedicine.com http://dx.doi.org/10.1016/j.ebiom.2017.04.023 2352-3964/© 2017 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/ef/95/main.PMC5405192.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ef/95/main.PMC5405192.pdf
"Also, administration of monoclo- nal antibody to eliminate CD8+ T cells would be a very informativeEBioMedicine 18 (2017) 17 –18 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2017.03.003 .",Non-OADS,/arxiv_data1/oa_pdf/97/be/main.PMC5405193.pdf
"http://dx.doi.org/10.1016/j.ebiom.2017.04.012 2352-3964/© 2017 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.",Non-OADS,/arxiv_data1/oa_pdf/97/be/main.PMC5405193.pdf
This is an open access arti cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/97/be/main.PMC5405193.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Prostate cancer Glycine N-Methyltransferase (GNMT) Chromatin immunoprecipitation exonuclease(ChIP-exo)Androgen receptorc-MycDNA damage 1.,Non-OADS,/arxiv_data1/oa_pdf/4f/90/main.PMC5405195.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.04.006 2352-3964/Crown Copyright © 2017 Published by Elsevier B.V.,Non-OADS,/arxiv_data1/oa_pdf/4f/90/main.PMC5405195.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4f/90/main.PMC5405195.pdf
The raw reads were aligned using novoalign ( http://www.novocraft.,OADS,/arxiv_data1/oa_pdf/4f/90/main.PMC5405195.pdf
"To obtain the MYC binding pro ﬁle which we called “MYC ENCODE compendium ”, we created a custom bed ﬁ le containing MYC peaks present in any of the following cell lines used by the ENCODE (Consortium, 2004 )(https://genome.ucsc.edu /): HeLa, H1-ESC, K562, HepG2 and HUVEC.",OADS,/arxiv_data1/oa_pdf/4f/90/main.PMC5405195.pdf
The imputed probe datasets were analyzed using the freely available J-Express 2012 software (http://jexpress.bioinfo.no/site/ ).,OADS,/arxiv_data1/oa_pdf/4f/90/main.PMC5405195.pdf
"KEGG and GO pathway analyses were performed using the genecodis tool ( http://genecodis.cnb.csic.es /) (Carmona-Saez et al., 2007 ).",OADS,/arxiv_data1/oa_pdf/4f/90/main.PMC5405195.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: KinasePhosphorylationTOPKPRPK Metastasis 1.,Non-OADS,/arxiv_data1/oa_pdf/07/d4/main.PMC5405196.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.04.003 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/07/d4/main.PMC5405196.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/07/d4/main.PMC5405196.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.03.0442352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/34/f5/main.PMC5405197.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/34/f5/main.PMC5405197.pdf
http://www.cancer.gov/about-nci/organization/ crchd/cancer-health-disparities-fact-sheet .,Non-OADS,/arxiv_data1/oa_pdf/34/f5/main.PMC5405197.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Keywords: Batf3CD8α +DCs Th1 cellsCCL5 Atherosclerosis 1.,Non-OADS,/arxiv_data1/oa_pdf/c0/53/main.PMC5405198.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.04.008 2352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/53/main.PMC5405198.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/53/main.PMC5405198.pdf
"Thus, while HDL is losing traction as therapy with its growing collection of failed clinical trials, novel approaches targeting TGs and clearance ofEBioMedicine 18 (2017) 15 –16 DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2017.03.018 .",Non-OADS,/arxiv_data1/oa_pdf/2a/0e/main.PMC5405199.pdf
http://dx.doi.org/10.1016/j.ebiom.2017.04.0042352-3964/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/2a/0e/main.PMC5405199.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/2a/0e/main.PMC5405199.pdf
"E-mail addresses: narayura630@gmail.com ,  narayura@m3.kcn.ne.jp http://dx.doi.org/10.1016/j.jdsr .2016.10.001 1882-7616/© 2016  The  Author(s).",Non-OADS,/arxiv_data1/oa_pdf/b8/45/main.PMC5405200.pdf
This  is  an  open  access article under  the  CC  BY -NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b8/45/main.PMC5405200.pdf
"Cancer  Gene  Ther 2016;23:107—13,  http://dx.doi.org/10.1038/cgt.2016.8 .",Non-OADS,/arxiv_data1/oa_pdf/b8/45/main.PMC5405200.pdf
http://dx.doi.org/10.1016/j.jdsr .2016.09.003 1882-7616/© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/c8/3c/main.PMC5405201.pdf
This  is  an  open  access article under  the  CC  BY -NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c8/3c/main.PMC5405201.pdf
http://dx.doi.org/10.1016/j.jdsr .2016.09.002 1882-7616/ï¾© 2016  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/8e/ce/main.PMC5405202.pdf
This  is  an  open  access article under  the  CC  BY -NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8e/ce/main.PMC5405202.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/awx052.PMC5405237.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/43/d1/awx051.PMC5405238.pdf
The spatial normalization of each individual electrode site was performed using FreeSurfer scripts ( http://surfer.nmr.,OADS,/arxiv_data1/oa_pdf/43/d1/awx051.PMC5405238.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/71/ad/awx064.PMC5405336.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0b/20/evx061.PMC5405338.pdf
"Pan-Genome and Phylogenetic Analyses With the goal of obtaining a rob ust core genome phylogeny, that is based on conserved regions among genomes, we used the tool SaturnV ( https://github.com/ejfresch/saturnV )w i t ht h e “strictest” algorithm.",OADS,/arxiv_data1/oa_pdf/0b/20/evx061.PMC5405338.pdf
"The resulting tree was visualized and midpoint rooted using FigTree version 1.4.3 ( http://tree.bio.ed.ac.uk/software/ ﬁgtree/ ; last accessed June 15, 2016).",OADS,/arxiv_data1/oa_pdf/0b/20/evx061.PMC5405338.pdf
"Average nucleotide identity (ANI) analysis between all genome pairs was per-formed using pyani ( https://github.com/widdowquinn/pyani ; last accessed June 15, 2016) with the MUMmer algorithm (Kurtz et al.",OADS,/arxiv_data1/oa_pdf/0b/20/evx061.PMC5405338.pdf
All protein sequences coded by each genome (according to the annotation) were compared with theNCBI database of proteins found on plasmids ( ftp://ftp.ncbi.nlm.,OADS,/arxiv_data1/oa_pdf/0b/20/evx061.PMC5405338.pdf
"Putative MGEs were annotated with the RAST webserver ( http://rast.nmpdr.org/ ; last accessed November 1, 2016, supplementary ﬁle 2, Supplementary Material online).",OADS,/arxiv_data1/oa_pdf/0b/20/evx061.PMC5405338.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c5/fb/evx056.PMC5405339.pdf
Sequence logos of the C-terminal motifs were generated with Weblogo Berkeley ( http://weblogo.berkeley.,OADS,/arxiv_data1/oa_pdf/c5/fb/evx056.PMC5405339.pdf
Please see detailed descriptio n of each experiment in PLEXdb ( http://www.plexdb.,Non-OADS,/arxiv_data1/oa_pdf/c5/fb/evx056.PMC5405339.pdf
"FLYLEAFABOUT COVER EDITORS FOR  THIS ISSUEContents AIM AND SCOPE April 26, 2017 |Volume 9 |ssue 4| WJSC|www.wjgnet.comWorld Journal of Stem Cells Volume 9  Number 4  April 26, 2017 EDITORIAL 	OFFICE Xiu-Xia Song, Director World Journal of  Stem Cells Baishideng Publishing Group Inc 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA Telephone: +1-925-2238242 Fax: +1-925-2238243 E-mail: editorialoffice@wjgnet.com Help Desk: http://www .f6publishing.com/helpdesk http://www.wjgnet.com PUBLISHER Baishideng Publishing Group Inc 7901 Stoneridge Drive, Suite 501,  Pleasanton, CA 94588, USA Telephone: +1-925-2238242 Fax: +1-925-2238243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www .f6publishing.com/helpdesk http://www.wjgnet.com PUBLICATION 	DATE April 26, 2017COPYRIGHT © 2017 Baishideng Publishing Group Inc.",Non-OADS,/arxiv_data1/oa_pdf/6f/8a/WJSC-9-68.PMC5405402.pdf
"INSTRUCTIONS 	TO	AUTHORS http://www .wjgnet.com/bpg/gerinfo/204 ONLINE 	SUBMISSION 	 http://www.f6publishing.comNAME 	OF	JOURNAL 	 World Journal of  Stem Cells ISSN ISSN 1948-0210 (online) LAUNCH 	DATE December 31, 2009 FREQUENCY Monthly EDITORS-IN-CHIEF Tong Cao, BM BCh, DDS, PhD, Associate Profes - sor, Doctor, Department of Oral Sciences, National  University of Singapore, Singapore 119083, Singapore Oscar Kuang-Sheng Lee, MD, PhD, Professor,  Medical Research and Education of Veterans General  Hospital-Taipei, No.",Non-OADS,/arxiv_data1/oa_pdf/6f/8a/WJSC-9-68.PMC5405402.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Miruna Mihaela Micheu, MD, PhD,  De - partment of Cardiology, Clinical Emergency Hospital of Bucharest,  Floreasca Street 8, 014461 Bucharest,  Romania.",Non-OADS,/arxiv_data1/oa_pdf/6f/8a/WJSC-9-68.PMC5405402.pdf
"During  the reporting per iod, conflicting results have been stated,  scientific papers have been under investigation, strategies Submit a Manuscript: http://www.f6publishing.com DOI: 10.4252/wjsc.v9.i4.68World J Stem Cells  2017 April 26; 9(4): 68-76 ISSN 1948-0210 (online)",Non-OADS,/arxiv_data1/oa_pdf/6f/8a/WJSC-9-68.PMC5405402.pdf
wjgnet.com/1948-0210/full/v9/i4/ 68.htm  DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/6f/8a/WJSC-9-68.PMC5405402.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/6f/8a/WJSC-9-68.PMC5405402.pdf
"The Port Macquarie News and Hastings River Advocate, 1906 (http://trove.nla.gov.au/ndp/del/article/119145483?searchTerm=sleep-walking&searchLimits=l-title=516).",Non-OADS,/arxiv_data1/oa_pdf/3d/72/bjporcpsych004390.PMC5405419.pdf
"The Tenterfield Intercolonial Courier and Fairfield and Wallangarra Advocate, 1903 (http://trove.nla.gov.au/ndp/del/article/108691990?searchTerm=Sleep-walkingaccidents&searchLimits=l-title=453).",Non-OADS,/arxiv_data1/oa_pdf/3d/72/bjporcpsych004390.PMC5405419.pdf
"The Advertiser, 1924 (http://trove.nla.gov.au/ndp/ del/article/36578592?searchTerm=Sleep-w alking&searchLimits=l-state=South + Australia|||l-title=34).",Non-OADS,/arxiv_data1/oa_pdf/3d/72/bjporcpsych004390.PMC5405419.pdf
Available online at https://www.researchgate.net/publication/308002769_A_ systematic_review_of_treatments_for_sleepwalking_100_years_of_case_studies.,Non-OADS,/arxiv_data1/oa_pdf/3d/72/bjporcpsych004390.PMC5405419.pdf
The typical result of  selective response preparation is faster RT and smaller error rate of the  this is an open access article under the cc B y-nc-nd license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/2f/58/acp-13-070.PMC5405448.pdf
this is an open access article under the cc B y-nc-nd license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/81/27/acp-13-083.PMC5405449.pdf
"6, 1302705 http://dx.doi.org/10.1080/20013078.2017.1302705 © 2017 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/7d/42/zjev-6-1302705.PMC5405560.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7d/42/zjev-6-1302705.PMC5405560.pdf
A spectral library was also generated using peptide tandem mass spectra from NIST database ( http://chemdata.nist.gov/ ).,OADS,/arxiv_data1/oa_pdf/7d/42/zjev-6-1302705.PMC5405560.pdf
"6, 1308779 http://dx.doi.org/10.1080/20013078.2017.1308779 © 2017 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/40/9a/zjev-6-1308779.PMC5405563.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/40/9a/zjev-6-1308779.PMC5405563.pdf
[updated 2015 ;c i t e d2 0 1 7J a n3 1 ] .A v a i l a b l e from: http://www.azonano .com/article.aspx?,Non-OADS,/arxiv_data1/oa_pdf/40/9a/zjev-6-1308779.PMC5405563.pdf
"6, 1314073 http://dx.doi.org/10.1080/20013078.2017.1314073 © 2017 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/ce/16/zjev-6-1314073.PMC5405564.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ce/16/zjev-6-1314073.PMC5405564.pdf
FastQ files were aligned to a reference consisting of pre-miRNA hairpins from miRBase v21 ( http://miRBase.org ).,OADS,/arxiv_data1/oa_pdf/ce/16/zjev-6-1314073.PMC5405564.pdf
"Alignment was performed using RNA-STAR v2.3.0 (reference: http://bioinformatics.oxford journals.org/content/29/1/15.full ) using the following parameters: “–runThreadN 16 –outSAMattributes All – outFilterMultimapNmax 1 ”, and all other parameters at default.",OADS,/arxiv_data1/oa_pdf/ce/16/zjev-6-1314073.PMC5405564.pdf
Feature alignment was performed using the transition of identification confidence algorithm (https://pypi.python.org/pypi/msproteomicstools ) and the R package SWATH2stats [ 26] was used to filter low scoring peak groups and remove proteins with less than two associated peptides.,OADS,/arxiv_data1/oa_pdf/ce/16/zjev-6-1314073.PMC5405564.pdf
"2016 ;A v a i l a b l ef r o m : http://biorxiv.org/content/early/ 2016/10/31/084533 [23] Guo T, Kouvonen P, Koh CC, et al.",Non-OADS,/arxiv_data1/oa_pdf/ce/16/zjev-6-1314073.PMC5405564.pdf
"6, 1305677 http://dx.doi.org/10.1080/20013078.2017.1305677 © 2017 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/cb/2a/zjev-6-1305677.PMC5405565.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cb/2a/zjev-6-1305677.PMC5405565.pdf
"This database was merged and, in conjunction with reverse and contami- nant databases, searched by X!Tandem (Sledge Hammer version 2013.09.01.1, http://www.thegpm.",OADS,/arxiv_data1/oa_pdf/cb/2a/zjev-6-1305677.PMC5405565.pdf
"Identified proteins were filtered and grouped using X!TandemPipeline ( http://pappso.inra.fr/bioinfo/ xtandempipeline/ ) according to the following require- ments: (i) a minimum of two different peptides with an E value smaller than 0.0; and (ii) a protein log (E value, calculated as the product of unique peptide E values) smaller than 2.10–3.",OADS,/arxiv_data1/oa_pdf/cb/2a/zjev-6-1305677.PMC5405565.pdf
All statistical pro- cedures were carried out under the R v3.1.1 environ- ment [ 31] using base packages developed by the PAPPSO platform ( http://pappso.inra.fr/index.php?,OADS,/arxiv_data1/oa_pdf/cb/2a/zjev-6-1305677.PMC5405565.pdf
http://f1000.com/prime/717950860.,Non-OADS,/arxiv_data1/oa_pdf/ce/47/CN-15-333.PMC5405604.pdf
"[http://dx.doi.org/10.1016/j.eurpsy.2008.07.006] [PMID: 18789854] [2] Virchow, R. One hundred years of general pathology.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1176/ajp.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1176/appi.ajp.160.1.4] [PMID: 12505793] [6] Aboraya, A.; France, C.; Young, J.; Curci, K.; Lepage, J.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jad.2015.04.057] [PMID: 26001664] [9] Mazza, M.; Di Nicola, M.; Della, M.G.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/ 10.1177/10738584070130041101] [PMID: 17644769] [10] Ahrens, B.; Müller-Oerlinghausen, B.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1055/s-2001-15878] [PMID: 11518473] [11] Reisberg, B.; Gershon, S. Side effects associated with lithium therapy.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1001/archpsyc.1979.01780080053013] [PMID: 454107] [12] Dickson, M.E.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1161/01.HYP.0000227932.13687.60] [PMID: 16754793] [13] Ross, K.A.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1186/1741-7015-9-12] [PMID: 21291537] [14] Schaub, M.A.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1093/bioinformatics/btp226] [PMID: 19477990] [15] Buck, C.; Baker, P.; B a s s ,  M .",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1161/01.HYP.9.2.204] [PMID: 3818017] [16] Zeng, C.; Sanada, H.; Watanabe, H.; Eisner, G.M.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1007/s11906-008-0051-9] [PMID: 18625155] [20] Watts, S.W.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1124/pr.111.004697] [PMID: 22407614] [21] van Enkhuizen, J.; Janowsky, D.S.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1016/j.ejphar.,OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1161/01.HYP.11.2.111] [PMID: 3277910] [23] Logan, R.W.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/S0006-3223(98)00139-5] [PMID: 9693387] [25] De Backer, D.; Biston, P.; Devriendt, J.; Madl, C.; Chochrad,  D.; Aldecoa, C.; Brasseur, A.; Defrance, P.; Gottignies, P.;  Vincent, J.L.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1056/NEJMoa0907118] [PMID: 20200382] [26] Brezenoff, H.E.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1002/ddr.430020305] [27] Drevets, W.C.; Zarate, C.A., Jr; Furey, M.L.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1093/brain/awf077] [PMID: 11912110] [30] Serafini, G.; Gonda, X.; Rihmer, Z.; Girardi, P.; Amore, M. White matter abnormalities: Insights into the pathophysiology of major affective disorders.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1371/journal.pone.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1097/YCO.0b013e32833299d4] [PMID: 19809321] [33] Kretschmer, E. Physique and Character; Macmillan: New York, 1936, p. 266.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jad.2006.03.027] [PMID: 16777235] [35] Yates, W.R.; Wallace, R. Cardiovascular risk factors in affective disorder.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.3109/13814788.2013.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1159/000357364] [PMID: 24752132] [39] McCarron, P.; Gunnell, D.; Harrison, G.L.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1136/jech.57.11.888] [PMID: 14600116] [40] Yan, L.L.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/ 10.1136/ewjm.173.6.412] [PMID: 11112762] [43] Jacobs, D.; Silverstone, T. Dextroamphetamine-induced arousal in human subjects as a model for mania.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1017/S0033291700009132] [PMID: 3726006] [44] Malison, R.T.; Best, S.E.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1007/BF02246266] [PMID: 8657833] [45] de Souza Gomes, J.A.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1016/j.euroneuro.2015.08.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1093/ med/9780199300532.003.0030] [47] Hälbig, T.D.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/S0072-9752(07)84032-2] [PMID: 18808941] [48] Beaulieu-Boire, I.; Lang, A.E.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1002/ mds.26121] [PMID: 25491470] [49] Ramirez, C.E.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1161/ HYPERTENSIONAHA.114.04225] [PMID: 25185131] [50] Guney, E.; Uneri, O.S.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1089/cap.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1007/s40263-012-0019-9] [PMID: 23160939],Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.pnpbp.2015.03.004] [PMID: 25784603] [53] Sanacora, G.; Berman, R.M.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1038/sj.npp.1300418] [PMID: 15010697] [54] Grossman, E.; Rosenthal, T.; Peleg, E.; Holmes, C.; Goldstein, D.S.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1097/00005344-199307000-00004] [PMID: 7690091] [55] Goldberg, M.R.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1161/01.HYP.5.5.772] [PMID: 6352483] [56] Demling, J. Mianserin: pharmacology and clinical aspects of an effective antidepressive agents.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1111/j.1600-0447.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.4088/ JCP.v59n1002] [PMID: 9818630] [60] Licht, C.M.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.126698] [PMID: 19237679] [61] Fava, M.; Rush, A.J.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.4088/PCC.v07n0305] [PMID: 16027765] [62] Thase, M.E.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/ 10.1097/JCP.0b013e318172424e] [PMID: 18480687] [63] Calhoun, D.A.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1378/chest.09-2954] [PMID: 20682533] [64] Osti, R.M.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1159/000287431] [PMID: 7208758] [65] Sparrenberger, F.; Cichelero, F.T.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1038/jhh.2008.74] [PMID: 18615099] [66] Proudfoot, J.; Doran, J.; Manicavasagar, V.; Parker, G. The precipitants of manic/hypomanic episodes in the context of bipolar disorder: a review.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jad.2010.10.051] [PMID: 21106249] [67] Alastalo, H.; Räikkönen, K.; Pesonen, A.K.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1038/jhh.2012.6] [PMID: 22336905] [68] Riley, E.H.; Wright, R.J.; Jun, H.J.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1136/jech.2009.095109] [PMID: 20445210] [69] Carballo, J.J.; Harkavy-Friedman, J.; Burke, A.K.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jad.2007.12.225] [PMID: 18221790] [70] Maniglio, R. Prevalence of child sexual abuse among adults and youths with bipolar disorder: a  s y s t e m a t i c  r e v i e w .",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1016/j.cpr.2013.,OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.12816/ 0006044] [PMID: 24421749] [72] Freis, E.D.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1056/NEJM195412162512504] [PMID: 13214379] [73] Stanton, A.V.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1001/jama.288.3.351] [PMID: 12117400] [77] Baumeister, A.A.; Hawkins, M.F.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1076/jhin.12.2.207.15535] [PMID: 12953623] [78] Dose, M.; Emrich, H.M.; Cording-Tömmel, C.; von Zerssen, D. Psychiatry the State of the Art; Pharmacopsychiatry; Plenum Press: New York, 1985, Volume 3.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/0006-3223(89)90157-1] [PMID: 2649156] [80] Giannini, A.J.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1176/ajp.141.12.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1038/sj.mp.4001793] [PMID: 16432528] [83] Moller, H.J.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1055/s-0028-1094624] [PMID: 386388] [85] Shahrbabaki, M.E.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1097/00007611-198412000-00036] [PMID: 6505774] [87] de Souza, G.C.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1155/2015/692541] [88] MacDougall, A.I.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1176/ajp.143.11.1450] [PMID: 3535543] [90] Tudorache, B.; Diacicov, S. The effect of clonidine in the treatment of acute mania.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1056/NEJM195301082480202] [PMID: 13002681] [92] Watt, D.C.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/ 10.7196/sajp.456] [94] Wolf, W.A.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1176/ajp.122.10.1185] [PMID: 5325470] [96] DeMuth, G.W.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1176/ajp.140.5.534] [PMID: 6846579] [97] Fitzgerald, P.J.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1111/aap.12019] [PMID: 25271382] [98] Gironacci, M.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1177/1753944715599875] [PMID: 26287021] [99] Deicken, R.F.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/0006-3223(86) 90334-3] [PMID: 3539210] [100] Cohen, B.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1097/00004714-198804000-00018] [PMID: 3286687] [101] Zubenko, G.S.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1176/ajp.141.1.110] [PMID: 6318579] [102] Gajula, R.P.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1176/ ajp.150.9.1429] [PMID: 8352361] [103] Peet, M.; Peters, S. Drug-induced mania.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.2165/00002018-199512020-00007] [PMID: 7766338] [104] Burnier, M.; Brunner, H.R.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.2165/11591710-000000000-00000] [PMID: 21790209] [106] Khasawneh, F.T.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1080/15622970801910399] [PMID: 18609444] [109] Talbott, J.H.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1007/978-1-4614-3710-9_3] [113] Goldstein, B.I.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2009.00735.x] [PMID: 19689508] [114] Klumpers, U.M.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jad.2006.03.027] [PMID: 16777235] [116] Hildrum, B.; Mykletun, A.; Stordal, E.; Bjelland, I.; Dahl, A.A.; Holmen, J.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1136/ jech.2005.044966] [PMID: 17183016] [117] Hildrum, B.; Mykletun, A.; Holmen, J.; Dahl, A.A. Effect of anxiety and depression on blood pressure: 11-year longitudinal population study.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1192/bjp.bp.107.045013] [PMID: 18669991] [118] Tikhonoff, V.; Hardy, R.; Deanfield, J.; Friberg, P.; Kuh, D.; Muniz, G.; Pariante, C.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1097/HJH.0000000000000244] [PMID: 24906173] [119] Ginty, A.T.; Carroll, D.; Roseboom, T.J.; Phillips, A.C.; de Rooij, S.R.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1192/bjp.176.5.464] [PMID: 10912223] [121] Hammerton, G.; Harold, G.; T h a p a r ,  A .",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.4088/JCP.09m05585ora] [PMID: 20584522] [123] Forty, L.; Ulanova, A.; Jones, L.; Jones, I.; Gordon-Smith, K.; Fraser, C.; Farmer, A.; McGuffin, P.; Lewis, C.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.4061/2011/306367] [126] Wysokiński, A.; Kłoszewska, I.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1007/s11064-014-1305-3] [PMID: 24723220] [127] Prieto, M.L.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1111/acps.12293] [PMID: 24850482] [128] Allen, C.L.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1111/j.1747-4949.2008.00187.x] [PMID: 18706004] [129] Chiu, Y.C.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1097/MD.0000000000001520] [130] Perugi, G.; Toni, C. Comorbidity between panic-disorder and bipolar disorder.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/S0002-9343(99) 00237-5] [PMID: 10527031] [132] Kaplan, N.M. Anxiety-induced hyperventilation.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1001/archinte.1997.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jpsychires.2015.04.014] [PMID: 25937504] [134] Diaz, F.J.; James, D.; Botts, S.; Maw, L.; Susce, M.T.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1111/j.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1097/YPG.0b013e32835bd5f1] [PMID: 23196875] [139] Fergusson, D.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1017/ S0033291703008596] [PMID: 14672244] [140] Calkin, C.V.; Gardner, D.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.3109/07853890.2012.687835] [PMID: 22621171] [141] Reaven, G.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1111/j.1751-7176.2011.00439.x] [PMID: 21466618] [142] Cheung, B.M.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1007/s11883-012-0227-2] [PMID: 22281657] [143] Fuchs, F.D.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1161/01.HYP.37.5.1242] [PMID: 11358935] [144] Klimkiewicz, A.; Klimkiewicz, J.; Jakubczyk, A.; Kieres-Salomoński, I.; Wojnar, M. [Comorbidity of alcohol dependence with other psychiatric disorders.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.12740/PP/ 25704] [PMID: 26093591] [145] Frye, M.A.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1176/appi.ajp.160.5.883] [PMID: 12727691] [146] Azorin, J .",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1038/hr.2014.80] [PMID: 24804613] [148] Kelly, T.; Douglas, L.; Denmark, L.; Brasuell, G.; Lieberman, D.Z.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jad.2013.05.047] [PMID: 23769606] [149] Maina, G.; Salvi, V.; Vitalucci, A.; DAmbrosio, V.; Bogetto, F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/j.jad.2007.12.233] [PMID: 18234351] [150] Guha, P.; Bhowmick, K.; Mazumder, P.; Ghosal, M.; Chakraborty, I.; Burman, P. Assessment of insulin resistance and metabolic syndrome in drug naive patients of bipolar disorder.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1007/s12291-012-0292-x] [PMID: 24478549] [151] Lasser, K.; Boyd, J.W.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1001/jama.284.20.2606] [PMID: 11086367] [152] Mendelsohn, C.P.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1177/1039856214562076] [PMID: 25512967] [153] Simon, N.M.; Fischmann, D. The implications of medical and psychiatric comorbidity with panic disorder.",Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1016/ j.jad.2013.02.019] [PMID: 23510547] [155] Schröder, C.M.",OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
[http://dx.doi.org/10.1016/j.jad.,OADS,/arxiv_data1/oa_pdf/03/8a/CN-15-424.PMC5405605.pdf
"[http://dx.doi.org/10.1001/archpsyc.64.5.543] [PMID: 17485606] [2] Van Meter, A.R.",Non-OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.4088/ JCP.10m06290] [PMID: 21672501] [3] Leverich, G.S.",Non-OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
[http://dx.doi.org/10.1016/j.jpeds.2006.10.,OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2009.00686.x] [PMID: 19500092] [5] Birmaher, B.; Axelson, D.; Goldstein, B.; Strober, M.; Gill, M.K.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1016/j.jaac.2011.07.005] [PMID: 21961775] [7] Frías, Á.; Palma, C.; Farriols, N. Comorbidity in pediatric bipolar disorder: prevalence, clinical impact, etiology and treatment.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1016/ j.jad.2014.12.008] [PMID: 25545605] [8] Safer, D.J.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/ 10.1001/jamapsychiatry.2014.1746] [PMID: 25426673] [9] Fergus, E.L.; Miller, R.B.",Non-OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1016/ S0165-0327(02)00176-3] [PMID: 14550937] [10] Luckenbaugh, D.A.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2009.00684.x] [PMID: 19500097] [11] Faedda, G.L.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.4088/JCP.13r08900] [PMID: 26035191] [12] Faedda, G.L.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1016/j.jad.2014.07.013] [PMID: 25086290] [13] Nurnberger, J.I., Jr; McInnis, M.; Reich, W.; Kastelic, E.; Wilcox, H.C.; Glowinski, A.; Mitchell, P.; Fisher, C.; Erpe, M.; Gershon, E.S.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1016/j.jad.2012.04.023] [PMID: 22771141] [15] Duffy, A.; Alda, M.; Hajek, T.; Sherry, S.B.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1016/j.jad.2009.05.022] [PMID: 19541368] [16] Reichart, C.G.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1016/j.jad.2005.09.007] [PMID: 16260043] [17] Mesman, E.; Nolen, W.A.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
[http://dx.doi.org/10.1176/appi.,Non-OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
[http://dx.doi.org/10.1016/j.jad.2008.10.,OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
[http://dx.doi.org/10.1111/j.1399-5618.2005.,Non-OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/ 10.4088/JCP.08m04994yel] [PMID: 20667291] [23] Berk, M.; Dodd, S.; Callaly, P.; Berk, L.; Fitzgerald, P.; de Castella, A.R.",OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
[http://dx.doi.org/10.1016/j.eurpsy.2008.07.006] [PMID: 18789854],OADS,/arxiv_data1/oa_pdf/b6/fc/CN-15-380.PMC5405606.pdf
"[http://dx.doi.org/10.1002/0470017953.ch10] [2] Koukopoulos, A.; Ghaemi, S.N.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.eurpsy.2008.07.006] [PMID: 18789854] [3] Brown, J.; Beddoes, T.; Blake, W. The Elements of Medicine: Of John Brown, M. D. Translated From the Latin, With Comments and Illustrations By the Author.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/ j.jad.2006.08.031] [PMID: 16997381] [9] Yamada, M.; Uddin, L.Q.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.jclinepi.2009.06.005] [PMID: 19631508] [13] Anand, A.; Li, Y.; Wang, Y.; Lowe, M.J.; Dzemidzic, M. Resting state corticolimbic connectivity abnormalities in unmedicated bipolar disorder and unipolar depression.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1016/j.pscychresns.2008.03.,OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/ j.pscychresns.2010.04.002] [PMID: 20493671] [15] Dickstein, D.P.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/ j.biopsych.2010.06.029] [PMID: 20739018] [16] Chai, X.J.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1038/npp.2011.88] [PMID: 21654735] [17] Liu, C.H.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.neulet.2012.03.083] [PMID: 22503728] [18] Liu, C.H.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1371/ journal.pone.0048181] [PMID: 23133615] [19] Liu, C.H.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.pscychresns.2012.02.007] [PMID: 23017873] [20] Liu, C.H.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.pnpbp.2012.11.010] [PMID: 23200830] [21] Liang, M.J.; Zhou, Q.; Yang, K.R.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1371/journal.pone.0057978] [PMID: 23526961],Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.3390/brainsci3031357] [PMID: 24961532] [25] Torrisi, S.; Moody, T.D.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1111/bdi.12047] [PMID: 23347587] [26] Mamah, D.; Barch, D.M.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1093/cercor/bht165] [PMID: 23825317] [31] Anticevic, A.; Yang, G.; Savic, A.; Murray, J.D.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1093/schbul/sbu100] [PMID: 25031221] [32] Anticevic, A.; Savic, A.; Repovs, G.; Yang, G.; McKay, D.R.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/ 10.1093/schbul/sbt092] [PMID: 23851068] [34] Favre, P.; Baciu, M.; Pichat, C.; Bougerol, T.; Polosan, M. fMRI evidence for abnormal resting-state functional connectivity in euthymic bipolar patients.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.jad.2014.04.054] [PMID: 24882198] [35] Gao, W.; Jiao, Q.; Lu, S.; Zhong, Y.; Qi, R.; Lu, D.; Xiao, Q.; Yang, F.; Lu, G.; Su, L. Alterations of regional homogeneity in pediatric bipolar depression: a resting-state fMRI study.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1186/s12888-014-0222-y] [PMID: 25095790] [36] Rashid, B.; Damaraju, E.; Pearlson, G.D.; Calhoun, V.D.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.3389/fnhum.2014.00897] [PMID: 25426048] [37] Rashid, B.; Arbabshirani, M.R.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1111/ bdi.12221] [PMID: 24938878] [39] Liu, H.; Tang, Y.; Womer, F.; Fan, G.; Lu, T.; Driesen, N.; Ren, L.; Wang, Y.; He, Y.; Blumberg, H.P.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1093/schbul/sbt044] [PMID: 23599250] [40] Lu, D.; Jiao, Q.; Zhong, Y.; Gao, W.; Xiao, Q.; Liu, X.; Lin, X.; Cheng, W.; Luo, L.; Xu, C.; Lu, G.; Su, L. Altered baseline brain activity in children with bipolar disorder during mania state: a resting-state study.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/ 10.1111/bdi.12206] [PMID: 24725219] [44] Das, P.; Calhoun, V.; Malhi, G.S.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1016/j.nicl.2014.08.,OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1016/j.pscychresns.2014.11.,OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1371/journal.pone.0107829] [PMID: 25343370] [48] Lui, S.; Yao, L.; Xiao, Y.; Keedy, S.K.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1017/ S003329171400110X] [PMID: 25066779] [49] Liu, Y.; Wu, X.; Zhang, J.; Guo, X.; Long, Z.; Yao, L. Altered effective connectivity model in the default mode network between bipolar and unipolar depression based on resting-state fMRI.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1016/j.jad.,OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/ j.neuroimage.2015.07.054] [PMID: 26216278] [51] Jie, N.F.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1109/TAMD.2015.2440298] [PMID: 26858825] [52] Jie, N-F.; Osuch, E.A.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1111/bdi.12321] [PMID: 26291695] [54] Li, M.; Huang, C.; Deng, W.; Ma, X.; Han, Y.; Wang, Q.; Li, Z.; Guo, W.; Li, Y.; Jiang, L.; Lei, W.; Hu, X.; Gong, Q.; Merikangas, K.R.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/ 10.1016/j.jad.2014.10.044] [PMID: 25462396] [55] Satterthwaite, T.D.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1016/j.pscychresns.,OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1111/acps.12429] [PMID: 25929680] [60] Wang, Y.; Zhong, S.; Jia, Y.; Zhou, Z.; Wang, B.; Pan, J.; Huang, L. Interhemispheric resting state functional connectivity abnormalities in unipolar depression and bipolar depression.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1111/bdi.12315] [PMID: 26241359] [61] Wang, Y.; Zhong, S.; Jia, Y.; Sun, Y.; Wang, B.; Liu, T.; Pan, J.; Huang, L. Disrupted resting-state functional connectivity in nonmedicated bipolar disorder.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"Epub ahead of print [http://dx.doi.org/10.1148/radiol.2016151641] [PMID: 26909649] [62] Altinay, M.I.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
Epub ahead of print [http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1002/hbm.23070] [PMID: 26611711] [64] He, H.; Yu, Q.; Du, Y.; Vergara, V.; Victor, T.A.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/ 10.1016/j.jad.2015.10.042] [PMID: 26551408] [65] Lv, D.; Lin, W.; Xue, Z.; Pu, W.; Yang, Q.; Huang, X.; Zhou, L.; Yang, L.; Liu, Z.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1002/hbm.22655] [PMID: 25307723] [67] Martino, M.; Magioncalda, P.; Huang, Z.; Conio, B.; Piaggio, N.; Duncan, N.W.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"USA, 2016. pii: 201517558 [Epub ahead of print] [http://dx.doi.org/10.1073/ pnas.1517558113] [68] Rey, G.; Piguet, C.; Benders, A.; Favre, S.; Eickhoff, S.B.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1503/jpn.150159] [PMID: 26854755] [70] Solé-Padullés, C.; Castro-Fornieles, J.; de la Serna, E.; Romero, S.; Calvo, A.; Sánchez-Gistau, V.; Padrós-Fornieles, M.; Baeza, I.; Bargalló, N.; Frangou, S.; Sugranyes, G. Altered cortico-striatal connectivity in offspring of schizophrenia patients relative to offspring of bipolar patients and controls.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1371/journal.pone.0148045] [PMID: 26885824] [71] Souza-Queiroz, J.; Boisgontier, J.; Etain, B.; Poupon, C.; Duclap, D.; dAlbis, M.A.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/ 10.1016/j.jad.2016.04.038] [PMID: 27136413] [72] Brady, R.O., Jr; Masters, G.A.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.jad.2016.04.052] [PMID: 27177299] [73] Weissman, P. The primacy of mania in some forms of cyclothymic states.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1007/s00702-010-0404-9] [PMID: 20411397] [77] Decety, J.; N o r m a n ,  G .",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/ 10.1098/rstb.2015.0077] [PMID: 26644596] [79] Catmur, C.; Cross, E.S.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1098/rstb.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/j.neuropsychologia.2015.12.025] [PMID: 26727304] [81] Silk, J.B.; House, B.R.",OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1098/rstb.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.org/10.1016/j.neubiorev.,OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.3389/fpsyg.2011.00330] [PMID: 22084637] [85] Strakowski, S.M.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.1016/B978-0-12-397025-1.00052-X] [87] Stegman, J.K.; Branger, E. Stedman's Medical Dictionary, 28th ed; Lippincott Williams & Wilkins: Baltimore, Md., 2006.",Non-OADS,/arxiv_data1/oa_pdf/3b/5b/CN-15-339.PMC5405607.pdf
"[http://dx.doi.org/10.3109/10673229509017185] [PMID: 9384947] [2] Van Meter, A.R.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.4088/ JCP.10m06290] [PMID: 21672501] [3] Wozniak, J.; Faraone, S.V.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.4088/ JCP.12m07770] [PMID: 23140652] [4] Strober, M.; Carlson, G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1001/ archpsyc.1982.04290050029007] [PMID: 7092488] [5] Geller, B.; Fox, L.W.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1097/00004583-199405000-00003] [PMID: 8005898] [6] Goodwin, F.K.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/j.jad.2003.12.011] [PMID: 15465590] [9] Geller, B.; Zimerman, B.; Williams, M.; Bolhofner, K.; Craney, J.L.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1089/10445460050167269] [PMID: 11052405] [10] Geller, B.; Zimerman, B.; Williams, M.; Delbello, M.P.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1089/10445460252943533] [PMID: 12014591] [11] Matza, L.S.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.4088/JCP.v66n1114] [PMID: 16420081] [12] Leverich, G.S.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1016/j.jpeds.2006.10.,OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.2165/00023210-200317070-00003] [PMID: 12751919] [14] Baldessarini, R.J.; Tondo, L.; Hennen, J.; Floris, G. Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1034/j.1399-5618.1999.010206.x] [PMID: 11252665] [15] Post, R.M.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1097/ 00004583-200010000-00011] [PMID: 11026178] [17] American Psychiatric Association.,Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1176/appi.ajp.158.1.125] [PMID: 11136645] [23] Leibenluft, E.; Charney, D.S.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1176/appi.,Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1111/ j.1399-5618.2004.00128.x] [PMID: 15225148] [25] Biederman, J.; Faraone, S.V.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/j.jad.2004.05.021] [PMID: 15571789] [26] Luby, J.; Belden, A.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1017/S0954579406060482] [PMID: 17064425] [27] Tillman, R.; Geller, B.; Craney, J.L.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1176/appi.ajp.161.,Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1111/j.1399-5618.2005.00261.x] [PMID: 16403174],Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1097/ CHI.0b013e3181a565db] [PMID: 19465878] [32] Demeter, C.A.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/j.jad.2012.11.021] [PMID: 23219057] [33] Faedda, G.L.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.4088/JCP.13r08900] [PMID: 26035191] [34] Serra, G.; Koukopoulos, A.; De Chiara, L.; Napoletano, F.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/j.jad.2014.10.050] [PMID: 25462407] [35] Hunt, J.I.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.4088/JCP.12m07874] [PMID: 23419232] [36] Axelson, D.; Birmaher, B.; Strober, M.; Gill, M.K.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1001/archpsyc.63.10.1139] [PMID: 17015816] [37] Geller, B.; Tillman, R.; Bolhofner, K.; Zimerman, B.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1111/j.1399-5618.2008.,Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.4088/JCP.11m07504] [PMID: 23058936] [40] Lish, J.D.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/0165-0327(94)90104-X] [PMID: 7989643] [41] Perlis, R.H.; Miyahara, S.; Marangell, L.B.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/ j.biopsych.2004.01.022] [PMID: 15110730] [42] Faedda, G.L.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/j.jad.2014.07.013] [PMID: 25086290] [43] Duffy, A.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2009.00686.x] [PMID: 19500092] [45] Wozniak, J.; Petty, C.R.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1016/j.jpsychires.2010.,OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1176/appi.ajp.2014.13091213] [PMID: 24781389] [49] Axelson, D.; Findling, R.L.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.4088/JCP.12m07674] [PMID: 23140653] [50] Baldessarini, R.J.; Faedda, G.L.",Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1016/j.jad.2012.10.033] [PMID: 23219059] [51] Morcillo, C.; Duarte, C.S.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2008.00533.x] [PMID: 18199242] [53] Staton, D.; Volness, L.J.",OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
[http://dx.doi.org/10.1016/j.jad.2007.05.015] [PMID: 17604120],OADS,/arxiv_data1/oa_pdf/b1/fa/CN-15-386.PMC5405608.pdf
"[http://dx.doi.org/10.1002/0470017953.ch10] [2] Koukopoulos, A.; Sani, G.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1016/ j.jad.2006.08.031] [PMID: 16997381] [3] Hippocrates, (460 b.C.–377 b.C.).",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1016/S0010-440X(75)80014-9] [PMID: 1192716] [15] Kukopulos, A.; Reginaldi, D.; Laddomada, P.; Floris, G.; Serra, G.; Tondo, L. Course of the manic-depressive cycle and changes caused by treatment.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1016/0278-5846(87)90060-1] [PMID: 3114828] [17] Haag, H.; Heidorn, A.; Haag, M.; Greil, W. Sequence of affective polarity and lithium response: preliminary report on Munich sample.",OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1016/0278-5846(87)90061-3] [PMID: 3628828] [18] Maj, M.; Pirozzi, R.; Starace, F. Previous pattern  of c ourse of the  illness as a predictor of response to lithium prophylaxis in bipolar patients.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/ 10.1016/0165-0327(89)90005-0] [PMID: 2529291] [19] Faedda, G.L.",OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1176/ajp.148.9.1237] [PMID: 1883005] [20] Koukopoulos, A.; R e g i n a l d i ,  D .",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
[http://dx.doi.org/10.1016/j.jad.2013.05.059] [PMID: 23827534] [22] American Psychiatric Association.,Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
[http://dx.doi.org/10.1136/jnnp.23.1.,Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1192/bjp.133.5.429] [PMID: 728692] [26] Koukopoulos, A.; Ghaemi, S.N.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1016/j.eurpsy.2008.07.006] [PMID: 18789854] [27] Kraepelin, E. Psychiatrie.",OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/ 10.1002/hup.700] [PMID: 15957153] [29] Bond, D.J.",OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.4088/JCP.v69n1009] [PMID: 19192442] [30] Sani, G.; Napoletano, F.; Vöhringer, P.A.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1159/000358808] [PMID: 24970376] [31] Koukopoulos, A.; Sani, G.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
[http://dx.doi.org/10.1176/appi.ajp.,Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
[http://dx.doi.org/10.1111/j.1399-5618.2012.,Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1111/j.1600-0447.2009.01493.x] [PMID: 19895623] [35] Bersani, F.S.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.1080/ 13554794.2012.690429] [PMID: 22827578] [36] Lostia, A.M.; Mazzarini, L.; Pacchiarotti, I.; Lionetto, L.; De Rossi, P.; Sanna, L.; Sani, G.; Kotzalidis, G.D.; Girardi, P.; Simmaco, M.; Tatarelli, R. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
"[http://dx.doi.org/10.2174/092986709787909604] [PMID: 19355900] [38] Post, R.M.",Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
[http://dx.doi.org/10.1097/00005053-198212000-00002] [PMID: 6754868],Non-OADS,/arxiv_data1/oa_pdf/96/24/CN-15-394.PMC5405609.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/AJP.0b013e3181c49d2e] [PMID: 20026962] [4] Pert, C.B.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1126/science.179.4077.1011] [PMID: 4687585] [5] Hughes, J.; Smith, T.W.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1038/258577a0] [PMID: 1207728] [6] Snyder, S.H.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.neuropharm.2004.06.006] [PMID: 15464143] [7] Reinecke, H.; Sorgatz, H. S3 guideline LONTS.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1007/s00482-009-0839-9] [PMID: 19730894] [8] Kissin, I.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.2147/JPR.S47182] [PMID: 23874119] [9] Furlan, A.D.; Sandoval, J.A.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1503/cmaj.051528] [PMID: 16717269] [10] Nicholson, B.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.2165/11630030-000000000-00000] [12] Treede, R.D.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.neubiorev.2012.07.010] [PMID: 22975446] [16] Lebovits, A.H.; Lefkowitz, M.; McCarthy, D.; Simon, R.; Wilpon, H.; Jung, R.; Fried, E. The prevalence and management of pain in patients with AIDS: a review of 134 cases.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/00002508-198909000-00009] [PMID: 2520410] [17] Liu, B.; Liu, X.; Tang, S.J.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.3389/fmicb.2016.00103] [PMID: 26903982] [18] Svendsen, K.B.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1001/archneur.60.8.1089] [PMID: 12925364] [19] Potter, L.E.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1186/s12974-016-0609-4] [PMID: 27282914] [20] Arnér, S.; Meyerson, B.A.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/0304-3959(88)90198-4] [PMID: 2454440] [21] Courteix, C.; Bardin, M.; Chantelauze, C.; Lavarenne, J.; Eschalier, A.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/S0306-4522(97)00240-6] [PMID: 9483516] [27] Porreca, F.; Tang, Q.B.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1007/ BF02245203] [PMID: 7862839] [32] van Rijn, R.M.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1007/ s13365-012-0096-z] [PMID: 22528479] [37] Gironi, M.; Furlan, R.; Rovaris, M.; Comi, G.; Filippi, M.; Panerai, A.E.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1203/PDR.0b013e3180db2949] [PMID: 17622962] [42] Alexander, J.K.; DeVries, A.C.; Kigerl, K.A.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.bbi.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1155/2012/140832] [PMID: 22110940] [44] Afari, N.; Ahumada, S.M.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1097/PSY.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.psyneuen.2008.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1002/jnr.23802] [PMID: 27402412] [48] Ploj, K.; Roman, E.; Nylander, I.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1523/JNEUROSCI.3652-05.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1111/j.1526-4610.2011.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1007/s11916-016-0554-z] [PMID: 26936357] [52] Schiavone, S.; Colaianna, M.; Curtis, L. Impact of early life stress on the pathogenesis of mental disorders: relation to brain oxidative stress.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.4172/foa.1000105] [55] Kolberg, C.; Horst, A.; Moraes, M.S.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ j.jmpt.2014.11.003] [PMID: 25487299] [56] Inanır, A.; Sogut, E.; Ayan, M.; Inanır, S. Evaluation of Pain Intensity and Oxidative Stress Levels in Patients with Inflammatory and Non-Inflammatory Back Pain.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1517/14728222.2013.818657] [PMID: 23834645] [58] Raut, A.; Iglewski, M.; Ratka, A.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.neulet.2006.05.055] [PMID: 16808998] [59] Raut, A.; Rao, V.R.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ j.neulet.2007.06.015] [PMID: 17611027] [60] Wallace, D.R.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1016/j.neuro.2005.07.008] [PMID: 16168488] [61] Yang, Y.; Xia, X.; Zhang, Y.; Wang, Q.; Li, L.; Luo, G.; Xia, Y. delta-Opioid receptor activation attenuates oxidative injury in the ischemic rat brain.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/ 10.1016/j.expneurol.2012.05.006] [PMID: 22609332],OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1007/s00018-012-1167-2] [PMID: 23014992] [64] Prommer, E.E.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1146/ annurev.biochem.73.011303.073940] [PMID: 15189164] [68] Snyder, S.H.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1016/S0165-6147(03)00066-X] [PMID: 12707007] [69] Fukuda, K.; Kato, S.; Morikawa, H.; Shoda, T.; Mori, K. Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1126/science.1902986] [PMID: 1902986] [72] Law, P.Y.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.2174/1381612033454838] [PMID: 12769740] [77] Teschemacher, H. Opioid receptor ligands derived from food proteins.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1093/med/9780199236640.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1016/j.jpainsymman.2003.10.006] [PMID: 15120769] [81] Park, H.J.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.2165/00126839-200708010-00005] [PMID: 17249849] [84] Raffa, R.B.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1517/14656566.2012.696097] [PMID: 22698264] [85] Schiene, K.; De Vry, J.; Tzschentke, T.M.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1124/jpet.111.181263] [PMID: 21816956] [86] Williams, D.G.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1093/bja/aef284] [PMID: 12453926] [87] Smith, H.S.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1517/14740338.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1213/ANE.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ j.rdc.2008.04.001] [PMID: 18638682] [95] Leffler, A.; Frank, G.; Kistner, K.; Niedermirtl, F.; Koppert, W.; Reeh, P.W.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ 0024-3205(92)90144-E] [PMID: 1315897] [97] Gomes, I.; Gupta, A.; Filipovska, J.; Szeto, H.H.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1017/erm.2012.5] [PMID: 22490239] [99] Yaksh, T.L.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1111/j.1399-6576.1997.tb04623.x] [PMID: 9061092] [100] Dickenson, A.H. Central acute pain mechanisms.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.3109/07853899509031963] [PMID: 7632418] [101] Moochhala, S.M.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1111/j.1476-5381.1984.tb10773.x] [PMID: 6203593],Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1126/science.278.5336.275] [PMID: 9323204] [103] Khasabov, S.G.; Rogers, S.D.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1124/mol.106.026740] [PMID: 17005903] [105] Martin, W.R. Pharmacology of opioids.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1038/nm0897-831] [PMID: 9256267] [107] Sacerdote, P. Opioid-induced immunosuppression.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/ SPC.0b013e3282f5272e] [PMID: 18685388] [108] Sacerdote, P.; Bianchi, M.; Gaspani, L.; Manfredi, B.; Maucione, A.; Terno, G.; Ammatuna, M.; Panerai, A.E.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/00000539-200006000-00028] [PMID: 10825330] [109] Nestler, E.J.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/S0074-7742(09)85019-8] [PMID: 19607975] [111] Bagetta, G.; Sakurada, S. Understanding anomalous adaptation in chronic pain for successful development of disease modifying drugs.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1016/j.coph.2011.11.002] [PMID: 22172234] [112] Hervera, A.; Negrete, R.; Leánez, S.; Martín-Campos, J.; Pol, O.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1124/jpet.110.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1385/MN:21:1-2:021] [PMID: 11327148] [118] Whistler, J.L.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1073/ pnas.95.17.9914] [PMID: 9707575] [119] Bohn, L.M.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/00001756-199510010-00007] [PMID: 8580422] [121] deGroot, J.F.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1016/0304-3940(95)12034-2] [PMID: 8584236] [123] Zurek, J.R.; Nadeson, R.; Goodchild, C.S.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ j.brainres.2003.08.042] [PMID: 14625068] [128] Narita, M.; Oe, K.; Kato, H.; Shibasaki, M.; Narita, M.; Yajima, Y.; Yamazaki, M.; Suzuki, T. Implication of spinal protein kinase C in the suppression of morphine-induced rewarding effect under a neuropathic pain-like state in mice.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.neuroscience.2004.02.022] [PMID: 15099668] [129] Niikura, K.; Narita, M.; Butelman, E.R.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.tips.2010.04.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.brainres.2011.06.023] [PMID: 21762883] [131] Sánchez-Blázquez, P.; Gómez-Serranillos, P.; Garzón, J. Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/S0361-9230(00)00448-2] [PMID: 11275413] [132] Jordan, B.A.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1038/21441] [PMID: 10385123] [133] Bolan, E.A.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1002/ syn.10277] [PMID: 14579421] [134] Zukin, R.S.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1074/jbc.M000345200] [PMID: 10842167],Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1096/fj.06-7793com] [PMID: 17384143] [138] Kabli, N.; Martin, N.; Fan, T.; Nguyen, T.; Hasbi, A.; Balboni, G.; ODowd, B.F.; George, S.R.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1111/j.1476-5381.2010.00944.x] [PMID: 20977461] [139] von Zastrow, M. Role of endocytosis in signalling and regulation of G-protein-coupled receptors.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1042/bst0290500] [PMID: 11498017] [140] Sterne-Marr, R.; Benovic, J.L.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/S0083-6729(08)61039-0] [PMID: 7483322] [141] Rodríguez-Muñoz, M.; Sánchez-Blázquez, P.; Vicente-Sánchez, A.; Berrocoso, E.; Garzón, J.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1038/npp.2011.155] [PMID: 21814188] [142] Mayer, D.J.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/0006-8993(92)90193-D] [PMID: 1362520] [144] Yajima, Y.; Narita, M.; Usui, A.; Kaneko, C.; Miyatake, M.; Narita, M.; Yamaguchi, T.; Tamaki, H.; Wachi, H.; Seyama, Y.; Suzuki, T. Direct evidence for the involvement of brain-derived neurotrophic factor in the development of a neuropathic pain-like state in mice.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"Pharmacol., 2013. pii: S0014-2999(13)00164-7 [http://dx.doi.org/10.1016/j.ejphar.2013.01.066] [146] Meller, S.T.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/0014-2999(91) 90333-L] [PMID: 1665419] [148] Hervera, A.; Leánez, S.; Negrete, R.; Pol, O.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1007/s00210-009-0436-6] [PMID: 19636536] [149] Leánez, S.; Hervera, A.; Pol, O.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.ejphar.2008.11.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1038/sj.bjp.0706227] [PMID: 15852037] [152] Sánchez-Blázquez, P.; Rodríguez-Muñoz, M.; Garzón, J. Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1073/pnas.76.12.6666] [PMID: 230519] [155] Lai, S.L.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1186/1471-2202-12-41] [PMID: 21569381] [157] Raghavendra, V.; Tanga, F.; Rutkowski, M.D.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/S0304-3959(03)00138-6] [PMID: 12927638] [158] Narita, M.; Suzuki, M.; Narita, M.; Yajima, Y.; Suzuki, R.; Shioda, S.; Suzuki, T. Neuronal protein kinase C gamma-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo a d m i n i s t r a t i o n  o f  m o r p h i n e .",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1111/j.0953-816X.2003.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.bbi.2008.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.neuroscience.2005.11.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1213/ane.0b013e3181ae5f13] [PMID: 19690270] [164] Due, M.R.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1186/1742-2094-9-200] [PMID: 22898544] [165] Hutchinson, M.R.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.bbi.2008.05.004] [PMID: 18599265] [166] Hutchinson, M.R.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.bbi.2009.08.004] [PMID: 19679181] [167] Fukagawa, H.; Koyama, T.; Kakuyama, M.; Fukuda, K. Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1007/s00540-012-1469-4] [PMID: 22926420] [168] Johnston, I.N.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.pain.2006.03.018] [PMID: 16697108] [170] Reeve, A.J.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ j.pain.2005.02.003] [PMID: 15836969] [173] Eichelbaum, M.; Evert, B.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1111/j.1440-1681.1996.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1038/clpt.2011.287] [PMID: 22205192] [176] Galley, H.F.; Mahdy, A.; Lowes, D.A.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.2217/14622416.6.8.849] [PMID: 16296947] [177] Samer, C.F.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1111/j.1476-5381.2010.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.2217/14622416.8.7.743] [PMID: 17638512] [179] Wang, S.C.; Ho, I.K.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/JCP.0b013e318222b5dd] [PMID: 21694616] [180] Yuan, R.; Zhang, X.; Deng, Q.; Wu, Y.; Xiang, G. Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.cca.2010.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1177/0091270010388033] [PMID: 21209234] [182] Duguay, Y.; Báár, C.; Skorpen, F.; Guillemette, C. A novel functional polymorphism in the uridine diphosphate-glucuronosyl- transferase 2B7 promoter with significant impact on promoter activity.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1002/ajh.21051] [PMID: 17724700] [184] Somogyi, A.A.; Barratt, D.T.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"Pharmacol., 2004, 57(5), 600-610. a [http://dx.doi.org/ 10.1111/j.1365-2125.2003.02053.x] [PMID: 15089813] [188] Kharasch, E.D.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"Pharmacol., 2004, 44(3), 224-233. b [http://dx.doi.org/10.1177/ 0091270003262075] [PMID: 14973303] [189] Ameyaw, M.M.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/00008571-200104000-00005] [PMID: 11337937] [190] Cascorbi, I.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.pharmthera.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1067/mcp.2002.129196] [PMID: 12426522] [192] Argoff, C.E.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ j.neulet.2012.06.074] [PMID: 22796651] [195] Menon, S.; Lea, R.A.; Roy, B.; Hanna, M.; Wee, S.; Haupt, L.M.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1007/s10194-012-0468-z] [PMID: 22752568] [196] Olsen, M.B.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/ 10.1136/jmg.2005.036079] [PMID: 16882734] [198] Rakvåg, T.T.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.pain.2005.03.032] [PMID: 15927391] [199] Tammimäki, A.; Männistö, P.T.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1097/FPC.0b013e3283560c46] [PMID: 22722321] [200] Reyes-Gibby, C.C.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1158/1055-9965.EPI-08-0125] [PMID: 18990769] [201] Bessler, H.; Shavit, Y.; Mayburd, E.; Smirnov, G.; Beilin, B. Postoperative pain, morphine consumption, and genetic polymorphism of IL-1beta and IL-1 receptor antagonist.",Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.neulet.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/j.coph.2011.10.021] [PMID: 22088890] [203] Ji, R.R.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
"[http://dx.doi.org/10.1016/ j.tins.2003.09.017] [PMID: 14624855] [204] Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease.",OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.cell.2007.12.,OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1002/glia.22451] [PMID: 23361941],Non-OADS,/arxiv_data1/oa_pdf/9a/02/CN-15-444.PMC5405610.pdf
[http://dx.doi.org/10.1016/j.pbb.2006.06.,OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1111/j.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1176/ajp.115.5.459] [PMID: 13583250] [8] Crane, G.E.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1176/ajp.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1176/appi.ajp.2007.07121931] [PMID: 18316425] [13] O’Brien, C.P.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1111/j.1600-0447.2007.01058.x] [PMID: 17688462] [17] Diehl, D.J.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1001/archpsyc.64.3.327] [PMID: 17339521] [19] Bennabi, D.; Vandel, P.; Papaxanthis, C.; Pozzo, T.; Haffen, E. Psychomotor retardation in depression: a systematic review of diagnostic, pathophysiologic, and therapeutic implications.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1155/2013/158746] [20] van Enkhuizen, J.; Geyer, M.A.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1016/j.jad.2013.08.041] [PMID: 24287168] [21] Saito, S.; Shioda, K.; Nishijima, K. Dopamine dysregulation syndrome including mania related to coadministration of droxidopa.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1037/0033-295X.94.4.469] [PMID: 3317472] [24] Wise, R.A.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1097/01.ALC.0000091226.18969.B9] [PMID: 14574223] [26] Di Chiara, G.; Bassareo, V.; Fenu, S.; De Luca, M.A.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/j.coph.2006.11.003] [PMID: 17174602] [28] Wise, R.A.; Rompre, P.P.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1097/00004647-199703000-00010] [PMID: 9119906] [31] Pearlson, G.D.; Wong, D.F.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1001/archpsyc.1995.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/0165-0173(83)90007-3] [PMID: 6318882] [36] Willner, P.; Hale, A.S.; Argyropoulos, S. Dopaminergic mechanism of antidepressant action in depressed patients.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/j.jad.2004.12.010] [PMID: 15820269] [37] Brodie, B.B.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/ B978-0-08-011195-7.50019-8] [38] Serra, G.; Argiolas, A.; Klimek, V.; Fadda, F.; Gessa, G.L.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/ 0024-3205(79)90573-3] [PMID: 481130] [39] Spyraki, C.; Fibiger, H.C. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/0014-2999(81)90531-8] [PMID: 7198991] [40] Ho, B.T.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1002/jps.2600610602] [PMID: 4558257] [41] Bein, H.J.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/0166-2236(82)90017-0] [42] Serra, G.; Gessa, G.L.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/j.euroneuro.2012.05.010] [PMID: 22743048] [44] Papp, M.; Muscat, R.; Willner, P. Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1007/BF02246965] [PMID: 7870876] [45] Willner, P.; DAquila, P.S.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1177/026988119500900302] [PMID: 22297759] [46] DAquila, P.S.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1007/BF00187257] [PMID: 3124165] [48] DAquila, P.; Monleon, S.; Borsini, F.; Brain, P.; Willner, P. Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0014-2999(97)01412-X] [PMID: 9537806] [49] Willner, P.; Muscat, R.; Papp, M. Chronic mild stress-induced anhedonia: a realistic animal model of depression.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/ S0149-7634(05)80194-0] [PMID: 1480349] [50] Willner, P.; Lappas, S.; Cheeta, S.; Muscat, R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1177/ 0269881113494104] [PMID: 23904408] [52] Zesiewicz, T.A.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/ 0014-2999(80)90049-7] [PMID: 7398766] [57] Diggory, G.L.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/0014-2999(84)90617-4] [PMID: 6510470] [58] Dziedzicka-Wasylewska, M.; Willner, P.; Papp, M. Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1097/00008877-199711000-00017] [PMID: 9832973] [59] Holcomb, H.H.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1007/BF00212853] [PMID: 3131802] [61] Serra, G.; Argiolas, A.; Fadda, F.; Gessa, G.L.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0031-6989(80)80149-4] [PMID: 7403234] [62] Serra, G.; Argiolas, A.; Fadda, F.; Melis, M.R.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1007/BF00429217] [PMID: 6785815] [63] Serra, G.; Melis, M.R.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1016/0014-2999(81)90310-1] [PMID: 7262191],OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1002/(SICI)1098-2396(199703) 25:3<309::AID-SYN11>3.0.CO;2-R] [PMID: 9068130] [65] DAquila, P.S.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1016/S0014-2999(00)00566-5] [PMID: 11033341] [66] Gershon, A.A.; Vishne, T.; Grunhaus, L. Dopamine D2-like receptors and t h e  a n t i d e p r e s s a n t  r e s p o n s e .",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1007/BF01244974] [PMID: 1652984] [69] Serra, G.; Collu, M.; DAquila, P.S.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1111/j.1600-0773.1992.tb01631.x] [PMID: 1480562] [70] Willner, P. The mesolimbic dopamine system as a target for rapid antidepressant action.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1097/00004850-199707003-00002] [PMID: 9347387] [71] Collu, M.; Poggiu, A.S.; Devoto, P.; Serra, G. Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0014-2999(97)00006-X] [PMID: 9098678] [72] Fibiger, H.C.; Phillips, A.G.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1126/science.7197394] [PMID: 7197394] [73] Gessa, G.L.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/j.neuropharm.2008.08.015] [PMID: 18789340] [78] Serra, G.; Fadda, F.; Argiolas, A.; Collu, M.; Gessa, G.L.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0014-2999(97)01019-4] [PMID: 9228409] [83] DAquila, P.S.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0014-2999 (01)00876-7] [PMID: 11282119] [84] DAquila, P.S.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/j.ejphar.2006.02.016] [PMID: 16533507] [85] Battisti, J.J.; Shreffler, C.B.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0091-3057(00) 00324-5] [PMID: 11124387] [86] Grönig, M.; Atalla, A.; Kuschinsky, K. Effects of dizocilpine [(+)-MK-801] on the expression of associative and non-associative sensitization to D-amphetamine.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1007/ s00210-003-0855-8] [PMID: 14673514] [87] Ohmori, T.; Abekawa, T.; Muraki, A.; Koyama, T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/0091-3057(94)90318-2] [PMID: 7938110] [88] Pacchioni, A.M.; Gioino, G.; Assis, A.; Cancela, L.M.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1111/j.1749-6632.2002.tb04165.x] [PMID: 12105099] [89] Vezina, P.; Queen, A.L.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1007/s002130000463] [PMID: 10972464] [90] Wolf, M.E.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0361-9230(99)00268-3] [PMID: 10758338] [92] Heusner, C.L.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1523/JNEUROSCI.1474-05.2005] [PMID: 16014726] [93] Li, Y.; White, F.J.; Wolf, M.E.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/0361-9230(96)00006-8] [PMID: 8736582] [95] Rompré, P.P.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1016/j.bbr.,OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/S0924-977X(99)00038-3] [PMID: 10625119] [98] Kalivas, P.W.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/0376-8716(94)01063-Q] [PMID: 7758408] [99] Rockhold, R.W.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1007/s00213-002-1015-4] [PMID: 12073164] [101] Jeziorski, M.; White, F.J.; Wolf, M.E.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1002/syn.890160207] [PMID: 8197575] [102] Trujillo, K.A.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1093/alcalc/ 34.3.283] [PMID: 10414602] [104] Camarini, R.; Frussa-Filho, R.; Monteiro, M.G.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1111/j.1530-0277.2000.tb04609.x] [PMID: 10776664] [105] Kotlinska, J.; Bochenski, M.; Danysz, W. N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1097/01.fbp.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1007/s00213-004-2023-3] [PMID: 15517195] [107] Park, S.Y.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1016/j.ejphar.2015.01.041] [PMID: 25661848] [110] DAquila, P.S.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/ S0014-2999(00)00189-8] [PMID: 10794822] [111] Koukopoulos, A.; Reginaldi, D.; Serra, G.; Koukopoulos, A.; Sani, G.; Serra, G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1111/ j.1399-5618.2010.00803.x] [PMID: 20565444] [112] Koukopoulos, A.; Serra, G.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1016/j.jad.2011.09.040] [PMID: 22030128] [113] Keck, P.E., Jr; Hsu, H.A.",OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1097/WNF.0b013e318184fae2] [PMID: 19620854] [114] Serra, G.; De Chiara, L.; Koukopoulos, A.; Serra, G. Antimanic and long-lasting mood stabilizing effect of memantine in bipolar I mood disorder: two case reports.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1097/JCP.0b013e31829b62ba] [PMID: 24002206] [115] Serra, G.; De Chiara, L.; Manfredi, G.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/ 10.1177/2045125313507737] [PMID: 24490033] [116] Serra, G.; DE Chiara, L.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
"[http://dx.doi.org/10.1097/ 01.pra.0000450324.44661.12] [PMID: 24847998] [117] De Chiara, L.; Serra, G.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.4088/ JCP.13m08956] [PMID: 25650685],Non-OADS,/arxiv_data1/oa_pdf/89/33/CN-15-417.PMC5405612.pdf
[http://dx.doi.org/10.1034/j.1399-5618.2000.20308.,Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1016/j.jad.2014.03.035] [PMID: 24836088] [6] Rosa, A.R.",OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1111/acps.12179] [PMID: 23865756] [8] Mazzarini, L.; Pacchiarotti, I.; Colom, F.; Sani, G.; Kotzalidis, G.D.; Rosa, A.R.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.org/10.1016/j.jad.,OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.org/10.1016/j.jad.2009.11.,OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.4088/ JCP.08m04011] [PMID: 19192456] [13] Koukopoulos, A.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1016/j.eurpsy.2008.07.006] [PMID: 18789854] [15] Forty, L.; Jones, L.; Jones, I.; Smith, D.J.",OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.org/10.1111/j.1399-5618.2008.00654.,Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1192/bjp.133.5.429] [PMID: 728692] [20] Hamilton, M. A rating scale for depression.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.org/10.1136/jnnp.23.1.,Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2007.00561.x] [PMID: 18199235] [23] Mandelli, L.; Mazza, M.; Di Nicola, M.; Zaninotto, L.; Harnic, D.; Catalano, V.; Tedeschi, D.; Martinotti, G.; Bria, P.; Janiri, L.; Serretti, A.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1159/000330364] [PMID: 22398509] [24] Levin, F.R.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1016/ j.biopsych.2004.05.008] [PMID: 15556118] [25] Di Nicola, M.; De Risio, L.; Battaglia, C.; Camardese, G.; Tedeschi, D.; Mazza, M.; Martinotti, G.; Pozzi, G.; Niolu, C.; Di Giannantonio, M.; Siracusano, A.; Janiri, L. Reduced hedonic capacity in euthymic bipolar subjects: a trait-like feature?",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1016/ j.jad.2012.10.004] [PMID: 23122985] [26] Rakofsky, J.J.; Dunlop, B.W.",OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1016/j.jad.2012.06.012] [PMID: 22858208] [27] Vieta, E.; Colom, F.; Martínez-Arán, A.; Benabarre, A.; Reinares, M.; Gastó, C. Bipolar II disorder and comorbidity.",OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1053/comp.2000.9011] [PMID: 11011829] [28] Zaninotto, L.; Souery, D.; Calati, R.; Di Nicola, M.; Montgomery, S.; Kasper, S.; Zohar, J.; Mendlewicz, J.; Robert Cloninger, C.; Serretti, A.; Janiri, L. Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1097/00131746-200103000-00004] [PMID: 15990511] [30] Weiss, R.D.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.3109/ 00952998609083740] [PMID: 3788897] [31] Vieta, E.; Berk, M.; Wang, W.; Colom, F.; Tohen, M.; Baldessarini, R.J. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1016/j.jad.2009.02.028] [PMID: 19324419] [32] Janiri, L.; Martinotti, G.; Di Nicola, M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results  from a pilot study.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1097/JCP.0b013e318150c841] [PMID: 17873691] [33] Musenga, A.; Saracino, M.A.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.2174/092986709787909604] [PMID: 19355900] [34] Centorrino, F.; Fogarty, K.V.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/ 10.1002/hup.700] [PMID: 15957153] [35] Goldberg, J.F.",OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.4088/JCP.v60n1103] [PMID: 10584760] [36] Diagnostic and statistical manual of mental disorders, 5th e d ;  American Psychiatric Publishing: Arlington, VA, 2013.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1111/j.1600-0447.2007.00963.x] [PMID: 17280571] [38] Koukopoulos, A.; Sani, G. DSM-5 criteria for depression with mixed features: a farewell to mixed depression.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1111/acps.12140] [PMID: 23600771] [39] Himmelhoch, J.M.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.1001/archpsyc.1976.01770090052004] [PMID: 962490] [40] Mazza, M.; Mandelli, L.; Zaninotto, L.; Nicola, M.D.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"[http://dx.doi.org/10.3109/08039488.2011.593101] [PMID: 21728783] [41] Koukopoulos, A.; Sani, G.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/96/73/CN-15-409.PMC5405613.pdf
"https://doi.org/ 10.4088/JCP.8125tx11c [2] Blanco, C.; Laje, G.; Olfson, M.; Marcus, S.C.; Pincus, H.A.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 2002, 159(6), 1005-1010. https://doi.org/10.1176/appi.ajp.159.6.1005 [3] Judd, L.L.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry Rep., 2003, 5(6), 417-418. https://doi.org/10.1007/s11920-003-0077-2 [4] Judd, L.L.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2009, 11(5), 453-473. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2010, 51(5), 497-503. https://doi.org/10.1016/ j.comppsych.2010.02.001 [9] Weinstock, L.M.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord, 2009, 11(3), 289-297. https://doi.org/10.1111/j.1399-5618.2009.00681.x [10] Anderson, I.M.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychopharmacol., 2008, 22(4), 343-396. https://doi.org/10.1177/ 0269881107088441 [11] Centorrino, F.; Fogarty, K.V.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychopharmacol., 2005, 20(5), 355-358. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2008, 24(1), 10-17. https://doi.org/10.1097/YCT.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Serv., 2001, 52(8), 1033-1036. https://doi.org/10.1176/appi.ps.52.8.1033 [14] Sachs, G.S.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Neuropsychopharmacol., 2014, 17(7), 1053-1061. https://doi.org/ 10.1017/S1461145713000953 [15] Bates, J.A.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2010, 12(5), https://doi.org/10.4088/pcc.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Med., 2007, 356(17), 1711-1722. https://doi.org/10.1056/NEJMoa064135 [17] Velligan, D.I.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Gen. Psychiatry, 2010, 67(4), 339-347. https://doi.org/10.1001/archgenpsychiatry.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2012, 14(2), 146-150. https://doi.org/10.1111/j.1399-5618.2012.00997.x [20] Kellner, C.H.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"https://doi.org/10.4088/JCP.14com09498 [21] Kho, K.H.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"ECT., 2003, 19(3), 139-147. https://doi.org/10.1097/ 00124509-200309000-00005 [22] Loo, C.; Katalinic, N.; Mitchell, P.B.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J Affect Disord, 2011, 132(1-2), 1-13. https://doi.org/10.1016/ j.jad.2010.08.017 [23] Mukherjee, S.; Sackeim, H.A.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 1994, 151(2), 169-176. https://doi.org/10.1176/ ajp.151.2.169 [24] UK ECT Review Group.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Lancet, 2003, 361(9360), 799-808. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2008, 23 53-56. https://doi.org/ 10.1016/j.eurpsy.2007.10.011 [26] American; Psychiatric; Association.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2002, 3(3), 115-124. https://doi.org/10.3109/ 15622970209150612 [28] Grunze, H.; Kasper, S.; Goodwin, G.; Bowden, C.; Baldwin, D.; Licht, R.W.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2003, 4(1), 5-13. https://doi.org/10.3109/15622970309167904 [29] Kusumakar, V.; Yatham, L.N.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 2012, 169(12), 1238-1244. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2000, 16(1), 1-2. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 1995, 152(8), 1130-1138. https://doi.org/10.1176/ajp.152.8.1130 [35] Ghaemi, S.N.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2003, 5(6), 421-433. https://doi.org/10.1046/j.1399-5618.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Med., 1982, 12(3), 615-624. https://doi.org/10.1017/S0033291700055720 [37] Medda, P.; Perugi, G.; Zanello, S.; Ciuffa, M.; Cassano, G.B.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Disord., 2009, 118(1-3), 55-59. https://doi.org/10.1016/j.jad.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Disord., 2009, 112(1-3), 212-218. https://doi.org/10.1016/j.jad.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Gen. Psychiatry, 1974, 30(3), 320-321. https://doi.org/10.1001/ archpsyc.1974.01760090038006 [40] Black, D.W.; Winokur, G.; Nasrallah, A. ECT in Unipolar and Bipolar Disorders: A Naturalistic E v a l u a t i o n  o f  4 6 0  P a t i e n t s .",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2002, 4 (Suppl 1), 91-93. https://doi.org/10.1034/j.1399-5618.4.s1.40.x [42] Daly, J.J.; Prudic, J.; Devanand, D.P.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord, 2001, 3(2), 95-104. https://doi.org/10.1034/j.1399-5618.2001.030208.x [43] Sienaert, P.; Vansteelandt, K.; Demyttenaere, K.; Peuskens, J. Ultra-brief pulse ECT in bipolar and unipolar depressive disorder: differences in speed of response.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2009, 11(4), 418-424. https://doi.org/10.1111/j.1399-5618.2009.00702.x [44] Schoeyen, H.K.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 2015, 172(1), 41-51. https://doi.org/10.1176/appi.ajp.2014.13111517 [45] Pacchiarotti, I.; Mazzarini, L.; Kotzalidis, G.D.; Valenti, M.; Nivoli, A.M.; Sani, G.; Torrent, C.; Murru, A.; Sanchez-Moreno, J.; Patrizi, B.; Girardi, P.; Vieta, E.; Colom, F. Mania and depression.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"[46] Perugi, G.; M https://doi.org/10.1016/j.jad.2011.03.037edda, P.; Reis, J.; Rizzato, S.; Giorgi, M. M.; Mauri, M. Clinical subtypes of severe bipolar mixed states.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Disord., 2013, 151(3), 1076-1082. https://doi.org/10.1016/j.jad.2013.08.037 [47] Swann, A.C.; Lafer, B.; Perugi, G.; Frye, M.A.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 2013, 170(1), 31-42. https://doi.org/10.1176/appi.ajp.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord, 2005, 7(3), 205-215. https://doi.org/10.1111/j.1399-5618.2005.00197.x [49] Swann, A.C.; Bowden, C.L.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Gen. Psychiatry, 1997, 54(1), 37-42. https://doi.org/10.1001/archpsyc.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Scand., 2008, 118(5), 347-356. https://doi.org/10.1111/j.1600-0447.2008.01257.x [51] Goldberg, J.F.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 2001, 158(8), 1265-1270. https://doi.org/10.1176/appi.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"https://doi.org/10.1192/ bjp.178.41.s169 [53] Ahlfors, U.G.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Scand., 1981, 64(3), 226-237. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2000, 12(3), 167-170. https://doi.org/10.3109/10401230009147107 [55] Post, R.M.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"CNS Drugs, 2007, 21(1), 47-71. https://doi.org/10.2165/00023210-200721010-00005 [56] Calabrese, J.R.; Rapport, D.J.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2007, 31(3), 727-730. https://doi.org/10.1016/j.pnpbp.2007.01.006 [58] Shorter; Healy.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Scand., 2010, 121(6), 431-436. https://doi.org/10.1111/j.1600-0447.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Scand., 2014, 129(1), 4-16. https://doi.org/10.1111/acps.12140 [61] Perugi, G.; Akiskal, H.S.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Disord., 2001, 67(1-3), 105-114. https://doi.org/10.1016/S0165-0327(01)00443-8 [62] Angst, J.; Azorin, J.M.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Gen. Psychiatry, 2011, 68(8), 791-798. https://doi.org/10.1001/archgenpsychiatry.2011.87 [63] Stromgren, L.S.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"ECT., 2000, 16(2), 183-188. https://doi.org/10.1097/00124509-200006000-00010 [65] Devanand, D.P.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2000, 16(1), 32-37. https://doi.org/10.1097/ 00124509-200003000-00004 [66] Ciapparelli, A.; Dell'Osso, L.; Tundo, A.; Pini, S.; Chiavacci,  M.C.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2010, 26(2), 82-86. https://doi.org/10.1097/YCT.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2012, 15(1), 1-44. https://doi.org/10.1111/bdi.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2010, 26(4), 278-279. https://doi.org/10.1097/YCT.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Pract., 2013, 19(1), 15-28. https://doi.org/10.1097/ 01.pra.0000426324.67322.06 [72] Barekatain, M.; Jahangard, L.; Haghighi, M.; Ranjkesh, F.  Bifrontal versus bitemporal electroconvulsive therapy in severe manic p a t i e n t s .",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2008, 24(3), 199-202. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2008, 10(6), 701-707. https://doi.org/ 10.1111/j.1399-5618.2008.00608.x [74] Jahangard, L.; Haghighi, M.; Bigdelou, G.; Bajoghli, H.; Brand, S. Comparing efficacy of ECT with and without concurrent sodium valproate therapy in manic patients.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2012, 28(2), 118-123. https://doi.org/10.1097/YCT.0b013e31824b64b5 [75] Mohan, T.S.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2009, 11(2), 126-134. https://doi.org/10.1111/j.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Br J Psychiatry, 1994, 164(6), 806-810. https://doi.org/10.1192/bjp.164.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Gen. Psychiatry, 1988, 45(8), 727-732. https://doi.org/10.1001/ archpsyc.1988.01800320037004 [78] Vanelle, J.M.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Suppl, 2013, (441), 1-47. https://doi.org/10.1111/acps.12038 [80] Moskowitz, A.K.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 1996, 60(3), 326-332. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Affect Disord., 2003, 74(3), 279-285. https://doi.org/10.1016/S0165-0327(02)00088-5 [86] Blumer, D. Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 1997, 38(4), 193-201. https://doi.org/10.1016/S0010-440X(97)90027-4 [87] Fink, M.; Kellner, C.H.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2014, 5, 181. https://doi.org/10.3389/fpsyt.2014.00181 [89] England, M.L.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Neurosci., 2011, 23(2), 223-226. https://doi.org/10.1176/jnp.23.2.jnp223 [90] Hatta, K.; Miyakawa, K.; Ota, T.; Usui, C.; Nakamura, H.; Arai, H. Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2007, 23(4), 233-235. https://doi.org/ 10.1097/yct.0b013e3181587949 [91] McCall, W.V.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Neurosci., 2012, 262(5), 425-430. https://doi.org/10.1007/s00406-011-0285-4.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Disord., 1993, 29(4), 255-261. https://doi.org/10.1016/0165-0327(93)90015-C [95] Unal, A.; Bulbul, F.; Alpak, G.; Virit, O.; Copoglu, U.S.; Savas, H.A.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2013, 29(3), 206-209. https://doi.org/10.1097/YCT.0b013e3182887a1a [96] van Waarde, J.A.T.J., Verwey, B., van der Mast, R.C.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2010, 26(4), 248-252. https://doi.org/10.1097/YCT.0b013e3181c18a13 [97] REGIONE; TOSCANA.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Disord., 2009, 116(1-2), 106-112. https://doi.org/10.1016/ j.jad.2008.11.001 [99] Hamilton, M. A rating scale for depression.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 1960, 23, 56-62. https://doi.org/10.1136/jnnp.23.1.56 [100] Overall, J.E.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Rep., 1962, 10, 799-812. https://doi.org/10.2466/pr0.1962.10.3.799 [101] Young, R.C.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. Psychiatry, 1978, 133, 429-435. https://doi.org/10.1192/bjp.133.5.429 [102] Folstein, M.F.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Scand., 1996, 93(2), 129-136. https://doi.org/10.1111/ j.1600-0447.1996.tb09814.x [105] Shapira, B.; Tubi, N.; Lerer, B.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"J. ECT, 2000, 16(2), 97-109. https://doi.org/ 10.1097/00124509-200006000-00002 [106] Petrides, G.; Divadeenam, K.M.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 1997, 42(5), 375-381. https://doi.org/ 10.1016/S0006-3223(96)00378-2 [107] Greenberg, R.M.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Psychiatry, 2002, 63(2), 146-151. https://doi.org/10.4088/ JCP.v63n0210 [113] Sienaert, P.; Peuskens, J. Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder.",Non-OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"Bipolar Disord., 2006, 8(3), 304-306. https://doi.org/10.1111/j.1399-5618.2006.",OADS,/arxiv_data1/oa_pdf/57/3f/CN-15-359.PMC5405614.pdf
"[http://dx.doi.org/10.1159/000358808] [PMID: 24970376] [2] Koukopoulos, A.; Ghaemi, S.N.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1016/j.eurpsy.2008.07.006] [PMID: 18789854] [3] Keller, M.B.",OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1016/S0193-953X(05)70270-7] [PMID: 8677213] [4] Havens, L.L.",OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1001/archgenpsychiatry.2011.87] [PMID: 21810644] [8] Koukopoulos, A.; Sani, G.; Koukopoulos, A.E.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.org/10.1016/j.jad.,OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1097/YCO.0b013e32833299d4] [PMID: 19809321] [11] Kretschmer, E. Physique and Character.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/ 10.1016/j.jad.2010.07.016] [PMID: 20699193] [13] Ghaemi, S.N.",OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2008.00639.x] [PMID: 19594510] [14] Bienvenu, O.J.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1017/ S003329171000084X] [PMID: 20459884] [15] Roth, S.M.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1111/j.1600-0447.2008.01257.x] [PMID: 18727689] [18] Wehr, T.A.",OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.org/10.1001/archpsyc.1979.,Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.4088/ JCP.08m04909gre] [PMID: 20409444] [20] Coryell, W.; Solomon, D.; Turvey, C.; Keller, M.; Leon, A.C.; Endicott, J.; Schettler, P.; Judd, L.; Mueller, T. The long-term course of rapid-cycling bipolar disorder.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.org/10.1001/archpsyc.60.9.,Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.org/10.1176/appi.ajp.,Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1046/j.1399-5618.2003.00074.x] [PMID: 14636365] [25] Hirschfeld, R.M.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"[http://dx.doi.org/10.1111/acps.12140] [PMID: 23600771] [27] Koukopoulos, A.; Sani, G.; Ghaemi, S.N.",Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.org/10.1192/bjp.bp.,Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
[http://dx.doi.org/10.1001/archgenpsychiatry.2009.166] [PMID: 19996037],Non-OADS,/arxiv_data1/oa_pdf/34/b2/CN-15-402.PMC5405615.pdf
"1958, 80, 2587. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"FASEB J., 2004, 18, 537-539. https://doi.org/10.1096/fj.03-0694fje [4] Champier, J.; Claustrat, B.; Besancon, R.; Eymin, C.; Killer, C.; Jouvet, A.; Chamba, G.; Fevre-Montange, M. Evidence for tryptophan hydroxylase and hydroxyindol-O-methyl-transferase mRNAs in human blood platelets.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Life Sci., 1997, 60, 2191-2197. https://doi.org/10.1016/S0024-3205(97)00234-8 [5] Conti, A.; Conconi, S.; Hertens, E.; Skwarlo-Sonta, K.; Markowska, M.; Maestroni, J.M.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2000, 28, 193-202. https://doi.org/10.1034/j.1600-079X.2000.280401.x [6] Martin, M.T.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Lett., 1981, 22, 285-288. https://doi.org/10.1016/0304-3940(81)90120-8 [8] Slominski, A.; Fischer, T.W.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Endocrine, 2005, 27, 137-148. https://doi.org/10.1385/ENDO:27:2:137 [9] Slominski, A.; Wortsman, J.; Tobin, D.J.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"FASEB J., 2005, 19, 176-194. https://doi.org/10.1096/fj.04-2079rev [10] Raikhlin, N.T.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Acta Histochem., 1976, 55, 19-24. https://doi.org/10.1016/S0065-1281(76)80092-X [11] Illerova, H. Melatonin rhythm in the human milk.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2005, 39, 215-216. https://doi.org/10.1111/j.1600-079X.2005.00261.x [13] Reppert, S.M.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Endocrinology, 1978, 102, 582-588. https://doi.org/10.1210/endo-102-2-582 [14] Illnerova, H.; Buresova, M.; Presl, J. Melatonin rhythm in human milk.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Lact., 2016 Apr 27. pii: 0890334415625217; [Epub head of print] https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2013, 55 (3), 240-246https://doi.org/10.1111/jpi.12066 [17] Axelrod, J.; Weissbach, H. Enzymatic O-methylation of N-acetylserotonin to melatonin.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Science, 1995, 270(5242), 1681-1683. https://doi.org/10.1126/science.270.5242.1681 [19] Simonneaux, V.; Ribelayga, C. Generation of the melatonin endocrine message in mammals: A review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Rev., 2003, 55, 325-395. https://doi.org/10.1124/pr.55.2.2 [20] Klein, D.C.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Rhythms 2004, 19, 264-279. https://doi.org/10.1177/ 0748730404267340 [21] Touitou, Y.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"1997, 336(3), 186-195. https://doi.org/10.1056/NEJM199701163360306 [23] Karasek, K.; Winczyk, K. Melatonin in humans.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Lancet, 1984, 1(8373), 362-365. https://doi.org/10.1016/S0140-6736(84)90412-4 [28] Iguchi, H.; Kato, K.I.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"1982, 54(5), 1025-1027. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Psycho- pharmacology, 1990, 100(2), 222-226. https://doi.org/10.1007/ BF02244410 [30] Claustrat, B.; Brun, J.; Chazot, G. The basic physiology and pathophysiology of melatonin.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Rev., 2005, 9(1), 11-24. https://doi.org/10.1016/j.smrv.2004.08.001 [31] Di, W.L.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Med., 1997, 336(14), 1028-1029. https://doi.org/10.1056/NEJM199704033361418 [32] Lynch, H.J.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Science, 1975, 187(4172), 169-171. https://doi.org/10.1126/science.1167425 [33] Dubocovich, M.L.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res, 1997, 23, 32-39. https://doi.org/10.1111/ j.1600-079X.1997.tb00332.x [37] Li, D.Y.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Pharmacol., 2008, 154(6), 1182-1195. https://doi.org/10.1038/bjp.2008.184 [39] Zawilska, J.B.; Skene, D.J.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Reports, 2009, 61, 383-410. https://doi.org/10.1016/ S1734-1140(09)70081-7 [40] Benitez-King, G.; Anton-Tay, F. Calmodulin mediates melatonin cytoskeletal effects.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Int., 1994, 24, 101-146. https://doi.org/ 10.1016/0197-0186(94)90100-7 [44] Liu, J.; Clough, S.J.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Toxicol., 2016, 56, 361-383. https://doi.org/10.1146/annurev-pharmtox-010814-124742 [45] Jin, X.; Von Gall, C.; Pieschl, R.L.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Cell Biol., 2003, 23(3), 1054-1060. https://doi.org/10.1128/MCB.23.3.1054-1060.2003 [46] Von Gall, C.; Stehle, J.H.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Cell  Tissue Res., 2002, 309, 151-162. https://doi.org/10.1007/s00441-002-0581-4 [47] Axelrod, J.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Science, 1974, 184, 1341-1348. https://doi.org/10.1126/science.184.4144.1341 [48] Dahlitz, M.; Alavarez, B.; Vignau, J.; English, J.; Arendt, J.; Parkes, J.D.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Lancet, 1991, 337, 1121-1124. https://doi.org/10.1016/0140-6736(91)92787-3 [49] Zisapel, N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"CNS Drugs, 2001, 15, 311-328. https://doi.org/10.2165/00023210-200115040-00005 [50] Arendt, J. Melatonin: characteristics, concerns, and prospects.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Rhythms., 2005, 20(4), 291-303. https://doi.org/10.1177/ 0748730405277492 [51] Jan, J.E.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Neurol., 2012, 16(5), 403-412. https://doi.org/10.1016/j.ejpn.2012.01.002 [52] Mareš, J.; Stopka, P.; Nohejlová, K.; Rokyta, R. Oxidative stress induced by epileptic seizure and its attenuation by melatonin.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Neurosci., 2005, 22(8), 2111-2116. https://doi.org/10.1111/j.1460-9568.2005.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"2008, 28(4), 569-579. https://doi.org/10.1007/s10571-007-9212-7 [55] Moriya, T.; Horie, N.; Mitome, M.; Shinohara, K. Melatonin influences the proliferative and differentiative activity of neural stem cells.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"2007, 42(4), 411-418. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Biometeorol., 1991, 35(3), 169-175. https://doi.org/10.1007/BF01049063 [57] Iwasaki, S.; Nakazawa, K.; Sakai, J.; Kometani, K.; Iwashita, M.; Yoshimura, Y.; Maruyama, T. Melatonin as a local regulator of human placental function.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2005, 39, 261-265. https://doi.org/10.1111/j.1600-079X.2005.00244.x",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Perinatol., 2000, 24, 258-266. https://doi.org/ 10.1053/sper.2000.8594 [59] Niles, L.P.; Armstrong, K.J.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"BMC Neurosci., 2004, 5, 41. https://doi.org/10.1186/1471-2202-5-41 [60] Kennaway, D.J.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 1999, 27(2), 65-72. https://doi.org/10.1111/j.1600-079X.1999.tb00598.x [62] Torres-Farfan, C .",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2006, 41(1), 5 8-66. https://doi.org/10.1111/j.1600-079X.2006.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Endocrinology, 2006, 147(10), 4618-4626. https://doi.org/10.1210/en.2006-0628 [64] Torres-Farfan, C .",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"2006, 40(1), 64-70. https://doi.org/10.1111/j.1600-079X.2005.00279.x [65] Reiter, R.J.; Tan, D.X.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Update, 2014, 20(2), 293-307. https://doi.org/10.1093/humupd/dmt054 [66] Pandi-Perumal, S.R.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Physiology-Paris, 2011, 105, 170-182. https://doi.org/10.1016/j.jphysparis.2011.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Int., 2006, 29, 21-37. https://doi.org/10.1080/07420520500464361 [69] Arangino, S.; Cagnacci, A.; Angiolucci, M.; Vacca, A.M.B.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Cardiol., 1999, 83, 1417. https://doi.org/10.1016/S0002-9149(99)00112-5 [70] Cagnacci, A.; Arangino, S.; Angiolucci, M.; Maschio, E.; Melis, G.B.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Pharmacol., 1998, 345, 67-76 https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Eye Res., 2005, 24, 4 3 3-456. https://doi.org/10.1016/j.preteyeres.2005.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
https://doi.org/10.1067/mhj.,Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Hypertension 2004, 43, 192-197. https://doi.org/10.1161/01.HYP.0000113293.15186.3b [75] Pandi-Perumal, S.R.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Pathol., 2006, 87, 81-87. https://doi.org/10.1111/j.0959-9673.2006.00474.x [76] Carrillo-Vico, A.; Guerrero, J.M.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Endocrine, 2005, 27, 189-200. https://doi.org/10.1385/ENDO:27:2: 189 [77] Srinivasan, V.; Pandi-Perumal, S.R.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Res., 2005, 7, 293-318. https://doi.org/10.1007/BF03033887 [78] Regodon, S.; Martin-Palomino, P.; Fernadez-Montesinos, R.; Herrera, J.L.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Vaccine, 2005, 23, 5321-5327. https://doi.org/10.1016/j.vaccine.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Metab., 2005, 2, 22. https://doi.org/10.1186/1743-7075-2-22 [80] Esquifino, A.I.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Rev., 2004, 4, 423-433. https://doi.org/10.1016/ j.cair.2004.08.002 [81] Bartness, T.J.; Demas, G.E.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Res., 2003, 34, 143-151. https://doi.org/10.1034/j.1600-079X.2003.00021.x [83] Rasmussen, D.D.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Endocrinology, 2001, 142, 4264-4271. https://doi.org/10.1210/endo.142.10.8423 [85] Ladizesky, M.G.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Life Sci., 2001, 70, 557-565. https://doi.org/10.1016/S0024-3205(01)01431-X [86] Roth, J.A.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Chem., 1999, 274, 22041-22047. https://doi.org/10.1074/jbc.274.31.22041 [87] Koyama, H.; Nakade, O.; Takada, Y.; Kaku, T.; Lau, K.H.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Res., 2002, 17, 1219-1229. https://doi.org/10.1359/jbmr.2002.17.7.1219 [88] Nakade, O.; Koyama, H.; Ariji, H.; Yajima, A.; Kaku, T. Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2004, 36, 132-139. https://doi.org/10.1046/j.1600-079X.2003.00109.x [90] Sadat-Ali, M.; Habdan, I.; Othman, A. Adolescent idiopathic scoliosis.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Neuroendocrinology, 1987, 46, 48-55. https://doi.org/10.1159/ 000124795 [93] Roy, D.; Belsham, D.D.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Chem., 2001, 277, 251-258. https://doi.org/10.1074/jbc.M108890200 [94] Aleandri, V.; Spina, V.; Morini, A.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Reprod., 2000, 63, 769-774. https://doi.org/10.1095/biolreprod63.3.769 [96] Kauppila, A.; Kivela, A.; Pakarinien, A.; Vakkuri, O. Inverse seasonal relationship between melatonin and ovarian activity in humans in a region with a strong seasonal contrast in luminosity.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Metab., 1987, 65, 823-828. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Pathol., 2000, 52, 71-76. https://doi.org/10.1016/S0940-2993(00) 80022-6 [98] Anisimov, V.N.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Carcinogenesis, 1997, 18, 1549-1553. https://doi.org/10.1093/carcin/ 18.8.1549 [99] Blask, D.E.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Endocrine, 2005, 27, 179-188. https://doi.org/10.1385/ENDO:27:2:179 [100] Gilad, E.; Laufer, M.; Matzkin, H.; Zisapel, N. Melatonin receptors in PC3 human prostate tumor cells.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 1999, 26, 211-220. https://doi.org/10.1111/j.1600-079X.1999.tb00586.x [101] Hill, S.M.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Biol., 1999, 460, 345-362. https://doi.org/10.1007/0-306-46814-X_39 [102] Hu, D.N.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Melanoma Res., 1997, 7, 27-31. https://doi.org/10.1097/00008390-199702000-00005 [104] Kanashi, Y.; Kobayashi, Y.; Noda, S.; Ishizuka, B.; Saito, K. Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2000, 28, 227-233. https://doi.org/10.1034/j.1600-079X.2000.280405.x [105] Kiefer, T.; Ram, P.T.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Treat, 2002, 71, 37-45. https://doi.org/ 10.1023/A:1013301408464 [106] Petranka, J.; Baldwin, W.; Biermann, J.; Jayadev, S.; Barrett, J.C.; Murphy, E. The oncostatic action o f  m e l a t o n i n  i n  a n  o v a r i a n  carcinoma cell line.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Biol., 2001, 33, 735-753. https://doi.org/10.1016/S1357-2725(01)00059-0 [108] Klaunig, J.E.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Environ Health Perspect., 1998, 106(1), 289-295. https://doi.org/10.1289/ehp.98106s1289 [109] Brugger, P.; Marktl, W.; Herold, M. Impaired nocturnal secretion of melatonin in coronary heart disease.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"https://doi.org/10.1016/S0140-6736(95)92600-3 [110] Girotti, L.; Lago, M.; Ianovsky, O.; Carbajales, J.; Elizari, M.V.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2000, 29, 138-142. https://doi.org/10.1034/j.1600-079X.2000.290302.x [111] Girotti, L.; Lago, M.; Ianovsky, O.; Elizari, M.V.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Endocrine, 2003, 22, 245-248. https://doi.org/10.1385/ ENDO:22:3:245 [112] Yaprak, M.; Altun, A.; Vardar, A.; Aktoz, M.; Ciftci, S.; Ozbay, G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"2003, 89, 103-107. https://doi.org/10.1016/S0167-5273(02)00461-8 [113] Scheer, F.A.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Hypertens., 2005, 18, 1619-1620. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Scand., 1985, 71, 319-330. https://doi.org/10.1111/j.1600-0447.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Psychiatry Res., 1998, 81, 9-17. https://doi.org/10.1016/S0165-1781(98)00069-9 [116] Morera-Fumero, A.L.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Psychiatry Res., 1989, 28, 263-278. https://doi.org/10.1016/0165-1781(89)90207-2 [118] Milhiet, V.; Etain, B.; Boudebesse, C.; Bellivier, F. Circadian biomakers, circadian genes and bipolar disorders.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"General Psychiatry, 2000, 57(6), 572-579. https://doi.org/10.1001/archpsyc.57.6.572 [120] Golden, R.N.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Gen. Psychiatry, 1988, 45, 150-154. https://doi.org/10.1001/archpsyc.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Psychiatry, 1985, 147, 389-393. https://doi.org/10.1192/bjp.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
https://doi.org/10.1097/01.yic.,Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Lancet, 2014, 383, 896-910. https://doi.org/10.1016/S0140-6736(13)61539-1 [130] Gould, E .",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Genet., 2000, 95, 307-315. https://doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 1996, 20, 45-50. https://doi.org/10.1111/j.1600-079X.1996.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Blood Flow Metab., 1999, 19, 511-516. https://doi.org/10.1097/00004647-199905000-00005 [134] Pei, Z.; Pang, S.F.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Stroke, 2003, 34, 770-775. https://doi.org/10.1161/01.STR.0000057460.14810.3E [135] Sinha, K.; Degaonkar, M.N.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Pharmacol., 2001, 428, 185-192. https://doi.org/10.1016/S0014-2999(01)01253-5 [136] Lee, E.J.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2005, 38, 42-52. https://doi.org/10.1111/j.1600-079X.2004.00173.x [137] Lee, M.Y.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2007, 42, 297-309. https://doi.org/10.1111/ j.1600-079X.2007.00420.x [138] Kondoh, T.; Uneyama, H.; Nishino, H.; Torii, K. Melatonin reduces cerebral edema formation caused by transient forebrain ischemia in rats.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Life Sci., 2002, 72, 583-590. https://doi.org/ 10.1016/S0024-3205(02)02256-7 [139] Chen, T.Y.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2006, 40, 242-250. https://doi.org/10.1111/j.1600-079X.2005.00307.x [140] Kilic, E.; Kilic, U.; Bacigaluppi, M.; Guo, Z.; Ben Abdallah, N.; Wolfer, D.P.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"J. Pineal Res., 2008, 45, 142-148. https://doi.org/10.1111/j.1600-079X.2008.00568.x [141] Biran, V.; Phan Duy, A.; Decobert, F.; Bednarek, N.; Alberti, C.; Baud, O.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Child Neurol., 2014, 56(8), 717-723. https://doi.org/10.1111/dmcn.12415 [142] Arpino, C.; Compagnone, E.; Montanaro, M.L.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"2010, 26(9), 1139-1149. https://doi.org/10.1007/s00381-010-1125-y [143] Machado, Júnior, L.C.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Pediatr (Rio J), 2014, 90(3), 221-231. https://doi.org/10.1016/j.jped.2013.08.012 [144] Allen, M.C.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Neurol., 2008, 21(2), 123-128. https://doi.org/10.1097/ WCO.0b013e3282f88bb4 [145] Vincer, M.J.; Allen, A.C.; Allen, V.M.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"https://doi.org/10.1371/journal.pone.0093188 [147] Dean, J.M.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"2014, 75(1-2), 227-233. https://doi.org/10.1038/pr.2013.189 [148] Pineda, R.G.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"https://doi.org/10.1016/j.jpeds.2013.08.047 [149] Benders, M.J.; Kersbergen, K.J.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"2014, 41(1), 9-82. https://doi.org/10.1016/j.clp.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Dev., 2002, 68(2), 9 3-102. https://doi.org/10.1016/ S0378-3782(02)00018-X [152] Meerlo, P.; Mistlberger, R.E.",OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Rev., 2009, 13(3), 187-194. https://doi.org/10.1016/j.smrv.2008.07.004 [153] Polimeni, G.; Esposito, E.; Bevelacqua, V.; Guarneri, C.; Cuzzocrea, S. Role of melatonin supplementation in neurodegenerative disorders.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"(Landmark Ed), 2014, 19, 429-446. https://doi.org/10.2741/4217 [154] Guedeney, A.; Guedeney, N.; Tereno, S.; Dugravier, R.; Greacen, T.; Welniarz, B.",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
"Chem., 2010, 17, 2070-2095. https://doi.org/10.2174/ 092986710791233689",Non-OADS,/arxiv_data1/oa_pdf/98/a5/CN-15-434.PMC5405617.pdf
[http://dx.doi.org/10.1093/med/9780199300532.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1080/10673220500174833] [PMID: 16020028] [3] Baillarger, J.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
[http://dx.doi.org/10.1002/9780470986738] [5] Kraepelin.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
[http://dx.doi.org/10.1093/med/9780199300532.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1001/archpsyc.1976.01770010073014] [PMID: 1108832] [10] Kukopulos, A.; Reginaldi, D.; Girardi, P.; Tondo, L. Course of manic-depressive recurrences under lithium.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1016/S0010-440X(75) 80014-9] [PMID: 1192716] [11] Coryell, W.; Endicott, J.; Keller, M. Outcome of patients with chronic affective disorder: a five-year follow-up.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
[http://dx.doi.org/10.1176/ajp.147.12.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1001/ archpsyc.1997.01830230023003] [PMID: 9366655] [14] Tondo, L.; Baldessarini, R.J.; Vázquez, G.; Lepri, B.; Visioli, C. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1176/ajp.148.9.1237] [PMID: 1883005] [17] Grof, P.; Haag, M.; Grof, P.; Haag, H. Lithium response and the sequence of episode polarities: preliminary report on a Hamilton sample.",OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1016/0278-5846(87)90060-1] [18] Haag, H.; Heidorn, A.; Haag, M.; Greil, W. Sequence of affective polarity and lithium response: preliminary report on Münich sample.",OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1016/0278-5846(87)90061-3] [19] Kukopulos, A.; Reginaldi, D.; Laddomada, P.; Floris, G.; Serra, G.; Tondo, L. Course of the manic-depressive cycle and changes caused by treatment.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1016/j.jad.2013.05.059] [PMID: 23827534] [21] Maj, M.; Pirozzi, R.; Starace, F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients.",OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/ 10.1016/0165-0327(89)90005-0] [PMID: 2529291] [22] Tondo, L.; Lepri, B.; Baldessarini, R.J.",OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1111/j.1600-0447.2008.01178.x] [PMID: 18397362] [23] Snook, E.; Moseley-Dendy, K.; Hirschfeld, R.M.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1093/med/ 9780199300532.003.0003] [24] Baldessarini, R.J.; Salvatore, P.; Khalsa, H-M.; Tohen, M. Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1016/j.jad.2010.03.014] [PMID: 20427091] [25] Baldessarini, R.J.; Undurraga, J.; Vázquez, G.H.",OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1111/j.1600-0447.2011.01818.x] [PMID: 22188017] [26] Baldessarini, R.J.; Tondo, L.; Visioli, C. First-episode types in bipolar disorder: predictive associations with later illness.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
[http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1016/j.jad.2015.02.011] [PMID: 25797049] [28] Vieta, E.; Suppes, T. Bipolar II disorder: arguments for and against a distinct diagnostic entity.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1111/j.1399-5618.2007.00561.x] [29] Colom, F.; Vieta, E.; Daban, C.; Pacchiarotti, I.; Sánchez-Moreno, J.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1016/S0193-953X(05) 70095-2] [PMID: 10550855] [31] Baldessarini, R.J.",OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
"[http://dx.doi.org/10.1007/978-1-4614-3710-9] [32] Pacchiarotti, I.; Bond, D.J.",Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
[http://dx.doi.org/10.1176/appi.ajp.,Non-OADS,/arxiv_data1/oa_pdf/1d/00/CN-15-353.PMC5405618.pdf
The references of all these enzymes can be found in the Beta-Lactamase DataBase at http://www.bldb.eu/BLDB.php?class=A.,Non-OADS,/arxiv_data1/oa_pdf/42/b2/CDT-17-1006.PMC5405625.pdf
"Among the  26 assigned GES variants 25 have available sequence (Lahey  Clinics,  http://www.lahey.org/Studies/other.asp#OTHGES),  two have Gly170Asn (GES-2, GES-13) and 10 Gly170Ser",Non-OADS,/arxiv_data1/oa_pdf/42/b2/CDT-17-1006.PMC5405625.pdf
"[21] FigTree, Available from: http://tree.bio.ed.ac.uk/software/figtree/   [22] Larkin MA, Blackshields G, Brown NP , et al.",OADS,/arxiv_data1/oa_pdf/42/b2/CDT-17-1006.PMC5405625.pdf
Available from: http://www.who.int/mediacentre/ factsheets/fs310/en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/0d/d4/AMHSR-6-199.PMC5405630.pdf
Available from:  http://www.who.int/violence_injury_prevention/road_ safety_status/2013/en/.,Non-OADS,/arxiv_data1/oa_pdf/0d/d4/AMHSR-6-199.PMC5405630.pdf
Available from:  http://www.economist.com/news/middle‑east‑and‑africa /21579057‑why‑nigerias‑roads ‑can‑be‑terrifying‑time‑test.,Non-OADS,/arxiv_data1/oa_pdf/0d/d4/AMHSR-6-199.PMC5405630.pdf
Available  from: https://www.cdc.gov/violenceprevention/overview/ publichealthapproach.html.,Non-OADS,/arxiv_data1/oa_pdf/0d/d4/AMHSR-6-199.PMC5405630.pdf
Available from: http://www.civilica.com/ Paper‑NCMANENTER01‑NCMANENTER01_008.html.,Non-OADS,/arxiv_data1/oa_pdf/67/23/AMHSR-6-239.PMC5405636.pdf
"[34]The Directory of Open Access Journals, http://doaj.org, is an online directory that indexes and provides access to high- quality, open access, peer-reviewed journals.",OADS,/arxiv_data1/oa_pdf/6c/8f/JHRS-10-3.PMC5405644.pdf
Available from:http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html.,Non-OADS,/arxiv_data1/oa_pdf/6c/8f/JHRS-10-3.PMC5405644.pdf
Available from: http://www.who.int/features/factfiles/obesity/en/.,Non-OADS,/arxiv_data1/oa_pdf/ae/36/JHRS-10-37.PMC5405646.pdf
Available from: http://www.who.int/mediacentre/factsheets/fs311/en/.,Non-OADS,/arxiv_data1/oa_pdf/ae/36/JHRS-10-37.PMC5405646.pdf
Curr Opin Obstet Gynecol 1999;11:307-11.Available from: http://www.ncbi.nlm.nih.gov/pubmed/10369209.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://linkinghub.elsevier.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0015028210025409.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0015028212001744.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0015028213027349.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
http://linkinghub.elsevier.com/retrieve/pii/S0015028213005499.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0015028213004020.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://linkinghub.elsevier.com/retrieve/pii/S0015028213027519.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://www.jhrsonline.org/text.asp?2016/9/2/94/183512.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://www.pubmedcentral.nih.gov/articlerender.,OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from:http://linkinghub.elsevier.com/retrieve/pii/S0015028213005530.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/9f/39/JHRS-10-49.PMC5405648.pdf
Available from: https://www.nice.org.,Non-OADS,/arxiv_data1/oa_pdf/07/7b/UA-9-194.PMC5405669.pdf
"9, 1317578 http://dx.doi.org/10.1080/20002297.2017.1317578 © 2017 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/ab/e0/zjom-9-1317578.PMC5405711.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ab/e0/zjom-9-1317578.PMC5405711.pdf
"9, 1300366 http://dx.doi.org/10.1080/20002297.2017.1300366 © 2017 The Author(s).",Non-OADS,/arxiv_data1/oa_pdf/58/de/zjom-9-1300366.PMC5405727.pdf
"Published by Informa UK Limited, trading as Taylor & Francis Group This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/58/de/zjom-9-1300366.PMC5405727.pdf
"ORCID Natalie Verstraeten http://orcid.org/0000-0002-9548- 4647 Jan Michiels http://orcid.org/0000-0001-5829-0897 References [1] Costerton JW, Stewart PS, Greenberg EP.",Non-OADS,/arxiv_data1/oa_pdf/58/de/zjom-9-1300366.PMC5405727.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/74/81/main.PMC5405742.pdf
Indian Pacing Electrophysiol J2017;17(2):29 e33.http://dx.doi.org/10.1016/j.ipej.2016.11.008 .,OADS,/arxiv_data1/oa_pdf/74/81/main.PMC5405742.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com/locate/IPEJ Indian Pacing and Electrophysiology Journal 17 (2017) 27 e28 http://dx.doi.org/10.1016/j.ipej.2017.01.008 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/74/81/main.PMC5405742.pdf
http://dx.doi.org/10.1161/ CIRCULATIONAHA.111.023838 .,Non-OADS,/arxiv_data1/oa_pdf/74/81/main.PMC5405742.pdf
http://dx.doi.org/10.1016/ j.hrthm.2013.10.046.Mortality .,OADS,/arxiv_data1/oa_pdf/74/81/main.PMC5405742.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com /locate/IPEJ Indian Pacing and Electrophysiology Journal 17 (2017) 34 e35 http://dx.doi.org/10.1016/j.ipej.2017.04.001 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/2e/1e/main.PMC5405743.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/79/61/main.PMC5405744.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com /locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2017.02.001 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/79/61/main.PMC5405744.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f5/fc/main.PMC5405745.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com /locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2017.03.004 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/f5/fc/main.PMC5405745.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/1e/27/main.PMC5405746.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com /locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2017.03.005 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/1e/27/main.PMC5405746.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC5405747.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com/locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2016.11.008 0972-6292/Copyright ©2016, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/ad/8b/main.PMC5405747.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7f/1d/main.PMC5405748.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com /locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2017.02.004 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/7f/1d/main.PMC5405748.pdf
J Cardiovasc Electrophysiol 2016 Jul 29. doi: http://dx.doi.org/10.1111/jce.13058 .,Non-OADS,/arxiv_data1/oa_pdf/7f/1d/main.PMC5405748.pdf
doi: http://dx.doi.org/10.1111/jce.13047 .,Non-OADS,/arxiv_data1/oa_pdf/7f/1d/main.PMC5405748.pdf
doi: http://dx.doi.org/10.1093/europace/ euw080 .,Non-OADS,/arxiv_data1/oa_pdf/7f/1d/main.PMC5405748.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/af/f3/main.PMC5405749.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com /locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2017.02.002 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/af/f3/main.PMC5405749.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8e/9d/main.PMC5405750.pdf
"Contents lists available at ScienceDirect Indian Pacing and Electrophysiology Journal journal homepage: www.elsevier.com /locate/IPEJ http://dx.doi.org/10.1016/j.ipej.2017.01.004 0972-6292/Copyright ©2017, Indian Heart Rhythm Society.",Non-OADS,/arxiv_data1/oa_pdf/8e/9d/main.PMC5405750.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c0/95/afw234.PMC5405752.pdf
"The SNP in the ARMS2 gene leading to an A69S exchange is predicted to be probably damaging (PolyPhen-2, http:// genetics.bwh.harvard.edu/pph2/ , score of 0.994), since it introduces a Ser residue, which might be used as a new phos- phorylation site (score of 0.905, NetPhos 2.0. http://www.cbs.",Non-OADS,/arxiv_data1/oa_pdf/c0/95/afw234.PMC5405752.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non- commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4d/5e/afw247.PMC5405756.pdf
"IAGG 2016 Available at: URL: http://www.garn-network.org/documents/WHITE BOOKONFRAILTY-USVERSION.pdf 7.Puts MT, Toubasi S, Atkinson E et al.",OADS,/arxiv_data1/oa_pdf/4d/5e/afw247.PMC5405756.pdf
http://ec.europa.eu/research/innovation-union/ pdf/active-healthy-ageing/gp_a3.pdf .,Non-OADS,/arxiv_data1/oa_pdf/4d/5e/afw247.PMC5405756.pdf
http://ec.europa.eu/ research/innovation-union/ind ex_en.cfm?section=active- healthy-ageing&pg=documents .,Non-OADS,/arxiv_data1/oa_pdf/4d/5e/afw247.PMC5405756.pdf
"Available from: http://www.health.qld.gov.au/nutrition/resources/est_rqts.pdf .28.Deutz NEP, Bauer JM, Barazzoni R et al.",OADS,/arxiv_data1/oa_pdf/ef/2f/afw229.PMC5405758.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ef/2f/afw229.PMC5405758.pdf
Detailed documentation and data are freely available: http://www.ssc.wisc.edu/wlsresearch/ Conﬂicts of interest None declared.,Non-OADS,/arxiv_data1/oa_pdf/ef/2f/afw229.PMC5405758.pdf
"http://www.healthypeople.gov/2020/default.aspx : Washington, DC; 2011.",Non-OADS,/arxiv_data1/oa_pdf/ef/2f/afw229.PMC5405758.pdf
"The most common  approaches to assess listening effort include subjective, behavioral,  and physiological methods (for details see Table 1, and SDC Table  1, http://links.lww.com/EANDH/A335).",Non-OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"We counted the signs (+, =, − in Table 1, and SDC Table 1,   http://links.lww.com/EANDH/A335) corresponding to each mea- surement type for findings addressing HP1 and HP2 (more, equal,  or less effort).",OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"Of the 42 findings based on subjective assessment  or rating of listening effort, 31 findings resulted from V AS (Table 1,  and SDC Table 1, http://links.lww.com/EANDH/A335).",OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"In Table 1, and Supplemental  Digital Content Table 1, http://links.lww.com/EANDH/A335,  first all studies that applied subjective methods are listed in  alphabetical order, followed by the studies using behavioral and finally physiological measurement methods of listening effort.",Non-OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"Those studies contributed multiple rows in Table 1,   and Supplemental Digital Content Table 1, http://links.lww.com/EANDH/A335.",Non-OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"We counted two plus  signs (+) from the two corresponding studies in Table 1, and SDC  Table 1, http://links.lww.com/EANDH/A335, and the applied Sign test did not show a difference in listening effort (as indexed by pupillometry) between normal-hearing and hearing-impaired listeners (p  = 0.25).",Non-OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"Evidence on the Effect of Hearing Aid Amplification on  Listening Effort (Q2) See Tables 1 and 5 as well as Supplemental Digital Content  Table 1, http://links.lww.com/EANDH/A335 for detailed and  summarized tabulations of the results described in this section.",Non-OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"Finally, only 6 (out of n = 16 in total) of the studies provided sufficient power, which caused “serious imprecision.” We counted the “+,” “=,” and “−” signs in Table 1, and SDC Table 1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/43/30/aud-38-267.PMC5405775.pdf
"31Images of hybridized spots (400 mm in diameter) were captured with a scan- ner (Image-Scanner III; GE Healthcare, United Kingdom), and the hybridization signal intensity was quanti ﬁed using ImageJ software (http://imagej.nih.gov/ij/; National Institutes of Health, Bethesda,MD).",OADS,/arxiv_data1/oa_pdf/8d/9d/ecl-43-174.PMC5405777.pdf
Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048893.htm.,Non-OADS,/arxiv_data1/oa_pdf/8d/9d/ecl-43-174.PMC5405777.pdf
Available at: http://www.clspectrum.,Non-OADS,/arxiv_data1/oa_pdf/8d/9d/ecl-43-174.PMC5405777.pdf
Available at: http://contactlensupdate.com/2015/10/ 28/contact-lenses-and-microbes-latest-innovations/.,Non-OADS,/arxiv_data1/oa_pdf/8d/9d/ecl-43-174.PMC5405777.pdf
Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer http://www.nccn.org/professional s/physician_gls/pdf/ovarian.pdf ).,Non-OADS,/arxiv_data1/oa_pdf/a8/52/igj-27-675.PMC5405779.pdf
Available at:http://www.nccn.org/professional s/physician_gls/pdf/ovarian.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a8/52/igj-27-675.PMC5405779.pdf
"MeSH Keywords:  HIV • Immune Reconstitution Inflammatory Syndrome • Immunomodulation • Myasthenia Gravis  Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/903108Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Internal Medicine, Icahn School of Medicine at Mount Sinai,  Queens Hospital Center, Jamaica, NY, U.S.A. 2 Department of Research, Maimonides Medical Center, Brooklyn, NY, U.SA.",Non-OADS,/arxiv_data1/oa_pdf/bc/e2/amjcaserep-18-427.PMC5405782.pdf
"MeSH Keywords:  Antigens, CD34 • Antigens, Thy-1 • Mesenchymal Stromal Cells • Umbilical Cord  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/902186Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Department of Clinical Dermatology, Central Clinical Hospital of the Ministry of  the Interior and Administration in Warsaw, Warsaw, Poland 2 Department of Clinical Genetics, Medical University in Lublin, Lublin, Poland 3 Department of Obstetrics and Pathology of Pregnancy, Medical University in  Lublin, Lublin, Poland 4 Praesum Healthcare Services, Lake Worth, FL, U.S.A. 5 Chair and Department of Biology and Genetics, Medical University in Lublin,  Lublin, Polande-ISSN 1643-3750 © Med Sci Monit, 2017; 23: 1886-1895  DOI: 10.12659/MSM.902186 1886 Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]   [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]   [Chemical Abstracts/CAS] [Index Copernicus] LAB/IN VITRO RESEARCHThis work is licensed under Creative Common Attribution- NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/c8/2d/medscimonit-23-1886.PMC5405783.pdf
"MeSH Keywords:  Apoptosis • Cell Survival • Insulin-Like Growth Factor Binding Protein 1 • MAP Kinases •   Neural Stem Cells • Phosphatidylinositol 3-Kinases  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/901055Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection GDepartment of Children Rehabilitation, Jining No.",Non-OADS,/arxiv_data1/oa_pdf/75/ac/medscimonit-23-1872.PMC5405785.pdf
"MeSH Keywords:  Association • Case-Control Studies • Polymorphism, Genetic • Secretoglobins  Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/903983Authors’ Contribution:  Study Design A  Data Collection B  Statistical Analysis C Data Interpretation D  Manuscript Preparation E  Literature Search F Funds Collection G1 Kohwang Medical Research Institute, School of Medicine, Kyung Hee University,  Seoul, Republic of Korea 2 Department of Pharmacology, Graduate School, Kyung Hee University, Seoul,  Republic of Korea 3 Department of Dental Pharmacology, School of Dentistry, Dankook University,  Cheonan, Republic of Korea 4 Division of Allergy and Respiratory System, Department of Korean Internal  Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of  Korea 5 Department of Korean Physiology, College of Pharmacy, Kyung Hee University,  Seoul, Republic of Koreae-ISSN 1643-3750 © Med Sci Monit, 2017; 23: 1880-1885 DOI: 10.12659/MSM.903983 1880 Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]   [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]   [Chemical Abstracts/CAS] [Index Copernicus] MOLECULAR BIOLOGYThis work is licensed under Creative Common Attribution- NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)",Non-OADS,/arxiv_data1/oa_pdf/b4/6b/medscimonit-23-1880.PMC5405786.pdf
"Statistics To determine whether individual SNP was in equilibrium at  each locus in the population, we evaluated the Hardy–Weinberg  equilibrium (HWE) using SNPStats ( http://bioinfo.iconcologia.",OADS,/arxiv_data1/oa_pdf/b4/6b/medscimonit-23-1880.PMC5405786.pdf
1992;6(3):832-839. http://www.ncbi.nlm.nih.gov/ entrez/query.fcgi?cmd ¼Retrieve&db ¼PubMed&dopt ¼Citation& list_uids ¼1346768.,OADS,/arxiv_data1/oa_pdf/cd/3c/10.1177_1559325817701213.PMC5405787.pdf
1996;273(5276):801- 803. http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/cd/3c/10.1177_1559325817701213.PMC5405787.pdf
"For reprints and permission queries, plea se visit SAGE’s website at http://www.sagepub.com/journalsPermissions.nav.",Non-OADS,/arxiv_data1/oa_pdf/d5/e7/10.1177_2325967117703054.PMC5405788.pdf
METHODS The methods of this study are similar to those of a previous study.9A retrospective cohort analysis was performed by searching the ESPN and National Collegiate Athletic Asso- ciation (NCAA) archives for NFL (http://espn.go.com/nfl/ statistics) and NCAA (http://www.ncaa.org/champion- ships/statistics/ncaa-football-statistics) RBs.,Non-OADS,/arxiv_data1/oa_pdf/d5/e7/10.1177_2325967117703054.PMC5405788.pdf
"For the purpose of this article, we have explored these aspects for lower limb interventions after SCI based on existing syntheses of original research studies (www.scireproject.com; “Pain Management,” “Physical Activity,” and “Lower Limb” reviews), registered clinical trials (http://www.clinicaltrials.gov; search terms [spinal cord injury] AND [gait]; search performed on January 21, 2016; studies with status withdrawn or unknown excluded), and a convenience sample of 2 recent lower limb interven-tion studies that explicitly included individuals with SCI and pain and in which both gait and pain were considered relevant outcome parameters.",Non-OADS,/arxiv_data1/oa_pdf/84/31/10.1177_1545968316680491.PMC5405804.pdf
"49,50 Likewise, of the 36  clinical SCI gait trials registered on http://www.clinicaltri-als.gov, only 6 assessed (or are planning to assess) pain as an outcome parameter (NCT01087918, 7 NCT01740128,  NCT02104622, NCT02441179, NTC02562001, NCT0 2600013).",Non-OADS,/arxiv_data1/oa_pdf/84/31/10.1177_1545968316680491.PMC5405804.pdf
"Four out of the 36 clinical SCI trials registered on http://www.clinicaltrials.gov explicitly excluded certain patients with pain with variable criteria, for example, exclusion of any pain in the affected limbs (NCT01498991), excessive pain in the lower limbs as mea-sured by a score of >5/10 on a Visual Analog Scale (NCT01302522), pain precluding full weight bearing and ambulation (NCT02104622), and pain limiting participation (NCT01438671).",Non-OADS,/arxiv_data1/oa_pdf/84/31/10.1177_1545968316680491.PMC5405804.pdf
"MULTIPLE SCLEROSIS MSJJOURNAL https://doi.org/10.1177/1352458517690823 https://doi.org/10.1177/1352458517690823Multiple Sclerosis Journal 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/39/6b/10.1177_1352458517690823.PMC5405807.pdf
Reprints and permissions:   http://www.sagepub.co.uk/journalsPermissions.nav 704 journals.sagepub.com/home/msjOverview and historical perspective Walking is defined as advancing or traveling on foot such that there is always one foot on the ground in bipedal locomotion.,Non-OADS,/arxiv_data1/oa_pdf/39/6b/10.1177_1352458517690823.PMC5405807.pdf
"Cochrane Database Syst Rev 2015;  3, http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010750.pub2/abstract  25.",OADS,/arxiv_data1/oa_pdf/1c/7f/10.1177_0269216316663856.PMC5405809.pdf
"https://doi.org/10.1177/1046496416689308Small Group Research 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/31/1c/10.1177_1046496416689308.PMC5405810.pdf
"CLINICAL REHABILITATION https://doi.org/10.1177/0269215516648751Clinical Rehabilitation 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/f3/bb/10.1177_0269215516648751.PMC5405812.pdf
"https://doi.org/10.1177/1352458517690821 https://doi.org/10.1177/1352458517690821MULTIPLE SCLEROSIS MSJJOURNAL Multiple Sclerosis Journal 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/c7/08/10.1177_1352458517690821.PMC5405816.pdf
"Reprints and permissions:   http://www.sagepub.co.uk/journalsPermissions.nav journals.sagepub.com/home/msj 721Overview and historical perspective Slowed cognitive processing was identified as a core symptom of multiple sclerosis (MS) in 1877 by Charcot 1 who presciently observed that in many  patients, “conceptions are formed slowly and the intellectual and emotional faculties are blunted in their totality.” It would take a century for psycho-metric methods to be rigorously applied to this pop-ulation, confirming Charcot’s hypothesis that bradyphrenia is a core MS deficit.",Non-OADS,/arxiv_data1/oa_pdf/c7/08/10.1177_1352458517690821.PMC5405816.pdf
"https://doi.org/10.1177/0269216316669867Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/5b/d7/10.1177_0269216316669867.PMC5405817.pdf
"Options to transform advanced care, http://www.thectac.org/wp-con-tent/uploads/2016/03/C_TAC-Policy-Agenda.pdf (2015, accessed 30 July 2016).",Non-OADS,/arxiv_data1/oa_pdf/5b/d7/10.1177_0269216316669867.PMC5405817.pdf
"https://doi.org/10.1177/1526602817693805Journal of Endovascular Therapy 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/ab/c8/10.1177_1526602817693805.PMC5405818.pdf
"Retrieved September 5, 2013, from https://ic.fsc.org/download.facts-and-figures-september-2013.a-2388.pdf Gabadinho, A., Ritschard, G., Studer, M., et al.",OADS,/arxiv_data1/oa_pdf/b0/df/10.1177_1350508415609140.PMC5405819.pdf
"(2011) ‘Mining Sequence Data in R with the TraMineR  Package: A User Guide’, Retrieved January 28, 2015, from http://mephisto.unige.ch/pub/TraMineR/doc/TraMineR-Users-Guide.pdf Gale, F. and Haward, M. (2011) Global Commodity Governance: State Responses to Sustainable Forest and  Fisheries Certification.",Non-OADS,/arxiv_data1/oa_pdf/b0/df/10.1177_1350508415609140.PMC5405819.pdf
"88, Retrieved from http://openarchive.cbs.dk/handle/10398/8924",Non-OADS,/arxiv_data1/oa_pdf/b0/df/10.1177_1350508415609140.PMC5405819.pdf
"Boston, MA: Little Brown.Kivela, M. (2013) ‘Multilayer Networks Library Documentation’, Retrieved from http://people.maths.ox.ac.",Non-OADS,/arxiv_data1/oa_pdf/b0/df/10.1177_1350508415609140.PMC5405819.pdf
"ISBN 3-900051-07-0, URL http://www.R-project.org/.",Non-OADS,/arxiv_data1/oa_pdf/b0/df/10.1177_1350508415609140.PMC5405819.pdf
"Retrieved September 5, 2013, from https://ic.fsc.org/download.notes-on-the-early- years-of-fsc.a-798.pdf",Non-OADS,/arxiv_data1/oa_pdf/b0/df/10.1177_1350508415609140.PMC5405819.pdf
"https://doi.org/10.1177/1046496417689897Small Group Research 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/fb/19/10.1177_1046496417689897.PMC5405820.pdf
"https://doi.org/10.1177/1359104516672507Clinical Child Psychology and Psychiatry 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/60/30/10.1177_1359104516672507.PMC5405821.pdf
Retrieved  from http://www.ncbi.nlm.nih.gov/books/NBK53577/ National Institute for Health and Care Excellence.,Non-OADS,/arxiv_data1/oa_pdf/60/30/10.1177_1359104516672507.PMC5405821.pdf
"Retrieved from https://www.nice.org.uk/guidance/cg28/chapter/1-recommendations Nijhof, S. L., Bleijenberg, G., Uiterwaal, C. S., Kimpen, J. L., & van de Putte, E. M. (2012).",Non-OADS,/arxiv_data1/oa_pdf/60/30/10.1177_1359104516672507.PMC5405821.pdf
"Retrieved from http://www.rcpch.ac.uk/rcpch-guidelines-and-standards-clinical-practice#cfs-me Smith, M. S., Martin-Herz, S. P., Womack, W. M., & Marsigan, J. L. (2003).",Non-OADS,/arxiv_data1/oa_pdf/60/30/10.1177_1359104516672507.PMC5405821.pdf
"https://doi.org/10.1177/1049732317700853Qualitative Health Research 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/2e/ee/10.1177_1049732317700853.PMC5405822.pdf
"Ambitions for palliative and end of life care: a national  framework for local action 2015–2020, 2015, http://end-oflifecareambitions.org.uk/wp-content/uploads/2015/09/Ambitions-for-Palliative-and-End-of-Life-Care.pdf  (accessed 17 September 2015).",Non-OADS,/arxiv_data1/oa_pdf/b8/c9/10.1177_0269216316663881.PMC5405823.pdf
"Leeds: UK Institute of Health Informatics, 2001,  http://www.scmdt.mmu.ac.uk/cir/REF/Docs/CS1-6.pdf  22.",Non-OADS,/arxiv_data1/oa_pdf/b8/c9/10.1177_0269216316663881.PMC5405823.pdf
"Leeds city council, 2011, http://observatory.leeds.gov.uk/resource/view?resourceId=4172 (accessed 2  February 2016).",Non-OADS,/arxiv_data1/oa_pdf/b8/c9/10.1177_0269216316663881.PMC5405823.pdf
"https://doi.org/10.1177/1066896916677289International Journal of Surgical Pathology 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/b0/36/10.1177_1066896916677289.PMC5405824.pdf
"https://doi.org/10.1177/0269216317690994Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/55/dc/10.1177_0269216317690994.PMC5405827.pdf
"https://doi.org/10.1177/0269216316673550Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/41/15/10.1177_0269216316673550.PMC5405828.pdf
"https://doi.org/10.1177/1046496416689710Small Group Research 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/e2/16/10.1177_1046496416689710.PMC5405829.pdf
Quality was measured by the percentage of newly created content based  on a score determined by the software Wincopyfind 2.6 (http://wcopyfind.findmysoft.com/).,OADS,/arxiv_data1/oa_pdf/e2/16/10.1177_1046496416689710.PMC5405829.pdf
"Retrieved from https://scholar.google.nl/citations?view_op=view_citat ion&hl=nl&user=dkYgjzkAAAAJ&citation_for_view=dkYgjzkAAAAJ:roLk4NBRz8UC Molenaar, I.",OADS,/arxiv_data1/oa_pdf/e2/16/10.1177_1046496416689710.PMC5405829.pdf
"Retrieved from https://scholar.google.nl/citations?view_op=view_citation&hl=nl&user=dkYgjzkAAAAJ&citation_for_view=dkYgjzkAAAAJ:Y0pCki6q_DkC Molenaar, I.",OADS,/arxiv_data1/oa_pdf/e2/16/10.1177_1046496416689710.PMC5405829.pdf
"Retrieved from:  https://scholar.google.nl/citations?view_op=view_citation&hl=nl&user=dkYgjzkAAAAJ&citation_for_view=dkYgjzk AAAAJ:2osOgNQ5qMEC Nijstad, B.",OADS,/arxiv_data1/oa_pdf/e2/16/10.1177_1046496416689710.PMC5405829.pdf
"Retrieved from http://edepot.wur.nl/121278 Volet, S. E., Summers, M., & Thurman, J.",Non-OADS,/arxiv_data1/oa_pdf/e2/16/10.1177_1046496416689710.PMC5405829.pdf
"https://doi.org/10.1177/0269216316689015Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/ba/58/10.1177_0269216316689015.PMC5405831.pdf
"BMC Health  Serv Res 2013; 13(1): 275, http://bmchealthservres.biomed-central.com/articles/10.1186/1472-6963-13-275 (accessed 22 October 2016).",Non-OADS,/arxiv_data1/oa_pdf/ba/58/10.1177_0269216316689015.PMC5405831.pdf
"Global atlas of palliative  care at the end of life (Worldwide palliative care alliance,  World Health Organization), 2014, http://www.who.int/ nmh/Global_Atlas_of_Palliative_Care.pdf  12.",Non-OADS,/arxiv_data1/oa_pdf/ba/58/10.1177_0269216316689015.PMC5405831.pdf
"Medicare  hospice benefits, 2016, https://www.medicare.gov/Pubs/pdf/02154.pdf  13.",Non-OADS,/arxiv_data1/oa_pdf/ba/58/10.1177_0269216316689015.PMC5405831.pdf
"BMC Health Serv Res 2016; 16(1), http://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-016-1770-2 (accessed 22 October 2016).",Non-OADS,/arxiv_data1/oa_pdf/ba/58/10.1177_0269216316689015.PMC5405831.pdf
"Health Policy Monitor, 2016, http://www.hpm.org/en/Surveys/TU_Berlin_-_D/14/Better_funding_model_for_Inpatient_Hospice_Units.html  17.",Non-OADS,/arxiv_data1/oa_pdf/ba/58/10.1177_0269216316689015.PMC5405831.pdf
"The budget: health and social care funding, 2015, http://www.kingsfund.org.uk/publications/articles/briefing-budget-july-2015 (accessed 26 March 2016).",Non-OADS,/arxiv_data1/oa_pdf/ba/58/10.1177_0269216316689015.PMC5405831.pdf
"https://doi.org/10.1177/1046496417691614Small Group Research 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/c1/94/10.1177_1046496417691614.PMC5405832.pdf
"Retrieved  from http://www.aabri.com/manuscripts/142071.pdf Wesselink, R., De Jong, C., & Biemans, H. J.",Non-OADS,/arxiv_data1/oa_pdf/c1/94/10.1177_1046496417691614.PMC5405832.pdf
"https://doi.org/10.1177/0038038515622907Sociology 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/88/78/10.1177_0038038515622907.PMC5405834.pdf
Available at: http://gmdvp.org/domestic-violence/ types-domestic-abuse/.,Non-OADS,/arxiv_data1/oa_pdf/88/78/10.1177_0038038515622907.PMC5405834.pdf
Available at: http://www.socresonline.org.uk/12/1/hines.html.,Non-OADS,/arxiv_data1/oa_pdf/88/78/10.1177_0038038515622907.PMC5405834.pdf
Available at: https://www.gov.uk/domestic- violence-and-abuse.,Non-OADS,/arxiv_data1/oa_pdf/88/78/10.1177_0038038515622907.PMC5405834.pdf
Available at: http://www.socresonline.org.uk/12/1/monro.html.,Non-OADS,/arxiv_data1/oa_pdf/88/78/10.1177_0038038515622907.PMC5405834.pdf
Available at: http://www.lse.ac.uk/lsehealthandsocialcare/pdf/sscr_methods_review_2.pdf.,Non-OADS,/arxiv_data1/oa_pdf/88/78/10.1177_0038038515622907.PMC5405834.pdf
Available at: http://www.womensaid.org.uk/domestic- violence-articles.asp?section=00010001002200410001&itemid=1272&itemTitle=What+is+domestic+violence.,Non-OADS,/arxiv_data1/oa_pdf/88/78/10.1177_0038038515622907.PMC5405834.pdf
"https://doi.org/10.1177/0269216316665562Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/d1/33/10.1177_0269216316665562.PMC5405836.pdf
"Adelaide, SA, Australia: The Joanna  Briggs Institute, 2015, http://joannabriggs.org/assets/docs/ sumari/Reviewers-Manual_Methodology-for-JBI-Scoping-Reviews_2015_v2.pdf (accessed 7 May–June 2016).",Non-OADS,/arxiv_data1/oa_pdf/d1/33/10.1177_0269216316665562.PMC5405836.pdf
"Oxford: CASP, 2014, http://www.casp-uk.net/ (accessed 30 June 2015).",Non-OADS,/arxiv_data1/oa_pdf/d1/33/10.1177_0269216316665562.PMC5405836.pdf
"https://doi.org/10.1177/1403494816688375© Author(s) 2017 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1403494816688375 journals.sagepub.com/home/sjpScandinavian Journal of Public Health, 2017; 45: 269–276 Introduction As a result of the contemporary management of cor- onary heart disease (CHD), an increasing proportion of patients survive and require optimal secondary prevention [1].",Non-OADS,/arxiv_data1/oa_pdf/5a/96/10.1177_1403494816688375.PMC5405837.pdf
Supplemental material  The online supplementary material is available at  http://sjp.sagepub.com/supplemental References  1.,Non-OADS,/arxiv_data1/oa_pdf/5a/96/10.1177_1403494816688375.PMC5405837.pdf
"https://doi.org/10.1177/1066896916679519International Journal of Surgical Pathology 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/eb/fe/10.1177_1066896916679519.PMC5405838.pdf
"https://doi.org/10.1177/1069397117691025Cross-Cultural Research 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
Scripts used to create and analyze the data available at https://github.com/rijpma/ea-anm.,OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
12. http://www.naturalearthdata.com/downloads/50m-physical-vectors/13.,Non-OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
Data available at http://webmap.ornl.gov/ogcdown/wcsdown.jsp?dg_id=10003_1 14.,OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
See http://eclectic.ss.uci.edu/~drwhite/worldcul/world.htm; and intersci.ss.uci.,Non-OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
"Retrieved from http://arxiv.org/abs/1406.5823 Bolt, J.",OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
"Retrieved from https://mpra.ub.uni-muenchen.de/61203/1/MPRA_paper_61203.pdf Hijmans, R. J.",Non-OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
"Retrieved  from https://CRAN.R-project.org/package=raster King, E. M., Peterson, J., Adioetomo, S. M., Domingo, L. J., & Syed, S. H. (1986).",Non-OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
"Retrieved from http://www.rand.org/pubs/reports/R3399/ Klein Goldewijk, K., Beusen, A., van Drecht, G., & de Vos, M. (2011).",OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
"Retrieved  from https://CRAN.R-project.org/package=gdistance Weidmann, N. B., Rød, J. K., & Cederman, L.-E. (2010).",OADS,/arxiv_data1/oa_pdf/8e/d1/10.1177_1069397117691025.PMC5405842.pdf
"https://doi.org/10.1177/0269216316670287Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"Understanding the cost of end of  life care in different settings, 2012, https://www.mariecurie.",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"RAND Labour and  Population working paper, October 2011, http://www.rand.org/pubs/working_papers/WR880.html (accessed 29 March 2016).",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"Guide to the methods of technology appraisal 2013, https://www.nice.org.uk/article/pmg9/chapter/foreword (2013, accessed 18 April 2016).",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"Reviewing end of life  care costing information to inform the QIPP end of life care  workstream, 2012, http://thewholesystem.co.uk/wp-content/uploads/2014/07/EoLC_QIPP_Costings_Report.pdf  54.",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"Country and lending group classifications  2016, http://data.worldbank.org/about/country-and-lending- groups#Upper_middle_income (accessed 29 March 2016).",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"Guidance  for assessing effectiveness, economic aspects, ethical  aspects, socio-cultural aspects and legal aspects in com- plex technologies, http://www.integrate-hta.eu/downloads/  (accessed 18 April 2016).",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"Dying well  at home: the case for integrated working: SCIE guide 48,  2013, http://www.scie.org.uk/publications/guides/guide48/  59.",Non-OADS,/arxiv_data1/oa_pdf/cf/d2/10.1177_0269216316670287.PMC5405843.pdf
"https://doi.org/10.1177/1352458517690824 https://doi.org/10.1177/1352458517690824MULTIPLE SCLEROSIS MSJJOURNAL Multiple Sclerosis Journal 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/38/a6/10.1177_1352458517690824.PMC5405844.pdf
"Reprints and permissions:   http://www.sagepub.co.uk/journalsPermissions.nav journals.sagepub.com/home/msj 711Overview and historical perspective Like walking disability, visual problems, and cogni-tive deficits, upper limb dysfunction is a core deficit affecting multiple sclerosis (MS) patients.",Non-OADS,/arxiv_data1/oa_pdf/38/a6/10.1177_1352458517690824.PMC5405844.pdf
"The man-ual, which can be downloaded from http://www.nationalmssociety.org, includes our recommended administration instructions, the placement of the NHPT apparatus compared to the tested hand, and frequently asked questions and answers documenting how to handle different situations a tester may face such as a peg ending up on the table or floor.",Non-OADS,/arxiv_data1/oa_pdf/38/a6/10.1177_1352458517690824.PMC5405844.pdf
"https://doi.org/10.1177/0269216316689652Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/50/bc/10.1177_0269216316689652.PMC5405846.pdf
Available at: https://www.zorginstituutnederland.nl /over-ons/werkwijzen-en-procedures/adviseren-over-en-  verduidelijken-van-het-basispakket-aan-zorg/beoordeling-van-geneesmiddelen/richtlijnen-voor-economische-   evaluatie.,Non-OADS,/arxiv_data1/oa_pdf/50/bc/10.1177_0269216316689652.PMC5405846.pdf
Available at: https://www.vumc.nl/afdelingen/meetinstr-palliatieve-zorg/ (accessed 27 January 2017).,Non-OADS,/arxiv_data1/oa_pdf/50/bc/10.1177_0269216316689652.PMC5405846.pdf
"MarketScan Database: Better understand health economics and treatment outcomes, http://truvenhealth.com/markets/life-sciences/products/data-tools/marketscan-databases (accessed 1 November 2016).",Non-OADS,/arxiv_data1/oa_pdf/13/9a/10.1177_0333102416678382.PMC5405847.pdf
"CLINICAL REHABILITATION https://doi.org/10.1177/0269215516642503Clinical Rehabilitation 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/c7/f9/10.1177_0269215516642503.PMC5405852.pdf
Available at: https://www.nbt.nhs.uk/sites/default/files/attachments/Your%20knee%20replace-ment_NBT002048.pdf (accessed 15 December 2011).,Non-OADS,/arxiv_data1/oa_pdf/c7/f9/10.1177_0269215516642503.PMC5405852.pdf
"https://doi.org/10.1177/2333794X17704607Global Pediatric Health Volume 4: 1 –2  © The Author(s) 2017Reprints and permissions: sagepub.com/journalsPermissions.nav  DOI: 10.1177/2333794X17704607 journals.sagepub.com/home/gph Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non- commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified  on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Brief Report Case A 10-year-old boy presented to clinic with history of pol- ypoid skin lesion on right lower chest for a month.",Non-OADS,/arxiv_data1/oa_pdf/66/a2/10.1177_2333794X17704607.PMC5405876.pdf
"https://doi.org/10.1177/2054358117703386Canadian Journal of Kidney Health  and Disease  Volume 4 : 1 –7 © The Author(s) 2017Reprints and permission:  sagepub.com/journalsPermissions.nav DOI: 10.1177/2054358117703386 journals.sagepub.com/home/cjkOriginal Research Article703386 CJKXXX10.1177/2054358117703386Canadian Journal of Kidney Health and DiseaseSamuel et al research-article 2017 Setting New Directions for Research in  Childhood Nephrotic Syndrome: Results From a National Workshop Susan M. Samuel1, Tomoko Takano2, Shannon Scott3,  Genevieve Benoit4, Martin Bitzan2, Cherry Mammen5,   Laurel Ryan1, Catherine Morgan3, and the Canadian Childhood  Nephrotic Syndrome Project Team Abstract Background: We report on the proceedings of a national workshop held in Canada with the aims to identify priorities for  research in childhood nephrotic syndrome and to develop a national strategy to address these priorities.Methods: A diverse group of participants attended the meeting, including patients, family members, researchers, and health  care providers.",Non-OADS,/arxiv_data1/oa_pdf/f6/9f/10.1177_2054358117703386.PMC5405877.pdf
"JLA Guidebook, version 6, February   2016. http://www.jla.nihr.ac.uk/jla-guidebook/.",Non-OADS,/arxiv_data1/oa_pdf/f6/9f/10.1177_2054358117703386.PMC5405877.pdf
"949, 2013, http://www.ifn.se/wfiles/wp/wp949.pdf  11.",Non-OADS,/arxiv_data1/oa_pdf/35/4c/10.1177_2050312117704862.PMC5405878.pdf
"27613, December 2010, https://mpra.ub.uni-muenchen.de/27613/1/An_Empirical_Analysis_of_the_Effects_of_GP_Competition_v3.pdf  26.",Non-OADS,/arxiv_data1/oa_pdf/35/4c/10.1177_2050312117704862.PMC5405878.pdf
"https://doi.org/10.1177/2333794X17703836Global Pediatric Health Volume 4: 1 –8  © The Author(s) 2017Reprints and permissions: sagepub.com/journalsPermissions.nav  DOI: 10.1177/2333794X17703836 journals.sagepub.com/home/gph Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non- commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified  on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Original Article Introduction Several professional societies have published recommen- dations for administering supplemental iron to neonates with risk factors for developing iron deficiency (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/db/52/10.1177_2333794X17703836.PMC5405879.pdf
"6 Global Pediatric Health iron dosing for IDM, SGA, and VLBW neonates at 10 to  14 days if they are feeding >100 mL/kg/day, and to use intravenous dosing for any who are not feeding this amount by 14 days (see Supplemental Material, avail-able online at http://journals.sagepub.com/home/gph).",Non-OADS,/arxiv_data1/oa_pdf/db/52/10.1177_2333794X17703836.PMC5405879.pdf
http://www.cdc.gov/mmwr/preview/mmwrhtml/   00051880.htm.,OADS,/arxiv_data1/oa_pdf/db/52/10.1177_2333794X17703836.PMC5405879.pdf
"https://doi.org/10.1177/1756283X16673981   https://doi.org/10.1177/1756283X16673981Ther Adv Gastroenterol 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/4c/0a/10.1177_1756283X16673981.PMC5405880.pdf
"Reprints and permissions:   http://www.sagepub.co.uk/journalsPermissions.nav Therapeutic Advances in Gastroenterology journals.sagepub.com/home/tag 353 Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License   (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission  provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Introduction Mast cells (MCs) play a role in tumour angiogen-esis and their involvement has been demonstrated in several animal and human malignancies [Gulubova and Vlaykova, 2009; Marech et  al.",Non-OADS,/arxiv_data1/oa_pdf/4c/0a/10.1177_1756283X16673981.PMC5405880.pdf
"https://doi.org/10.1177/1756283X17690480   https://doi.org/10.1177/1756283X17690480Ther Adv Gastroenterol 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/e4/74/10.1177_1756283X17690480.PMC5405882.pdf
"Reprints and permissions:   http://www.sagepub.co.uk/ journalsPermissions.nav Therapeutic Advances in Gastroenterology journals.sagepub.com/home/tag 373 Introduction Since the early 2000s, the incidence and severity of Clostridium difficile infection (CDI) has  increased dramatically, in part due to the emer-gence of the more virulent B1/NAP1/027 strain, but also due to host factors.",Non-OADS,/arxiv_data1/oa_pdf/e4/74/10.1177_1756283X17690480.PMC5405882.pdf
"https://doi.org/10.1177/1756283X17690990   https://doi.org/10.1177/1756283X17690990Ther Adv Gastroenterol 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/1a/64/10.1177_1756283X17690990.PMC5405883.pdf
"Reprints and permissions:   http://www.sagepub.co.uk/journalsPermissions.nav Therapeutic Advances in Gastroenterology journals.sagepub.com/home/tag 361 Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License   (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission  provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Introduction Lynch syndrome (LS) is the most common inherited colorectal cancer (CRC) syndrome, accounting for 3% of colorectal cancers.",Non-OADS,/arxiv_data1/oa_pdf/1a/64/10.1177_1756283X17690990.PMC5405883.pdf
"The NCCN Clinical Practice Guidelines  in Oncology TM Genetic/Familial High-Risk  Assessment: Colorectal National Comprehensive Cancer Network, http://www.nccn.org/ (2016,  accessed 31 July 2016).",Non-OADS,/arxiv_data1/oa_pdf/1a/64/10.1177_1756283X17690990.PMC5405883.pdf
"creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).",Non-OADS,/arxiv_data1/oa_pdf/67/2d/10.1177_2058460117703816.PMC5405886.pdf
"https://doi.org/10.1177/2055102917695176Health Psychology Open January-June 2017: 1 –8 © The Author(s) 2017Reprints and permissions:  sagepub.com/journalsPermissions.nav DOI: 10.1177/2055102917695176 journals.sagepub.com/home/hpo Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons  Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use,  reproduction and distribution of the work  without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).",Non-OADS,/arxiv_data1/oa_pdf/d2/8f/10.1177_2055102917695176.PMC5405887.pdf
"https://doi.org/10.1177/2055116917704089 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons   Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial  use, reproduction and distribution of the work  without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Journal of Feline Medicine and Surgery Open  Reports  1 –6 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2055116917704089 journals.sagepub.com/home/jfmsopenreports This paper was handled and processed   by the European Editorial Office (ISFM)   for publication in JFMS Open Reports Case description A 7-year-5-month-old neutered female domestic short- hair cat was referred to our neurological department with a history of acute non-ambulatory tetraparesis for a  duration of 20 h. Prior to the onset of clinical signs, the cat was healthy,  regularly vaccinated and dewormed.",Non-OADS,/arxiv_data1/oa_pdf/79/64/10.1177_2055116917704089.PMC5405888.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).Journal of the Royal Society of Medicine Open; 8(4) 1–3 DOI: 10.1177/2054270417692710",Non-OADS,/arxiv_data1/oa_pdf/6d/26/10.1177_2054270417692710.PMC5405890.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).",Non-OADS,/arxiv_data1/oa_pdf/df/e6/10.1177_2058460117701515.PMC5405894.pdf
"https://doi.org/10.1177/2055102917703260Health Psychology Open January-June 2017: 1  © The Author(s) 2017 Reprints and permissions:  sagepub.com/journalsPermissions.nav DOI: 10.1177/2055102917703260 journals.sagepub.com/home/hpo Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use,  reproduction and distribution of the work  without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).",Non-OADS,/arxiv_data1/oa_pdf/1d/7b/10.1177_2055102917703260.PMC5405895.pdf
"For reprints and permission queries, plea se visit SAGE’s website at http://www.sagepub.com/journalsPermissions.nav.",Non-OADS,/arxiv_data1/oa_pdf/3d/19/10.1177_2325967117701708.PMC5405897.pdf
"https://doi.org/10.1177/2055116917702984 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons   Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial  use, reproduction and distribution of the work  without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Journal of Feline Medicine and Surgery Open  Reports  1 –2 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2055116917702984 journals.sagepub.com/home/jfmsopenreports If you have been a regular visitor to JFMS Open Reports  since in its launch in 2015, you’ll likely have spotted some recent developments.",Non-OADS,/arxiv_data1/oa_pdf/e5/d4/10.1177_2055116917702984.PMC5405901.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).Journal of the Royal Society of Medicine Open; 8(4) 1–3 DOI: 10.1177/2054270417692709",Non-OADS,/arxiv_data1/oa_pdf/ee/cc/10.1177_2054270417692709.PMC5405902.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).Journal of the Royal Society of Medicine Open; 8(4) 1–3 DOI: 10.1177/2054270417692730",Non-OADS,/arxiv_data1/oa_pdf/9a/41/10.1177_2054270417692730.PMC5405905.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).Journal of the Royal Society of Medicine Open; 8(4) 1–4 DOI: 10.1177/2054270417692732",Non-OADS,/arxiv_data1/oa_pdf/ea/be/10.1177_2054270417692732.PMC5405907.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://uk.sagepub.com/en-us/nam/open-access-at-sage).Journal of the Royal Society of Medicine Open; 8(4) 1–7 DOI: 10.1177/2054270416675081",Non-OADS,/arxiv_data1/oa_pdf/ed/ae/10.1177_2054270416675081.PMC5405910.pdf
"https://doi.org/10.1177/1758834016687482   https://doi.org/10.1177/1758834016687482 Therapeutic Advances in Medical Oncology journals.sagepub.com/home/tam 235 Ther Adv Med Oncol 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/92/bd/10.1177_1758834016687482.PMC5405996.pdf
"Reprints and permissions:   http://www.sagepub.co.uk/journalsPermissions.nav Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License   (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission  provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Introduction Breast cancer is one of the most common malig-nant tumors worldwide.",Non-OADS,/arxiv_data1/oa_pdf/92/bd/10.1177_1758834016687482.PMC5405996.pdf
"https://doi.org/10.1177/0269216317690479Palliative Medicine 2017, Vol.",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
"Palliative Care Funding Review: funding the right care and support for everyone, https://www.gov.uk/government/uploads/system/uploads/attach   ment_data/file/215107/dh_133105.pdf (2011, accessed 15  February 2017).",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
"Critical success fac- tors that enable individuals to die in their preferred place  of death, 2012, http://webarchive.nationalarchives.gov.",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
"Whole systems partnership, 2012, http://thewholesystem.co.uk/wp-content/uploads/2014/07/EoLC_QIPP_Costings_Report.pdf (September 2012, accessed 15  February 2017).",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
"Carers UK, http://www.sociology.leeds.ac.uk/assets/files/Circle/carers- uk-report-6.pdf (2007, accessed 14 April 2016).",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
"In: Inside your hospital, http://www.enhancedrecoveryblog.",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
"Official statistics: English indices of deprivation, https://www.gov.uk/government/statistics/english-indices-of-   deprivation-2010 (2010, accessed 14 April 2016).",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
"Working Time Directive (2003/88/EC) Directive 2003/88/ EC of the European Parliament and of the Council of 4 November 2003 concerning certain aspects of the organi- zation of working time (statute on the internet) c2016,  http://data.europa.eu/eli/dir/2003/88/oj (accessed 17 April 2017).",Non-OADS,/arxiv_data1/oa_pdf/cd/04/10.1177_0269216317690479.PMC5406012.pdf
Medicine (2017) 96:16(e5876)Received: 3 September 2016 / Received in ﬁnal form: 6 December 2016 / Accepted: 15 December 2016 http://dx.doi.org/10.1097/MD.0000000000005876Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/20/72/medi-96-e5876.PMC5406037.pdf
"Each set of clusters resulted as statistically signi ﬁcant were used as regions of interest (ROIs) to extract, in FSL (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/), GU values at a single-subject level.",OADS,/arxiv_data1/oa_pdf/20/72/medi-96-e5876.PMC5406037.pdf
"1 and Supplemental Table 2, http://links.lww.com/MD/B624).",Non-OADS,/arxiv_data1/oa_pdf/20/72/medi-96-e5876.PMC5406037.pdf
"Selective modulation of CR on brain metabolism was found in the inferior and medial temporal gyrus bilaterally (Supplemental Table 3, http://links.lww.com/MD/B624).",Non-OADS,/arxiv_data1/oa_pdf/20/72/medi-96-e5876.PMC5406037.pdf
Medicine (2017) 96:16(e6076)Received: 20 December 2016 / Received in ﬁnal form: 13 January 2017 / Accepted: 16 January 2017 http://dx.doi.org/10.1097/MD.0000000000006076Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/a4/9f/medi-96-e6076.PMC5406038.pdf
Medicine (2017) 96:16(e6111)Received: 17 August 2016 / Received in ﬁnal form: 4 December 2016 / Accepted: 6 December 2016 http://dx.doi.org/10.1097/MD.0000000000006111Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/69/13/medi-96-e6111.PMC5406039.pdf
Medicine (2017) 96:16(e6201)Received: 11 July 2016 / Received in ﬁnal form: 31 January 2017 / Accepted: 31 January 2017 http://dx.doi.org/10.1097/MD.0000000000006201Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/96/5a/medi-96-e6201.PMC5406040.pdf
Medicine (2017) 96:16(e6210)Received: 17 November 2016 / Received in ﬁnal form: 2 February 2017 / Accepted: 3 February 2017 http://dx.doi.org/10.1097/MD.0000000000006210Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/5d/cb/medi-96-e6210.PMC5406041.pdf
Medicine (2017) 96:16(e6347)Received: 23 September 2016 / Received in ﬁnal form: 8 February 2017 / Accepted: 16 February 2017 http://dx.doi.org/10.1097/MD.0000000000006347Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/68/15/medi-96-e6347.PMC5406042.pdf
Medicine (2017) 96:16(e6353)Received: 2 November 2016 / Received in ﬁnal form: 26 January 2017 / Accepted: 21 February 2017 http://dx.doi.org/10.1097/MD.0000000000006353Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/f1/39/medi-96-e6353.PMC5406043.pdf
Medicine (2017) 96:16(e6384)Received: 23 December 2016 / Received in ﬁnal form: 20 February 2017 / Accepted: 23 February 2017 http://dx.doi.org/10.1097/MD.0000000000006384Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/12/5b/medi-96-e6384.PMC5406045.pdf
Medicine (2017) 96:16(e6391)Received: 9 July 2016 / Received in ﬁnal form: 10 February 2017 / Accepted: 22 February 2017 http://dx.doi.org/10.1097/MD.0000000000006391Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/2f/aa/medi-96-e6391.PMC5406046.pdf
Medicine (2017) 96:16(e6396)Received: 3 November 2016 / Received in ﬁnal form: 13 February 2017 / Accepted: 23 February 2017 http://dx.doi.org/10.1097/MD.0000000000006396Meta-Analysis of Observational Studies in Epidemiology Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/79/f1/medi-96-e6396.PMC5406047.pdf
Medicine (2017) 96:16(e6416)Received: 16 August 2016 / Received in ﬁnal form: 23 February 2017 / Accepted: 23 February 2017 http://dx.doi.org/10.1097/MD.0000000000006416Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/11/41/medi-96-e6416.PMC5406049.pdf
Medicine (2017) 96:16(e6450)Received: 11 October 2016 / Received in ﬁnal form: 28 January 2017 / Accepted: 2 March 2017 http://dx.doi.org/10.1097/MD.0000000000006450Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/35/2a/medi-96-e6450.PMC5406050.pdf
Medicine (2017) 96:16(e6459)Received: 7 January 2017 / Received in ﬁnal form: 21 February 2017 / Accepted: 25 February 2017 http://dx.doi.org/10.1097/MD.0000000000006459Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/66/f3/medi-96-e6459.PMC5406051.pdf
Medicine (2017) 96:16(e6479)Received: 21 January 2017 / Received in ﬁnal form: 1 March 2017 / Accepted: 6 March 2017 http://dx.doi.org/10.1097/MD.0000000000006479Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/5d/6a/medi-96-e6479.PMC5406052.pdf
Medicine (2017) 96:16(e6503)Received: 4 October 2016 / Received in ﬁnal form: 27 February 2017 / Accepted: 8 March 2017http://dx.doi.org/10.1097/MD.0000000000006503Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/de/e5/medi-96-e6503.PMC5406053.pdf
Medicine (2017) 96:16(e6521)Received: 8 December 2016 / Received in ﬁnal form: 10 February 2017 / Accepted: 9 March 2017 http://dx.doi.org/10.1097/MD.0000000000006521Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/49/db/medi-96-e6521.PMC5406054.pdf
"Database of Genomic Variants (http://projects.tcag.ca/ variation/), DECIPHER database (http://decipher.sanger.ac.uk/),UCSC (http://genome.ucsc.edu/), and Online Mendelian Inheri-tance in Man (http://www.omim.org/) were used for the interpretation of the results.",OADS,/arxiv_data1/oa_pdf/49/db/medi-96-e6521.PMC5406054.pdf
"FISH analysis of patient III.4 (Supplementaryonline material 1, http://links.lww.com/MD/B634) revealed derivative chromosome 21 resulting in a partial duplication of the terminal end of the long arm of chromosome 1 and a partialdeletion of the terminal end of the long arm of chromosome 21.",Non-OADS,/arxiv_data1/oa_pdf/49/db/medi-96-e6521.PMC5406054.pdf
"FISH analyses were performed for patient III.3 (Supplementary online material 1, http://links.lww.com/MD/B634) and his parents.",Non-OADS,/arxiv_data1/oa_pdf/49/db/medi-96-e6521.PMC5406054.pdf
"SNP-array analysis of the patient III.4 (Supplementary online material 2,http://links.lww.com/MD/B634) revealed a duplication of 8.5Mbin size at 1q43q44 (arr[hg19] 1q43q44(240,724,339 –249, 202,755) /C23) and a deletion of 6.8Mb in size at 21q22.2q22.3 (arr[hg19] 21q22.2q22.3(41,274,744 –48,098,824) /C21).",Non-OADS,/arxiv_data1/oa_pdf/49/db/medi-96-e6521.PMC5406054.pdf
"SNP-ar- ray analysis of patient III.3 (Supplementary online material 3, http://links.lww.com/MD/B634) revealed an opposite chromo- somal rearrangement: a deletion of 8.5Mb in size at 1q43q44 (arr[hg19] 1q43q44(240,724,339 –249,202,755) /C21) and a duplica- tion of 6.8Mb in size at 21q22.2q22.3 (arr[hg19] 21q22.2q22.3 (41,282,698 –48,098,824) /C23).",Non-OADS,/arxiv_data1/oa_pdf/49/db/medi-96-e6521.PMC5406054.pdf
"More detailed description of disease-causing genes included in the deleted and duplicated regions is provided in Supplementary online material 4, http://links.lww.com/MD/B634.",Non-OADS,/arxiv_data1/oa_pdf/49/db/medi-96-e6521.PMC5406054.pdf
Medicine (2017) 96:16(e6522)Received: 30 December 2016 / Received in ﬁnal form: 26 February 2017 / Accepted: 9 March 2017 http://dx.doi.org/10.1097/MD.0000000000006522Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/28/a4/medi-96-e6522.PMC5406055.pdf
Medicine (2017) 96:16(e6560)Received: 14 October 2016 / Received in ﬁnal form: 15 March 2017 / Accepted: 16 March 2017http://dx.doi.org/10.1097/MD.0000000000006560Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/ab/26/medi-96-e6560.PMC5406058.pdf
Medicine (2017) 96:16(e6562)Received: 30 December 2016 / Received in ﬁnal form: 18 February 2017 / Accepted: 14 March 2017 http://dx.doi.org/10.1097/MD.0000000000006562Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/3b/f7/medi-96-e6562.PMC5406059.pdf
Medicine (2017) 96:16(e6564)Received: 11 January 2017 / Received in ﬁnal form: 9 March 2017 / Accepted: 10 March 2017 http://dx.doi.org/10.1097/MD.0000000000006564Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/33/46/medi-96-e6564.PMC5406060.pdf
"1s, http://links.lww.com/MD/B635, which shows the DOR of US).",Non-OADS,/arxiv_data1/oa_pdf/33/46/medi-96-e6564.PMC5406060.pdf
"2s, http://links.lww.com/MD/B635 which shows the DOR of US).",Non-OADS,/arxiv_data1/oa_pdf/33/46/medi-96-e6564.PMC5406060.pdf
Medicine (2017) 96:16(e6566)Received: 26 January 2017 / Received in ﬁnal form: 5 March 2017 / Accepted: 14 March 2017 http://dx.doi.org/10.1097/MD.0000000000006566Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/24/6c/medi-96-e6566.PMC5406061.pdf
Medicine (2017) 96:16(e6567)Received: 8 March 2017 / Received in ﬁnal form: 15 March 2017 / Accepted: 16 March 2017 http://dx.doi.org/10.1097/MD.0000000000006567Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/6f/48/medi-96-e6567.PMC5406062.pdf
Medicine (2017) 96:16(e6573)Received: 3 February 2017 / Received in ﬁnal form: 16 March 2017 / Accepted: 17 March 2017 http://dx.doi.org/10.1097/MD.0000000000006573Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/e6/b5/medi-96-e6573.PMC5406065.pdf
Medicine (2017) 96:16(e6575)Received: 24 October 2016 / Received in ﬁnal form: 25 February 2017 / Accepted: 20 March 2017 http://dx.doi.org/10.1097/MD.0000000000006575Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/dd/28/medi-96-e6575.PMC5406066.pdf
Available at: http://www.uni-ulm.de/expane/docs/HLH%202004%20Study%20Protocol.pdf.,Non-OADS,/arxiv_data1/oa_pdf/dd/28/medi-96-e6575.PMC5406066.pdf
Medicine (2017) 96:16(e6579)Received: 14 April 2016 / Received in ﬁnal form: 27 July 2016 / Accepted: 17 March 2017 http://dx.doi.org/10.1097/MD.0000000000006579Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/9b/a0/medi-96-e6579.PMC5406067.pdf
"The control group (n =10) and the experiment group (n =29) had no differences in age, sex, ratio, body composition, exercise physiology, and serum myokine concentrations at baseline (Table 1,Supplemental Data, http://links.lww.com/MD/B654).",OADS,/arxiv_data1/oa_pdf/9b/a0/medi-96-e6579.PMC5406067.pdf
"However, serum myokine concentrations did not signi ﬁcantly change after CR in both groups (Table 2, Supplemental Dat a, http://links.lww.com/ MD/B654).",Non-OADS,/arxiv_data1/oa_pdf/9b/a0/medi-96-e6579.PMC5406067.pdf
Medicine (2017) 96:16(e6595)Received: 26 October 2016 / Received in ﬁnal form: 18 March 2017 / Accepted: 22 March 2017 http://dx.doi.org/10.1097/MD.0000000000006595Diagnostic Accuracy Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/4a/50/medi-96-e6595.PMC5406068.pdf
Medicine (2017) 96:16(e6602)Received: 13 January 2017 / Received in ﬁnal form: 21 March 2017 / Accepted: 22 March 2017 http://dx.doi.org/10.1097/MD.0000000000006602Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/c2/a9/medi-96-e6602.PMC5406069.pdf
Medicine (2017) 96:16(e6605)Received: 8 November 2016 / Received in ﬁnal form: 21 March 2017 / Accepted: 23 March 2017 http://dx.doi.org/10.1097/MD.0000000000006605Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8d/44/medi-96-e6605.PMC5406070.pdf
Medicine (2017) 96:16(e6606)Received: 14 February 2017 / Received in ﬁnal form: 21 March 2017 / Accepted: 23 March 2017 http://dx.doi.org/10.1097/MD.0000000000006606Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/e7/1c/medi-96-e6606.PMC5406071.pdf
Medicine (2017) 96:16(e6612)Received: 15 May 2016 / Received in ﬁnal form: 8 March 2017 / Accepted: 21 March 2017 http://dx.doi.org/10.1097/MD.0000000000006612Quality Improvement Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/6b/eb/medi-96-e6612.PMC5406072.pdf
"Figure S1 (Supplemental Digital Content 1, http://links.lww.com/MD/B643) illustrates the distribution of Eigen value, and the sum of the ﬁrst 5 Eigen values contains almost all data capacity ( >99%).",OADS,/arxiv_data1/oa_pdf/6b/eb/medi-96-e6612.PMC5406072.pdf
"According to the Table-S1 (Supplemental Digital Content 2, http://links.lww.com/MD/B644), the one with the best validation accuracy rate is picked, namely ( C,g)=(2 1,2–4)i na ne x t r e m ec a s e of the wsize -and- sint combination, 2.5-minute wsize and 2-second sint.",Non-OADS,/arxiv_data1/oa_pdf/6b/eb/medi-96-e6612.PMC5406072.pdf
"The histogram distributions and the testing outcome with Pvalue were presented in Fig-S2 (Supplemental Digital Content 3, http://links.lww.com/MD/B643) and Table 3.",OADS,/arxiv_data1/oa_pdf/6b/eb/medi-96-e6612.PMC5406072.pdf
Medicine (2017) 96:16(e6622)Received: 20 October 2016 / Received in ﬁnal form: 23 March 2017 / Accepted: 24 March 2017 http://dx.doi.org/10.1097/MD.0000000000006622Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/ce/ab/medi-96-e6622.PMC5406073.pdf
Medicine (2017) 96:16(e6629)Received: 11 September 2016 / Received in ﬁnal form: 23 March 2017 / Accepted: 25 March 2017 http://dx.doi.org/10.1097/MD.0000000000006629Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/f7/48/medi-96-e6629.PMC5406074.pdf
Medicine (2017) 96:16(e6634)Received: 9 January 2017 / Received in ﬁnal form: 21 March 2017 / Accepted: 25 March 2017http://dx.doi.org/10.1097/MD.0000000000006634Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8a/24/medi-96-e6634.PMC5406076.pdf
Medicine (2017) 96:16(e6638)Received: 27 October 2016 / Received in ﬁnal form: 22 March 2017 / Accepted: 25 March 2017 http://dx.doi.org/10.1097/MD.0000000000006638Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/medi-96-e6638.PMC5406079.pdf
Medicine (2017) 96:16(e6643)Received: 14 March 2017 / Received in ﬁnal form: 24 March 2017 / Accepted: 27 March 2017http://dx.doi.org/10.1097/MD.0000000000006643Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8a/9d/medi-96-e6643.PMC5406081.pdf
Medicine (2017) 96:16(e6646)Received: 8 November 2016 / Received in ﬁnal form: 24 March 2017 / Accepted: 27 March 2017 http://dx.doi.org/10.1097/MD.0000000000006646Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/fc/a7/medi-96-e6646.PMC5406082.pdf
Medicine (2017) 96:16(e6648)Received: 22 June 2016 / Received in ﬁnal form: 7 March 2017 / Accepted: 27 March 2017 http://dx.doi.org/10.1097/MD.0000000000006648Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/18/93/medi-96-e6648.PMC5406083.pdf
Medicine (2017) 96:16(e6650)Received: 10 March 2017 / Received in ﬁnal form: 28 March 2017 / Accepted: 29 March 2017 http://dx.doi.org/10.1097/MD.0000000000006650Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/6c/78/medi-96-e6650.PMC5406084.pdf
"[39]The basic characteristics of the included studies are summarized in supplemental Table S1, http://links.lww.com/MD/B656.",Non-OADS,/arxiv_data1/oa_pdf/6c/78/medi-96-e6650.PMC5406084.pdf
"Publication bias Possible publication bias was detected using Egger test (Figure S1, http://links.lww.com/MD/B656 and Table 3).",OADS,/arxiv_data1/oa_pdf/6c/78/medi-96-e6650.PMC5406084.pdf
Medicine (2017) 96:16(e6654)Received: 7 December 2016 / Received in ﬁnal form: 20 March 2017 / Accepted: 27 March 2017 http://dx.doi.org/10.1097/MD.0000000000006654Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/b4/2e/medi-96-e6654.PMC5406086.pdf
Medicine (2017) 96:16(e6655)Received: 24 February 2017 / Received in ﬁnal form: 23 March 2017 / Accepted: 30 March 2017 http://dx.doi.org/10.1097/MD.0000000000006655Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/98/1f/medi-96-e6655.PMC5406087.pdf
Medicine (2017) 96:16(e6658)Received: 27 December 2016 / Received in ﬁnal form: 28 March 2017 / Accepted: 29 March 2017 http://dx.doi.org/10.1097/MD.0000000000006658Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/f8/9f/medi-96-e6658.PMC5406088.pdf
Medicine (2017) 96:16(e6661)Received: 19 February 2017 / Received in ﬁnal form: 28 March 2017 / Accepted: 29 March 2017 http://dx.doi.org/10.1097/MD.0000000000006661Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/09/50/medi-96-e6661.PMC5406090.pdf
Medicine (2017) 96:16(e6663)Received: 9 January 2017 / Received in ﬁnal form: 24 March 2017 / Accepted: 29 March 2017http://dx.doi.org/10.1097/MD.0000000000006663Clinical Trial/Experimental Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/b6/cc/medi-96-e6663.PMC5406091.pdf
Medicine (2017) 96:16(e6669)Received: 3 November 2016 / Received in ﬁnal form: 24 March 2017 / Accepted: 28 March 2017 http://dx.doi.org/10.1097/MD.0000000000006669Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/74/b5/medi-96-e6669.PMC5406092.pdf
Medicine (2017) 96:16(e6670)Received: 12 October 2016 / Received in ﬁnal form: 6 March 2017 / Accepted: 24 March 2017 http://dx.doi.org/10.1097/MD.0000000000006670Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/ad/79/medi-96-e6670.PMC5406093.pdf
Medicine (2017) 96:16(e6678)Received: 23 November 2016 / Received in ﬁnal form: 24 March 2017 / Accepted: 27 March 2017 http://dx.doi.org/10.1097/MD.0000000000006678Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/8b/e7/medi-96-e6678.PMC5406096.pdf
Medicine (2017) 96:16(e6681)Received: 17 October 2016 / Received in ﬁnal form: 25 March 2017 / Accepted: 3 April 2017 http://dx.doi.org/10.1097/MD.0000000000006681Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/1f/08/medi-96-e6681.PMC5406097.pdf
Medicine (2017) 96:16(e6683)Received: 7 November 2016 / Received in ﬁnal form: 6 March 2017 / Accepted: 17 March 2017 http://dx.doi.org/10.1097/MD.0000000000006683Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/e0/91/medi-96-e6683.PMC5406098.pdf
"In all subgroups, similar proportions of patients were over the age of 85, men, with at least 1 major comorbidity, withtranscervical fracture type, and underwent ﬁxation (see Table, Supplemental Digital Content 1 –3, http://links.lww.com/MD/ B663).",Non-OADS,/arxiv_data1/oa_pdf/e0/91/medi-96-e6683.PMC5406098.pdf
"Higher proportion of patients were admitted from homefor lower volume teaching hospitals (65.2%) and community large hospitals (63.0%) than for higher volume teaching hospitals (54.2%) or community medium hospitals (54.6%) (see Table,Supplemental Digital Content 1 –3, http://links.lww.com/MD/ B663).",Non-OADS,/arxiv_data1/oa_pdf/e0/91/medi-96-e6683.PMC5406098.pdf
"Higher proportion of patients waited for surgery 2 or more days after admission for teaching hospitals (44.4%) thanfor community hospitals (30.8%) (see Table, SupplementalDigital Content 1 –3, http://links.lww.com/MD/B663).",Non-OADS,/arxiv_data1/oa_pdf/e0/91/medi-96-e6683.PMC5406098.pdf
"Available at: http://CRAN.R-project.org/package=cmprsk Accessed June 19, 2016.",Non-OADS,/arxiv_data1/oa_pdf/e0/91/medi-96-e6683.PMC5406098.pdf
"Available at: http://CRAN.R-project.org/package=prodlim Accessed June 19, 2016.",Non-OADS,/arxiv_data1/oa_pdf/e0/91/medi-96-e6683.PMC5406098.pdf
Medicine (2017) 96:16(e6688)Received: 14 November 2016 / Received in ﬁnal form: 17 March 2017 / Accepted: 20 March 2017 http://dx.doi.org/10.1097/MD.0000000000006688Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/2e/b9/medi-96-e6688.PMC5406099.pdf
Medicine (2017) 96:16(e6690)Received: 24 November 2016 / Received in ﬁnal form: 27 March 2017 / Accepted: 30 March 2017 http://dx.doi.org/10.1097/MD.0000000000006690Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/df/99/medi-96-e6690.PMC5406100.pdf
Medicine (2017) 96:16(e6702)Received: 29 December 2016 / Received in ﬁnal form: 29 March 2017 / Accepted: 31 March 2017 http://dx.doi.org/10.1097/MD.0000000000006702Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/f1/3e/medi-96-e6702.PMC5406103.pdf
Medicine (2017) 96:16(e6713)Received: 28 February 2017 / Received in ﬁnal form: 28 March 2017 / Accepted: 4 April 2017 http://dx.doi.org/10.1097/MD.0000000000006713Systematic Review and Meta-Analysis Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
"A full searchstrategy is provided as Supplemental Digital Content 1, http://links.lww.com/MD/B 669.",Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
"Tumor mass was often spread widelyacross the body in most studies (Supplemental Digital Content 2, http://links.lww.com/MD/B669).",Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
"Details on 18F-FDG PET/CT imaging in the included studies (dosage, use of contrastenhancement, and area of scan) can be found in Supplemental Digital Content 3, http://links.lww.com/MD/B669.",Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
"The respective Funnel plot was roughly symmetrical, but the 5 studies with the lowest detectionrates [20,27,29,30,33]as well as the 2 studies with the highest detection rates[19,28]were outside the funnel, possibly indicating publication bias (Supplemental Digital Content 4, http://links.lww.com/MD/B669).",Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
"3, based on Supplemental Digital Content 5, http://links.lww.com/MD/B669).",Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
"It is clear from the study characteristics (Table 1, Supplemental Digital Content 2 and 3, http://links.lww.com/MD/B669) that the evidence of PET/CT as a diagnostic tool in CUP is challenged by a signiﬁcant heterogeneity among included studies (see also I2= 95.9% and Fig.",Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
Available at: http://www-dep.iarc.fr/NORDCAN/English/ frame.asp.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
Available at: http://www.cancerresearchuk.org/ health-professional/cancer-statistics/statistics-by-cancer-type/cancer-of-unknown-primary/incidence.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
Available at: https://www.cancer.org/cancer/ cancer-unknown-primary/about/key-statistics.html.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
Available at: https://www.cancer.dk/hjaelp-viden/kraeftformer/metastaser-spredning/ukendt-primaer-tumor/statistik-ukendt-primaer-tumor/.,Non-OADS,/arxiv_data1/oa_pdf/bb/5f/medi-96-e6713.PMC5406105.pdf
Medicine (2017) 96:16(e6733)Received: 12 November 2016 / Received in ﬁnal form: 3 April 2017 / Accepted: 6 April 2017 http://dx.doi.org/10.1097/MD.0000000000006733Clinical Case Report Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/78/9a/medi-96-e6733.PMC5406107.pdf
Medicine (2017) 96:16(e6756)Received: 21 January 2017 / Received in ﬁnal form: 30 March 2017 / Accepted: 3 April 2017 http://dx.doi.org/10.1097/MD.0000000000006756Observational Study Medicine® OPEN 1,Non-OADS,/arxiv_data1/oa_pdf/39/16/medi-96-e6756.PMC5406108.pdf
"https://doi.org/10.1177/2333721417701687Gerontology & Geriatric Medicine Volume 3: 1 –3 © The Author(s) 2017Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/2333721417701687 journals.sagepub.com/home/ggm Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non- commercial use, reproduction and distribution of the work  without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Letter to the Editor Dear Editor: Estimates of the number of aging adult Americans  who need specialized care and the number of physi- cians trained to provide it tell of a serious disparity.",Non-OADS,/arxiv_data1/oa_pdf/84/47/10.1177_2333721417701687.PMC5406113.pdf
"https://doi.org/10.1177/2050313X17700744 SAGE Open Medical Case Reports Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution- NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction  and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages  (https://us.sagepub.com/en-us/nam/open-access-at-sage).SAGE Open Medical Case Reports Volume 5: 1 –3 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2050313X17700744 journals.sagepub.com/home/sco Introduction Hair loss is common among men worldwide and can poten- tially decrease the quality of life (QoL), reduce self-confidence, and if visible, may even cause depression.",Non-OADS,/arxiv_data1/oa_pdf/75/8b/10.1177_2050313X17700744.PMC5406114.pdf
"https://doi.org/10.1177/2054358117698666Canadian Journal of Kidney Health  and Disease  Volume 4 : 1 –8 © The Author(s) 2017Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/2054358117698666 journals.sagepub.com/home/cjkProgram Report698666 CJKXXX10.1177/2054358117698666Canadian Journal of Kidney Health and DiseaseGetchell et al research-article 2017 Increasing the Rate of Living Donor  Kidney Transplantation in Ontario: Donor- and Recipient-Identified  Barriers and Solutions Leah E. Getchell1, Susan Q. McKenzie2, Jessica M. Sontrop1,  Jade S. Hayward1, Megan K. McCallum1, and Amit X. Garg1 Abstract Purpose of Review: To hear from living kidney donors and recipients about what they perceive are the barriers to living donor kidney transplantation, and how patients can develop and lead innovative solutions to increase the rate and enhance the experiences of living donor kidney transplantation in Ontario.",Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
The definition and acceptability of public solicitation in centers needs to be standardized.A national registry for deceased and living donors (https://openparliament.ca/bills/42-1/C-223/).,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
http://www.kidney.ca/file/Facing-the-Facts-2015-infographic-portrait.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
2014;10:644-652. http://www.nature.com/doifinder/10.1038/nrneph.2014.145.,OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
2014. https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC2864&lang=en  8.,OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
1999;341:1725-1730. http://www.ncbi.nlm.nih.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
2015;47:1348-1351.  http://www.sciencedirect.com/science/article/pii/S00411345   15003577.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
2004;4:569-573. http://www.ncbi.nlm.nih.gov/pubmed/ 15023149.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
http://www.lkdn.org/kidneykampaign/Myths   _About_Living_Kidney_Donation.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
2007;98:  481-483. http://www.ncbi.nlm.nih.gov/pubmed/19039887.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
2006;21:1952-1960. http://www.ncbi.nlm.nih.gov/pubmed/16554329.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
https://www.blood.ca/sites/default/files/english_ldpe_brochure_donor.pdf.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
http://kdigo.org/ home/guidelines/livingdonor/.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
1986;54:416-423. http://www.ncbi.nlm.nih.gov/ pubmed/3745593.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
2013;13:1-36. http://papers.ssrn.com/ abstract=2366898.,Non-OADS,/arxiv_data1/oa_pdf/cd/fe/10.1177_2054358117698666.PMC5406116.pdf
"https://doi.org/10.1177/2333721417703735Gerontology & Geriatric Medicine Volume 3: 1 –4 © The Author(s) 2017Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/2333721417703735 journals.sagepub.com/home/ggm Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non- commercial use, reproduction and distribution of the work  without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Case Report Introduction Convergence insufficiency (CI) is a neuromuscular defi- ciency of binocular eye alignment (Grisham, 1988) characterized by a reduction in the degree of conver - gence or the inability to maintain the necessary conver - gence of the eyes on a near target while keeping this target single, clear, and comfortable to look at.",Non-OADS,/arxiv_data1/oa_pdf/a5/d6/10.1177_2333721417703735.PMC5406117.pdf
"https://doi.org/10.1177/2050313X17705803 SAGE Open Medical Case Reports Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution- NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction  and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages  (https://us.sagepub.com/en-us/nam/open-access-at-sage).SAGE Open Medical Case Reports Volume 5: 1 –4 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2050313X17705803 journals.sagepub.com/home/sco Introduction Ductal carcinoma in situ (DCIS) represents approximately  20% of newly diagnosed breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/cb/9b/10.1177_2050313X17705803.PMC5406118.pdf
"5th ed., ACR.org.http://www.acr.org/~/ media/acr/documents/pdf/qualitysafety/resources/birads/posters/birads%20reference%20card_web_f.pdf (accessed 8  September 2016).",Non-OADS,/arxiv_data1/oa_pdf/cb/9b/10.1177_2050313X17705803.PMC5406118.pdf
2015. http://www.heart.org/HEARTORG/Conditions/HeartFailure/ AboutHeartFailure/Classes- of-Heart-Failure_UCM_306328_ Article.jsp#.Vs3iVpw4HIU.,Non-OADS,/arxiv_data1/oa_pdf/76/38/10.1177_2333392817701050.PMC5406120.pdf
2016. http://www.cdc.gov/d hdsp/data_statistics/fact_ sheets/fs_heart_failure.htm.,OADS,/arxiv_data1/oa_pdf/76/38/10.1177_2333392817701050.PMC5406120.pdf
2016. https://www.cms.gov/Medi care/Medicare-Fee-for-Service- Payment/AcuteInpatientPPS/ Readmissions-Reduction-Program.html.,Non-OADS,/arxiv_data1/oa_pdf/76/38/10.1177_2333392817701050.PMC5406120.pdf
Comprehensive meta- analysis 2009. http://www.meta -analysis.com/index.php.,Non-OADS,/arxiv_data1/oa_pdf/76/38/10.1177_2333392817701050.PMC5406120.pdf
2014;20(10):783-792. http://www.ajmc.com/journals/issue/2014/2014-vol20-n10/a-com prehensive-hospital-based-intervention-to-reduce-readmissions- for-chronically-ill-patients- a-randomized-controlled-trial/.,Non-OADS,/arxiv_data1/oa_pdf/76/38/10.1177_2333392817701050.PMC5406120.pdf
